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Abstract 
 
New onset seizures associated with HIV infection have been studied.  The data investigating 
new onset seizures in HIV infected individuals have predominantly originated from 
developed countries and prior to the availability of anti-retroviral therapy. No longitudinal 
studies have been conducted.  
The HIV pandemic has its roots in Africa and South Africa currently bears the brunt of the 
burden. This study sought to evaluate the current profile of HIV infected individuals 
presenting with new onset seizures in the South African setting, and to follow up patients in 
whom no cause is identifiable at baseline.  
Two hundred Black African patients were recruited from the three major teaching hospitals 
affiliated to the University of the Witwatersrand, Johannesburg. They had clinical 
assessments and were extensively investigated to determine a cause for the seizure. In the 
present study the majority of HIV infected patients with new onset seizures had an underlying 
cause, the most common of which were meningitis and focal brain lesions. Infectious 
aetiologies predominated; specifically in patients with advanced disease i.e. HIV stages 2 and 
3. Tuberculosis and cryptococcal infections were the most frequent. This is consistent with 
the prevalent infections in our region. Our patients had advanced immune-suppression as 
evidenced by the mean CD4 count of 167 µµL. HAART coverage was sub-optimal with the 
majority of HAART-eligible patients not accessing therapy. The predominant seizure type 
was generalized tonic-clonic.  Neuroimaging abnormalities were present in most patients.  
Fifteen patients with no identifiable cause were enlisted in the long-term study. These 
patients had repeated clinical assessments; laboratory investigations; MRI and brain SPECT 
scans. All patients presented with generalized tonic-clonic seizures. Non-specific white 
matter lesions on MRI; temporal lobe abnormalities on visual SPECT scans and regional 
cerebral hypo-perfusion on quantitative SPECT scan analysis were common findings. The 
patients who initiated HAART during the study period improved on laboratory monitoring 
and on quantitative SPECT analysis. One patient developed HIV associated dementia during 
follow up.  
vi 
 
New Onset Seizures in HIV infected individuals in whom no cause is identifiable may 
possibly represent: 
 Early stages of the spectrum of neurocognitive dysfunction seen in HIV 
infection 
 A precursor for dementia  
These patients are likely to benefit from the initiation of anti-retroviral therapy. 
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CHAPTER ONE 
 INTRODUCTION 
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1.1 The Human Immunodeficiency Virus Pandemic 
1.1.1 History of the Global Pandemic 
There are reports of Human Immunodeficiency Virus (HIV) infection prior to 1970 but the 
current pandemic likely began in the mid-to late 1970s. The initial reports originated in the 
United States of America (USA). The Acquired Immunodeficiency Syndrome (AIDS) was 
recognized a few years later. 
In early 1981, Hymes et al identified a group of eight homosexual males with Kaposi’s 
sarcoma (KS), in New York. The disease in these patients was unusual in that it occurred in 
younger males, was generalized and more aggressive than previously described. [KS is now a 
well-recognized clinical manifestation of the disease.] Later that year Gottlieb et al described 
the unusual occurrence of Pneumocystis carinii pneumonia (PCP) in five homosexual men 
who had no obvious underlying immunodeficiency. Soon numerous reports began to emerge 
of opportunistic disease in homosexual men and later in intravenous drug abusers. The 
different presentations meant that there was no uniformity in recording these unusual 
presentations. In an attempt to address this, the Center Disease Control (CDC) published an 
update in the weekly Morbidity and Mortality Weekly Report (MMWR), Current Trends 
Update on AIDS September 24, 1982 recognizing the Acquired Immunodeficiency Syndrome 
(AIDS) as a specific entity. This name seemed appropriate as the condition was: 
 Acquired 
 Immune deficiency was a prominent feature 
 It was a syndrome rather than a disease, due to the variety of manifestations 
The recognition of AIDS as a specific entity occurred eighteen months after the first KS case 
reports from New York.  This initial classification included clinical criteria only.  
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Barre-Sinoussi et al originally isolated the virus causing AIDS at the Pasteur institute in 
France in May 1983 and named it the lymphadenopathy-associated virus (LAV). At the stage 
of identification of the virus the authors postulated that it may play a role in the causation of 
AIDS. A year later, Gallo and his colleagues published 4 articles (Gallo et al; Popovic et al; 
Sarngadharan et al and Schüpbach et al; Science. 1984) describing a retrovirus which they 
named Human T Lymphotrophic Virus-III (HTLVIII).  They believed that they had identified 
the “AIDS virus”. It soon became apparent that both the French and American scientists were 
describing the exact same virus. In 1986 Coffin et al wrote a letter in Nature labelling the 
virus HIV (Human Immunodeficiency Virus), and officially acknowledging it as the virus 
responsible for AIDS.  
 
The AIDS pandemic was in its infancy in 1986. The report of the Bureau of Hygiene & 
Tropical Diseases (1986) 'AIDS newsletter' stated that 38401 patients in 85 countries had 
acquired the disease. Significantly at this stage it was the Americas which bore the brunt of 
the disease. There were less than 2500 cases reported in Africa. During the thirty years since 
AIDS was formally recognized the epidemic has burgeoned. According to the  United 
Nations (UN) AIDS Report on the Global AIDS Epidemic 2013 there have been an estimated 
75 million people infected with HIV and 36 million deaths due to AIDS-related illnesses.
  
 
The profile of people living with HIV/ AIDS in the developed world is different to that in the 
developing world. In developed countries the main burden of the disease is amongst 
marginalized groups e.g. men who have sex with men (MSM), ethnic minorities, refugees 
and intravenous drug users. In developing countries the epidemic is mainly due to 
heterosexual transmission in the general population but the marginalized groups mentioned 
above maintain an increased risk.  
 
There has been some progress in controlling the pandemic in that the annual numbers of new 
HIV infections and deaths are decreasing. In 2001 new HIV infections peaked at 3.4 million, 
in 2012 this had reduced to 2.3 million. AIDS-related deaths spiked in 2005 when 2.3 million 
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were recorded. By 2012 the number had decreased to 1.6 million (UNAIDS Report on the 
Global AIDS Epidemic 2013).  
 
A significant tool in the management of the AIDS pandemic has been the development and 
increasing availability of anti-retroviral drugs. In 1987 azidothymidine (AZT) became the 
first drug approved by the U.S. Food and Drug Administration (FDA). There are currently 
more than 20 anti-retroviral drugs approved for use in the management of HIV infection. The 
current recommendations are for the use of Highly Active Antiretroviral Therapy (HAART). 
Multiple drugs are used in an effort to decrease drug resistance. The estimated number of 
people accessing therapy was 9.7 million in 2012; a significant increase from the 1.3 million 
in 2005 which was when it became readily available (UNAIDS Report on the Global AIDS 
Epidemic 2013).  
  
5 
 
1.1.2 HIV and AIDS in Africa  
There is evidence to confirm that HIV originated in Africa. Keele et al, 2006 proved that a 
strain of Simian Immunodeficiency Virus (SIV) isolated in chimpanzees in Cameroon is a 
viral ancestor of HIV-1, the cause of the current AIDS. It is believed that SIV was first 
transferred to humans in the 1930s and that in the 1960s people in Africa were already 
infected with HIV (Nahmias et al, 1986). The virus was isolated from stored samples of 
blood. 
 
The first African patients with AIDS most likely originated in Kinshasa, the capital city of the 
Democratic Republic of Congo. Medical workers documented increased numbers of patients 
with opportunistic disease i.e. cryptococcal meningitis; Kaposi’s sarcoma and miliary 
tuberculosis (TB). In Kinshasa the virus spread rapidly within the urban sexual network. This 
initiated the rapid heterosexual transmission of HIV in Africa. Numerous factors facilitated 
this spread: 
 Widespread labour migration 
 High ratio of men to women in the urban environment 
 Lack of circumcision 
 Prevalence of sexually transmitted diseases (STDs) 
Sex workers are believed to have been instrumental in the accelerated spread of HIV in 
Africa (Faria et al, 2014).  
 
In the 1980s the population in Uganda was severely affected by AIDS, but it had not been 
recognized as a specific entity. The disease was known locally as “Slim Disease”. The first 
cases had been seen in 1982 and the numbers had increased in the ensuing years. The cardinal 
features documented in these patients were severe wasting and weight loss, hence the name. 
There was no evidence to link this disease with the disease seen in white homosexual men in 
the USA. Clinicians recognized that their patients had some criteria consistent with AIDS but 
the extreme weight loss and diarrhoea were atypical (Quinn et al, 1986). 
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In 1984 Clumeck et al in Belgium diagnosed AIDS in 22 African patients. Their most 
significant finding was that none of their patients had the “traditional” risk factors that were 
presumed to be associated with the development of AIDS i.e. 
 Underlying immunosuppressive disease 
 Blood-product transfusion 
 Homosexuality 
 Intravenous-drug abuse 
This was the first report of AIDS in patients outside the well-recognized high risk groups 
documented in the USA. This study was both prospective and retrospective. The first case 
consistent with the diagnosis of AIDS had been seen in 1979. The realization that AIDS 
occurred in African patients led to prospective studies in both Rwanda and Zaire in efforts to 
identify potential cases. In less than a month, 26 patients were identified in Rwanda (van der 
Perre et al, 1984) and 38 in Zaire (Piot et al, 1984). During this period it became obvious that 
the AIDS epidemic in Africa was different in that it was related primarily to heterosexual 
transmission of the virus.  
 
The epidemic gained momentum during the late 1980s. In 1990 Chin estimated that there 
were 9 million people living with HIV infection in the world and of these 5.5 million were 
believed to be in Africa.  A prominent feature of the epidemic in Africa is the higher infection 
rate in women.  The infection continued to spread across the continent, especially in sub-
Saharan Africa (SSA). SSA remains the most seriously affected region worldwide, with an 
estimated 70% of the 35 million people living with HIV. The prevalence varies both between 
regions and within countries in SSA. Southern Africa has a higher prevalence than East and 
West Africa. In Southern Africa the highest prevalence is in Swaziland where it is presumed 
to be 27%.  SSA remains at the epicentre of the AIDS pandemic. In 2012 approximately 70% 
of new infections documented worldwide occurred in SSA (UNAIDS Report, 2013). 
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1.1.3 The HIV epidemic in South Africa 
Ras et al, 1983 first documented HIV infection in South Africa.  They described two white 
homosexual males with the clinical manifestations consistent with AIDS. During the early 
years it was believed to be a disease of predominantly homosexual men and recipients of 
blood transfusions. During the 1990s however it became obvious that, as in the rest of Africa, 
South Africa was experiencing an epidemic due to heterosexual transmission of the disease.   
 Approximately 18% of adults in South Africa are HIV-positive.  
 The rate among Blacks is higher than amongst other race groups.  
 The highest rates occur amongst sexually active young women.  
The initial response by the health authorities to the potential problem was inadequate and the 
number of infections rose dramatically, especially amongst women attending antenatal 
clinics.  
 In 1990 the HIV prevalence in women attending antenatal clinics was 0.7%. 
 The prevalence peaked in 2005 at 30%.  
 The prevalence rate appears to have stabilized and in 2011 and 2012, it was 
recorded at 29.5%. 
(The National Antenatal Sentinel HIV & Herpes Simplex Type-2 Prevalence Survey in South 
Africa, 2012).  
The rollout of HAART to patients in the public sector was delayed and only began in 2004. 
There has been substantial progress since in making the drugs available. According to 
Campion, 2015 an estimated 2.4 million adults and 156 000 children are accessing therapy. 
The effect of the widespread availability of anti-retroviral therapy is seen in the reduction in 
the number of new infections amongst all age groups. There are no retention figures on the 
number of people that remain on therapy twelve months after initiating HAART.  
South Africa continues, however to be severely affected. It is home to the highest number of 
people living with HIV (6.1 million) and in 2012 there were 350 000 new infections 
(UNAIDS Global Report, 2013).
 
    
 
8 
 
1.2 The Structure and Life Cycle of HIV 
 
Human Immunodeficiency Virus is a retrovirus, and is part of the subclass of lentiviruses. 
The HIV, like all viruses is unable to grow or reproduce by itself. It has to infect cells in a 
living organism to multiply. 
The virus is 0.1 microns in diameter. The virus consists of a: 
 Viral envelope 
o Composed of two lipid layers  
 Viral core which contains 
o Three enzymes required for replication i.e. reverse transcriptase; 
integrase and protease 
o Genetic material, two identical Ribonucleic acid (RNA) strands 
 
Figure 1.1  Structure of HIV 
Source: National Institutes of Health (NIH). Wikimedia Commons (2014) 
Legend: gp=glycoprotein 
9 
 
Most organisms store genetic material on Deoxyribonucleic acid (DNA). Retroviruses are 
unusual in that they utilize RNA.  This complicates the replication process. Replication is 
mainly restricted to human cells that carry the surface protein Cluster of Differentiation 4 
(CD4). The spikes on the surface of the HIV particle fuse with the CD4 and the contents are 
released into the cell. The reverse transcriptase enables the viral RNA to be converted into 
DNA. Integrase ensures that the DNA is incorporated into human DNA. The virus may 
remain dormant for a prolonged period before activation. Upon activation it is converted into 
messenger RNA before being transported outside the nucleus. New HIV enzymes and 
proteins are produced in this way. Protease cuts the protein strands into smaller pieces. These 
pieces build new viral core particles which infect other cells and continue the replication 
process.   
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1.3 HIV Subtypes 
There are two types of HIV:  
 HIV-1  
 HIV-2 
The two subtypes are similar in terms of: 
 Genetic composition (30-60%) 
 Structure 
 Transmission routes 
 Cellular targets 
Although HIV-1 infection is responsible for most of the global AIDS pandemic, HIV-2 is an 
important cause of disease in some regions of the world. HIV-2 was initially found in West 
African nations, but has spread to other parts of Africa, Europe, India, and the United States. 
HIV-2 is less virulent and the disease progression less aggressive.  HIV-1 is the type 
identified in South Africa. 
HIV-1 has been sub-divided into 3 groups: major (M); outlier (O) and non-M non-O (N). See 
Figure 1.2 below. In 2009 Plantier et al described a single case of a new HIV-1 lineage which 
they labeled group P. The M group is the most common circulating subtype within the HIV-1 
group and has been divided into subtypes (also called clades) denoted with letters and sub-
subtypes denoted with numerals. Subtype C is the most prevalent clade accounting for more 
than half of all infection.  HIV-1, subtype C viruses account for the vast majority of the South 
African epidemic ( Ariën , Vanham and Arts , 2007).       
 
Fig 1.2 HIV Sub-types  
HIV 
Group N Group M 
Subtypes A-J 
Group O 
HIV-1 HIV-2 
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1.4 Viral transmission  
 
The foremost modes of transmission are: 
 Sexual intercourse 
 Exposure to infected blood via transfusions or needle sharing 
 Perinatal transmission 
The mode of transmission varies between developed and developing nations. In developing 
countries vaginal sex accounts for the vast majority of infections. In developed countries 
male to male sex and intravenous drug abuse play a significant role. 
Beyrer, in 2007 documented the numerous established risk factors for heterosexual HIV 
transmission:  
 Co-infection with Herpes Simplex Virus-2  
 High risk sexual behaviour 
o High level of concurrent partnerships  
o Receptive anal sex 
 High viral load 
 Host and genetic factors  
o Gender inequalities 
o Young age of initial sexual activity 
 Labour migration patterns 
 Lack of circumcision 
 Low rates of condom use 
 Presence of ulcerative sexually transmitted infections 
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1.5 Pathogenesis of Neurologic Diseases in HIV 
Neurologic disease may be due to: 
 Direct effects of the HIV on the nervous system 
 HIV-related immune dysfunction with CD4 cell depletion 
The CD4 depletion renders the individual susceptible to opportunistic infections and 
neoplasms of the nervous system.  
Zayyad and Spudich, 2015 have reviewed this topic. The virus may enter the brain during the 
viraemia that accompanies the early systemic infection. This early seeding of the virus in the 
brain may set the scene for long-term low grade inflammation within the brain. The presence 
of HIV in the central nervous system (CNS) causes activation of the immune system and 
increased expression of inflammatory cytokines. The cytokines lead to a breakdown of the 
blood-brain barrier (BBB) and further cause damage to the surrounding glial cells and 
neurons. The virus may access the CNS at numerous stages during the course of the disease. 
This access may be provided by distinct events or a sustained vulnerability of the BBB during 
the course of the infection.  The term CNS compartmentalization has been coined. This refers 
to the localization of the HIV infection within the CNS and the ensuing genetic changes 
found in the viral strains within the cerebro-spinal fluid (CSF) and brain tissue.   
The HIV uses a minimum of two surface receptors to enter any target cell. The primary 
receptor is the CD4 molecule. This molecule is present on the surface of: 
 CD4 lymphocytes 
 Dendritic cells 
 Macrophages 
 Monocytes 
The virus initially binds to the CD4 receptor and then binds to a co-receptor which is either 
chemokine receptor 5 (CCR5) or chemokine receptor 4 (CCR4). During the initial phases of 
the infection CCR-5 tropic virus (R5) predominates. The virus that has an affinity for CCR4 
(X4) is a more pathogenic phenotype. During disease progression the X4 phenotype gains 
ascendancy.  
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Bilgrami and O’ Keefe, 2014 have described the numerous cell types involved in the 
pathogenesis: 
 Microglia 
o Express the CCR 5 co-receptor 
o Primary target cells of HIV 
 Monocytes and Macrophages 
o Express both co-receptors 
o Assist in HIV growth and replication 
 Astrocytes 
o May become infected, but are not involved in growth and replication 
o May have a role in neuronal dysfunction 
  Endothelial cells 
o They express both co-receptors and may become infected. 
o Precise role is unclear 
 Neurons and oligodendrocytes 
o Uninfected by HIV 
 
The virus is transported across the BBB in infected CD14
+ 
and CD 16
+ 
monocytes.  There has 
been recent evidence to suggest that the virus also causes a disruption of the BBB. The HIV 
affects the modifying proteins that maintain the endothelial tight junctions in the BBB.  Some 
of the monocytes differentiate into macrophages and perivascular microglia within the CNS. 
These macrophages are present in peri-vascular spaces, the meninges and the choroid plexus. 
The perivascular macrophages infect new cells using matrix metalloproteinase-9. The 
macrophages function as antigen-presenting cells and in the activated state produce 
neurotoxic substances.  The macrophages exist in three different activation states: 
 M1 causes a pro-inflammatory response 
o Activated by Interferon gamma (IFN-ý) 
 M2 causes an anti-inflammatory response 
o Activated by Interleukin (IL)-4 and IL-13 
 dM which causes immune-suppression 
o Activated by IL-10 
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In normal conditions during M1 and M2 activation there is an effective immune response to 
organisms that invade the CNS. HIV infection causes the system to be reversed. The virus 
uses M1 and M2 tracks to promote the dissemination of the virus. Macrophages can house 
unintegrated HIV DNA which supports the transcription of the viral genes nef and tat. These 
genes induce the cytokine ligands (CXCL) 9 and CXCL10 which are known neurotoxins. 
They can also stimulate macrophages to produce quinolinic acid, a neurotoxin. A further 
mechanism that macrophages use to cause disease in HIV infection is via the inhibition of 
long-term signal transmission between neurons.  Macrophage activation results in a toxic, 
inflammatory and deregulated environment within the CNS (Lamers et al, 2014).  
It has recently emerged that in addition to the gut and bone marrow, the CNS may be an 
additional reservoir for HIV. Canestri et al, 2010 have shown that the virus is able to multiply 
within the CNS in patients that have evidence of systemically effective HAART. This 
phenomenon has been termed “CSF escape”. 
 
Fig. 1.3 Neuropathogenesis of HIV-related CNS injury 
From Zayyad Z, Spudich S Curr HIV/AIDS Rep. 2015 Jan 22. Neuropathogenesis of HIV: From Initial 
Neuroinvasion to HIV-Associated Neurocognitive Disorder (HAND). Permission obtained, see Appendix A 
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1.6 Clinical Progression of HIV Infection 
 Viral Transmission 
 Acute (Primary)  HIV Infection   
 Chronic HIV Infection 
o Asymptomatic 
o Early Symptomatic HIV Infection   
o AIDS  
(CD4 cell count <200cells/µL or presence of AIDS-defining condition) 
o Advanced HIV Infection  
(CD4 cell count <50cells/µL)  
Progression of the disease is highly variable. Patients may develop a chronic symptomatic 
illness over a period of 6 months to 30 years following seroconversion. Some patients 
(referred to as Elite Suppressors) are able to naturally control the infection without HAART. 
In patients not receiving anti-retroviral therapy the mean time to the development of AIDS is 
between 10 and 11 years with survival thereafter of less than four years.   
Neurologic disease can occur at any stage of HIV infection, but occurs more commonly in 
patients with advanced disease.  
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1.7 Neurology of HIV Infection 
 
1.7.1 The Early Days 
Neurological disease represents a significant portion of the spectrum of both primary and 
opportunistic illnesses associated with HIV infection.  
Disorders of the central and peripheral nervous system were recognized early. In 1983 Snider 
et al analyzed fifty patients with neurological complications attributed to the recently 
described AIDS syndrome. HIV itself had not been isolated yet. They identified five 
categories of neurological complications: 
 Infections 
 Tumours 
 Vascular 
 Peripheral neuropathy 
 Undiagnosed 
Infections were the predominant finding and were present in 31 patients (62%).
 
The most 
commonly identified “infection” was progressive dementing encephalitis (subacute 
encephalitis) which was present in 18 patients. The patients presented with subtle cognitive 
changes, malaise, lethargy and social withdrawal. They were noted to have psychomotor 
retardation.  The affected individuals deteriorated over time and eventually developed 
features of a severe dementia. The symptoms and signs described in these patients are typical 
of the disease currently known as HIV Associated Neurocognitive Disorder (HAND).  It was 
believed that Cytomegalovirus (CMV) was the cause of the encephalitis because intracellular 
inclusions which were suggestive of CMV were present in some patients’ post-mortem. The 
other
 
infections detected were Toxoplasma gondii, patients presented with focal brain lesions; 
Progressive Multifocal leukoencephalopathy (PML), indicative of underlying John 
Cunningham virus (JCV) infection; cryptococcal meningitis; candida albicans and possible 
mycobacterium avium intracellulare. 
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The neoplasms identified in this group were lymphoma (primary neurological and 
metastatic); sarcoma and plasmacytoma in individual patients. Vascular complications 
included endocarditis, cerebral haemorrhage and cerebral arteritis. The undiagnosed group 
comprised patients with focal brain lesions; aseptic meningitis and retinopathy.   
The extent of neurological involvement in AIDS patients was well documented during the 
initial stages of the epidemic. In April 1985 Levy, Bredesen and, Rosenblum described the 
neurological symptoms in an unselected group of 352 homosexual patients with AIDS. One 
hundred and twenty-four patients (39%) were affected. The authors conceded that their figure 
may be an underestimate as mild disease may have been overlooked. This was borne out by 
their own autopsy series where 30 patients (73%) had neuropathological abnormalities. Their 
categorization of neurological complications was similar to that discussed above.  Viral and 
non-viral infections accounted for the majority (85%) of patients presenting with neurological 
disease. The most common complication identified in this cohort was sub-acute encephalitis 
which was present in 28% of patients. The authors believed that CMV could be responsible 
for the encephalitis. 
In late 1985 the Human T Lymphotropic Virus III (HTLV III) virus, as it was known was 
isolated in the CSF and neural tissues. Two independent studies (Ho et al and Levy JA et al, 
1985) were published describing the presence of the virus in patients with documented 
clinical neurological syndromes consistent with AIDS.  The authors concluded that the virus 
was neurotropic. It was proposed that the virus itself could cause acute and chronic 
meningitis; dementia; spinal cord degeneration and peripheral neuropathy. 
A seminal article by Berger in 1988 delineated the neurological complications of HIV 
infection and classified them into two groups: 
 Direct HIV Infection 
 Indirect HIV Infection 
Neurological complications in HIV have increased since then in parallel with the increased 
number of HIV-infected individuals.  The introduction of HAART has led to an improvement 
in the quality of life in some people with HIV.  In the face of this progress, neurologic 
complications still occur in approximately 70% of patients (Sacktor, 2002). HAART itself 
may contribute to the burden of neurological disease.  
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Table 1.1 Neurological Disorders in HIV 
 
 Primary HIV neurological disease  
(The virus is both necessary and sufficient by itself to cause the disease) 
 
o Acute HIV Infection 
o HIV Associated Neurocognitive Disorders  
 Asymptomatic Neurocognitive Impairment 
 Minor Neurocognitive Disorder 
 HIV Associated Dementia 
o Neuromuscular Syndromes 
o Peripheral neuropathies  
o HIV-associated Myopathies 
o Vacuolar myelopathy  
 
 
 
 Secondary/ Opportunistic Neurological Syndromes 
 
o Opportunistic Infections  
 Bacterial Infections 
 Neurologic Tuberculosis 
 Fungal Infections 
 Cryptococcal meningitis 
 Parasitic Infections 
 Malaria 
 Protozoal Infections 
 Toxoplasmosis 
 Viral Infections 
 Cytomegalovirus 
 JCV, causing PML 
o Opportunistic Malignancies  
 Primary Central Nervous System Lymphoma  
 
 
 Treatment Related Neurological Disease 
 
o Antiretroviral toxic neuropathy 
o Immune Reconstitution Inflammatory Syndrome 
o Toxic myopathy 
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1.7.2 Primary HIV-related Neurological Disease 
Acute HIV Infection 
The virus manifests itself clinically after an incubation period of 1 to 4 weeks. The initial 
symptoms are similar to that of an influenza-like illness. The majority of HIV-infected 
patients develop this self-limiting syndrome. The neurological manifestations of the acute 
illness include: 
 Meningitis 
o May be accompanied by cranial neuropathies 
o Usually aseptic 
o CSF abnormalities include a  pleocytosis and elevated protein 
 Headache 
o Dull, bilateral ache 
o Inconsistent descriptions of site; duration and response to therapy 
 Cranial Neuropathies 
o The nerves commonly affected are the trigeminal; facial and 
vestibulocochlear 
 Facial nerve is the most frequently affected nerve and in rare 
cases there may be bilateral involvement 
 Precedes seroconversion by 4–6 weeks 
 In the early stages of the infection, acyclovir and a short course 
of steroids may be given 
 Peripheral Neuropathies 
o Inflammatory demyelinating neuropathies predominate at this stage 
o Brachial neuritis; sensory neuropathy and ataxic neuropathy can occur 
but are rare 
 Myalgia 
o Common symptom 
o Can rarely be accompanied by rhabdomyolysis 
 
There may be a transient decrease in the CD4 counts during this phase.  
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The diagnosis is based on: 
 Presence of p24 antigen 
o Limited use  
 Identification of viral RNA 
o Viral load assays are widely available 
 
Fig. 1.4 Laboratory Diagnosis of HIV Infection 
  From https://depts.washington.edu/labweb/Divisions/Viro/HIVTest.htm.  
  Permission obtained , see Appendix B 
 
The management includes: 
 Psychosocial evaluation 
 Advice on  
o Heightened infectiousness 
o Effective transmission risk reduction strategies 
 Supportive care for the acute symptoms 
 The role for HAART is this setting is not yet well established, but does need to 
be considered 
The presence of severe symptoms during acute infection predicts more rapid clinical 
progression to AIDS 
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HIV Associated Neurocognitive Disorders (HAND) 
During the early stages of the HIV epidemic the entity of subacute encephalitis was 
recognized in HIV infected patients with features of dementia. The neuropathological 
hallmark was the presence of multinucleated giant cells on autopsy and the absence of other 
potential pathogens. The terms AIDS dementia complex (ADC) and HIV encephalopathy 
(HIVE) were coined later and described the clinical features and neuropathology of this 
primary HIV infection of the brain. A 1986 autopsy study by Navia, Jordan and Price  
indicated that two thirds of patients had evidence of this encephalopathy.
 
The syndrome was 
soon recognized as a spectrum of cognitive deficiency ranging from mild, to moderate, to 
severe. It was believed that the degree of immunosuppression correlated with the 
neuropathogenicity of the virus. The early stage described as a disturbance in intellect was 
characterized by: 
 Fatigue and malaise 
 Headache 
 Increasing social isolation 
 Loss of sexual drive 
Patients described increasing forgetfulness and a slowing of their thought processes. The 
clinical features were typical of a “sub-cortical dementia”.  
During the course of the syndrome they developed tremors, gait disturbances and imbalance. 
Patients with advanced disease were unable to care for themselves. The diagnosis of HIVE 
was based on the exclusion of other diseases and required serology, CSF examination and 
neuroimaging.  
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Neurocognitive dysfunction remains the most significant neurological disorder in patients on 
HAART. The currently advocated terminology for HIV-associated neurocognitive disorders 
(HAND) are the Frascati criteria, conceived by Antinori et al, 2007. This is based on and 
includes neuropsychological testing and the assessment of functional status and is not 
applicable at the bedside. The neuropsychological component of the evaluation requires 
assessment of the following ability domains:  
 Verbal/language 
 Attention/working memory 
 Abstraction/executive 
 Memory (learning; recall) 
 Speed of information processing 
 Sensory-perceptual  
 Motor skills 
Functional status is based on activities of daily living and may rely on self-reporting; require 
corroboration or long-term follow-up.   
Three categories are described based on the severity of the impairment. 
 Asymptomatic Neurocognitive Impairment (ANI): 
o Neurocognitive test performance 1 standard deviation (SD) below an 
appropriate normative mean in at least 2 cognitive domains, but  
 No decline in functional status.  
o Patients are asymptomatic and formal neuropsychological evaluation is 
necessary to confirm the diagnosis.  
 Mild Neurocognitive disorder (MND):  
o Neurocognitive test performance 1 SD  below mean in at least 2 cognitive 
domains  
o Mild impairment in activities of daily living.  
o Patients in this stage of the disease have minor cognitive impairment which 
impacts both on their home and work life.  
o There may be minor abnormalities on clinical examination.   
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 HIV-associated Dementia (HAD):  
o Severe cognitive impairment in two or more domains by 2 SD below 
mean  
o Notable impairment in activities of daily living.  
o Neurological dysfunction is evident and impacts on all spheres of the 
patients’ life.  
o Clinical deficits (spasticity, especially of lower limbs, clonus, frontal 
release signs, tremor and ataxia) develop with progression of the 
disease.  
o Seizures and myoclonus can occur in advanced disease.  
o Severe dementia may be accompanied by a co-occurring myelopathy 
and/or peripheral neuropathy.  
 
This advanced clinical picture is uncommon in regions where HAART usage 
is widespread, but continues to occur in patients with: 
o Non-adherence  
o Limited access to anti-retroviral therapy 
o Treatment failure  
 
The CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER) study (Heaton et al, 
2011) a large multi-centre study based in the US estimates current prevalence of HAD at less 
than 5%.  The milder subtypes of HAND, however, continue to be reported in patients despite 
sustained virological control. In the CHARTER study mild neurocognitive impairment was 
detected in 45% of patients: 
 ANI in 33%  
 MND in 12%  
About half of HAART –treated patients have milder forms of neurocognitive impairment 
(Heaton et al, 2007).  
  
24 
 
Possible reasons for the inadequate response to therapy include: 
 The “legacy effect” of HIV infection i.e. the lasting damage that occurs prior 
to the initiation of HAART  
 Persistent CNS disease activity due to a lack of viral suppression, secondary to 
poor CNS penetration effectiveness (CPE) of  HAART 
 Potential neurotoxicity of HAART 
 Associated comorbidities 
o Psychiatric illness 
o Substance abuse 
o Cerebrovascular disease 
o Ageing  
The current epidemiological pattern dominated by milder forms of HAND is applicable in 
developed countries. In developing regions which carry a much greater disease burden 
HAART availability has lagged behind.  Increasing the access to anti-retroviral therapy is 
likely to have the same effects as seen in the developed regions of the world with a 
considerable decrease in the disease burden of HAD and an increase in the milder HAND 
subtypes. 
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Neuromuscular Syndromes 
 
 Peripheral Neuropathies (PN) 
o HIV-associated distal sensory neuropathy 
 Increased frequency as the degree of immunosuppression 
increases 
 Symptoms include numbness and severe neuropathic pain 
 Clinical features include a stocking pattern of impaired 
sensation and decreased/ absent ankle reflexes 
 This is usually a diagnosis of exclusion 
 Effective therapy has not yet been established but lamotrigine, 
high dose topical capsaicin and recombinant nerve growth 
factor may provide symptomatic relief 
o Inflammatory Demyelinating Polyneuropathies 
 Usually occur with mild to moderate immunosuppression 
 Clinical, diagnostic features and management are similar to 
non-HIV infected patients  
o Autonomic neuropathy 
 Common in patients with advanced disease 
o PN associated with diffuse infiltrative lymphocytosis syndrome (DILS) 
 Uncommon  
 HIV-associated myopathies 
o HIV-associated Polymyositis 
 Can present at any stage 
 Clinical features vary from minimal weakness to debilitating 
weakness 
 Diagnosis and therapy is the same as in non-HIV infected 
patients 
o HIV wasting Syndrome 
 Significant in patients with advanced immunosuppression 
 Myalgia and proximal weakness are common 
 Initiation of HAART is associated with an improved survival 
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Vacuolar Myelopathy (VM) 
It is the commonest spinal cord pathology identified in the setting of HIV, typically occurring 
with advanced immunosuppression. Clinical myelopathy is uncommon, but the pathological 
findings consistent with the diagnosis are frequently described in autopsy studies. The 
influence of HAART on the occurrence of VM is poorly documented.  
The pathological hallmark of the disease is patchy vacuolation of the white matter affecting 
the dorsal and lateral columns.  
The clinical features which develop over weeks to months are: 
 Bilateral lower limb weakness and spasticity 
 Bladder, bowel and erectile dysfunction 
 Hyperactive deep tendon reflexes and an extensor plantar response 
 Unsteady gait 
 Variable sensory abnormalities 
VM and distal sensory polyneuropathy frequently occur in the same patient. This 
combination can lead to a mixed clinical picture where lower limb hyper-reflexia can be 
present in conjunction with absent ankle jerks and extensor plantar responses.  
The diagnosis is one of exclusion: 
 Serology 
o Serum vitamin B12 and copper levels should be normal 
o Syphilis and human T-lymphotrophic virus-1 (HTLV-1) negative 
 CSF analysis 
o Helps to exclude other infectious aetiologies 
 Magnetic Resonance Image (MRI) spine 
o Atrophy of the thoracic cord 
o Non-specific  hyper- intensities on T2 weighted images which do not 
enhance 
There is no specific therapy as HAART has not been proven to delay the progression or 
improve the underlying deficits in patients with VM. Symptomatic treatment of spasticity, 
urinary urgency and erectile dysfunction is advocated.    
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1.7.3 Secondary/  Opportunistic Neurological Syndromes 
 
Opportunistic Infections 
The epidemiology of neurological complications of HIV-infection has changed since the 
introduction of HAART. Opportunistic neurological diseases have decreased in the 
developed world. In developing nations opportunistic infections continue to be a significant 
cause of morbidity, even in patients on HAART. Tan et al, in 2012 reviewed HIV-associated 
opportunistic infections of the CNS: 
 
 Usually occur when the CD4 cell count is less than 200cells/µL 
 Diagnosis should be based on: 
o Clinical presentation 
o Temporal evolution 
o CSF features 
o Radiology findings 
 Multiple infections may be present and some may only be discovered after 
HAART is initiated 
 HAART should be started/ modified or continued in association with 
appropriate antimicrobial therapy 
 Prophylactic antimicrobial therapy may be required until immune recovery 
occurs (CD4 cell count greater than 200cells/µL 
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The incidence of opportunistic infections varies in different regions and is dependent on the 
underlying prevalence.  
 
Table 1.2 Regional Infections in HIV 
 
 Asia and Pacific regions 
o Cerebral toxoplasmosis 
o Cryptococcal meningitis 
o Japanese encephalitis B 
o Tubercuolous meningitis 
 Europe and North America 
o Cerebral toxoplasmosis 
o Cryptococcal meningitis 
o Progressive Multifocal Leukoencephalopathy 
 South America 
o Cerebral toxoplasmosis 
o Cryptococcal meningitis 
o Tubercuolous meningitis 
o Chagas Disease 
 Sub-Saharan Africa 
o Cryptococcal meningitis 
o Tubercuolous meningitis 
o Cytomegalovirus 
o Malaria 
   from Tan et al, HIV-associated opportunistic infections of the CNS, 2007 
 
The common opportunistic infections; especially those in SSA will be reviewed.   
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Tuberculosis (TB) of the Central Nervous System 
Nearly one third of the global population is infected with Mycobacterium tuberculosis. 
Disseminated forms of TB, including neurologic disease in tuberculosis occur more 
commonly in patients co-infected with HIV. The co-infection rates are highest in Sub-
Saharan Africa.  
The varied presentations include: 
 Tuberculous meningitis (TBM) 
 Focal Brain Lesions (FBLs) 
o Tuberculoma 
o TB abscess 
 Spinal TB 
o TB myeloradiculopathy 
o Tuberculoma 
 
The clinical features depend on the specific presentation.  
The features associated with TBM are: 
 Initially non-specific i.e. anorexia; headache; malaise; myalgia and pyrexia 
 Focal neurological deficits which can progress to an altered level of 
consciousness and later coma 
 Cranial nerve palsies which may be the initial presenting feature 
FBLs 
 The signs and symptoms depend on the location and include ataxia and 
movement disorders  
 Focal or generalized seizures can occur during any stage, including after 
therapy has been completed 
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Spinal TB 
 Features of cord compression including bladder and bowel dysfunction 
 Spinal or radicular hyperaesthesia; pain or paresthesiae 
 
Early diagnosis of neurological TB is crucial but can be difficult. The clinical features, 
especially in TBM are non-specific and the currently available diagnostic tests are either non-
specific or timeous.  
 The CSF features include: 
o Low glucose; lymphocytic pleocytosis and a raised protein 
o Positive Ziehl-Neesen stain, which has variable sensitivity 
Repeated large volume lumbar punctures (LPs) may improve the yield. 
The Mycobacterium tuberculosis and resistance to Rifampicin (Xpert 
MTB/RIF) assay can assist in both the diagnosis and the detection of drug 
resistance in CSF samples. The assay utilizes nucleic acid amplification 
technology (NAAT) which can decrease detection times and improve 
sensitivities 
 
 Neuro-imaging 
o In patients with TBM there may be basilar enhancement; 
hydrocephalus and infarcts in the basal ganglia or cortex 
o FBLs are usually associated with basal meningeal enhancement 
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The therapy is based on standard regimens: 
 A four drug regimen is given for 2 months: 
o Ethambutol; Isoniazid; Pyrazinamide and Rifampicin 
 A combination of Isoniazid and Rifampicin is given for a further 9-12 months   
The therapy for neurological multi-drug resistant TB (MDR-TB) is based on 
guidelines accepted for the treatment of pulmonary MDR-TB 
 Adjuvant corticosteroids may have a role but this has not been conclusively 
established in the setting of HIV 
 The optimal timing of HAART in patients with TB is dependent on the 
immune status of the patient as there is a risk of Immune Reconstitution 
Inflammatory Syndrome (IRIS).  
IRIS is higher in patients with advanced immune-suppression. Initiating HAART and TB 
medications simultaneously is not recommended. 
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Cryptococcal Meningitis (CM) 
Cryptoccus neoformans is the most common cause of meningitis in HIV-infected patients. In 
Sub-Saharan Africa it is the commonest cause identified in adult patients. The meningitis 
typically occurs in patients with advanced disease; (CD4 cell count is below 50cells/µl). The 
introduction of antiretroviral therapy and use of fluconazole has led to a decrease in the 
incidence of CM in the developed world.  
The clinical presentation is that of sub-acute meningitis and the symptoms include: 
 Fever; headache and malaise 
 Patients with elevated intracranial pressure can present with: 
o Symptoms of encephalopathy i.e. altered level of consciousness; 
lethargy; memory loss and personality changes  
o Focal signs including abducens nerve palsy and hearing loss; in 
patients with basilar meningitis there may be abnormalities of multiple 
cranial nerves 
The diagnosis is based on: 
 CSF examination:  
o The cell count; glucose and protein level may be normal 
o Detection of cryptococcal antigen which is both highly sensitive and 
specific 
o Culture of the organism remains the gold standard but can delay the 
diagnosis 
 Radiology 
o Not routinely available in resource poor settings 
o Either Computed Tomography (CT) or MRI scans of the brain are 
recommended prior to the performance of a LP in patients with focal 
deficits or clinical features suggestive of increased intracranial 
pressure 
NB! The serum cryptococcal antigen can be helpful as an initial screening tool, especially in 
patients initiating HAART. 
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The therapy of CM is multi-faceted and includes: 
 Antifungal therapy  
o Induction Phase  
 Amphotericin B and Flucytosine (if available) 
 Minimum period of two weeks  
o Consolidation Phase 
 Fluconazole 400mg orally for eight weeks 
o Maintenance Phase 
 Fluconazole 200mg orally until the patient is asymptomatic and 
the CD4 cell count is greater than 200cells/µl for a period of six 
months, whilst on HAART  
 
 Decreasing intracranial pressure if necessary 
o The opening CSF pressure should be recorded at the time of the 
diagnostic Lumbar puncture (LP) 
o The pressure should be decreased with daily LPs  
o A lumbar drain; ventricolostomy or ventriculoperitoneal shunt should 
be considered if the elevated pressure is not resolved with serial LPs  
 
 Improvement of immune function by the initiation or optimization of HAART 
o The timing of initiation should be delayed for 2-10 weeks until the 
CSF culture becomes negative 
 
 Management of IRIS, if necessary 
o IRIS is more common in HAART-naïve patients with high HIV RNA 
levels 
o Antifungal therapy and HAART need to be continued 
o Corticosteroids may be of value in severe cases 
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Malaria 
Infection is due to the parasitic protozoan organisms, genus Plasmosium. In HIV-infected 
patients malaria is a leading cause of morbidity especially in geographical regions where the 
two diseases overlap: 
 South America 
 Southeast Asia  
 Sub-Saharan Africa 
HIV infection increases both the risk and the severity of malaria infection. The prevalence of 
malaria increases as the CD4 count cell decreases. Increased burden of the parasite expedites 
malaria transmission. The malaria in turn is associated with CD4 cell activation and cytokine 
up regulation. The resultant milieu creates an ideal environment for the spread and 
transmission of HIV. Acute malarial infection is accompanied by an increase in the HIV 
burden and a decrease in the number of CD4 cells. These changes resume normalcy 
following successful treatment of malaria.  
The clinical features are similar to that in non HIV-infected patients but there is an increased 
prevalence of: 
 Anaemia 
 Severe malaria 
 Treatment failure 
 Malaria-attributable mortality 
Therapy is similar to that in HIV-uninfected patients but there may be a reactivation of drug-
resistant organisms. Follow-up is therefore imperative. 
In malaria-endemic areas: 
 Bed nets and prophylaxis with trimethoprim-sulfamethoxazole are 
recommended 
 Pregnant patients should receive monthly sulfadoxine-pyrimethamine 
during the pregnancy  
 HAART should be initiated/ optimized as it decreases the incidence 
of malaria 
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Cerebral Toxoplasmosis 
The incidence of neurological toxoplasmosis has decreased since the introduction of 
HAART, but it remains the commonest opportunistic neurological infection identified. 
Toxoplasma encephalitis (TE) is due to reactivation, rather than a primary infection. The 
incidence rates are dependent on the seroprevalence of toxoplasma gondii (T. gondii) in the 
general population.  
The risk factors include: 
 Degree of immunosuppression 
o The risk increases as the cell count falls below 100cells/µl 
 Use of prophylaxis  
o Bactrim is effective for prevention 
The neurological clinical features include: 
 Non-specific features 
o Headache; pyrexia; lethargy 
 Focal signs and symptoms 
o Ataxia; hemiparesis 
The diagnosis is usually based on a combination of: 
 Characteristic neuroimaging findings (MRI is more sensitive than CT) 
o Multiple ring-enhancing lesions with variable mass effect and oedama 
o Predilection for the basal ganglia and corticomedullary junction 
 Positive serologic test for Immunoglobulin G (IgG) antibodies to T gondii  
 Clinical and radiologic improvement following empiric therapy.  
 Polymerase Chain Reaction (PCR) of the CSF: 
o Highly specific but not very sensitive in detecting the parasite 
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Toxoplasma therapy requires a combination of antimicrobial therapy and HAART for 
immune recovery. The antimicrobial therapy is given in two phases: 
 Initial phase (6 weeks) 
o Treats the acute symptoms, a combination of sulfadiazine (or 
clindamycin), pyrimethamine and leukovorin 
o Corticosteroids may be indicated if there are features of severe raised 
intracranial pressure 
 Maintenance phase 
o Goal is to prevent relapse 
o Can be discontinued in asymptomatic patients with immune recovery 
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Cytomegalovirus (CMV) Encephalitis 
The virus is part of the herpes group and is endemic worldwide. The risk of severe 
neurological disease depends on: 
 CD4 cell count (<50 cells/µL) and/ or HIV RNA level (>100 000/mL) 
 Host genetic risk factors 
 Neurovirulence of the CMV strain 
 Previous CMV infection (IgG positive) 
The incidence of CMV infection and the associated mortality has decreased in regions where 
HAART is readily available. 
The spectrum of neurological presentations includes: 
 Encephalitis 
o Brainstem signs and symptoms 
o Hyponatraemia (adrenal disease) 
o Rapidly progressive encephalopathy 
o Seizures 
 Mononeuritis multiplex 
o Asymmetric, progressive, multi-focal 
o Motor symptoms are more prominent than sensory 
 Radiculomyelitis 
o Lumbosacral region usually affected 
o Rapidly progressive cauda equine syndrome (resembles Guillain-Barre 
Syndrome) 
 Retinitis 
o Can occur in patients with extra-ocular disease 
o Symptoms include central scotoma; floaters and loss of peripheral 
vision 
o Visual loss due to retinal necrosis 
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The diagnostic investigations performed depend on the specific clinical presentation and 
include: 
 CSF analysis 
o Neutrophil predominance and negative bacterial culture 
o PCR assay for CMV is highly sensitive and specific 
 It can be used to monitor the effectiveness of therapy 
 Fundoscopy 
o Haemorrhagic infarction 
o Perivascular sheathing 
o Retinal opacification 
 Neuroimaging 
o Contrast-enhanced and thickened nerve roots on MRI 
(Patients with radiculomyelitis)  
o Meningeal enhancement or periventricular inflammation 
 Biopsy 
o Useful to confirm the diagnosis but not routinely performed 
The response to specific anti-CMV therapy is unpredictable and is usually more effective if 
administered early during the course of the infection. 
 Induction Phase 
o Ganciclovir and Foscarnet should be administered intravenously until 
there is improvement (may take months) 
 Maintenance 
o Foscarnet intravenously and  Valganciclovir orally until immune 
recovery occurs 
HAART should be initiated within two weeks of starting anti-CMV therapy.  
The risk of the patients developing IRIS is a concern, especially as it can lead to blindness in 
patients with retinopathy and even death in rare instances  
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Progressive Multifocal Leukoencephalopathy (PML) 
The disorder is a progressive, demyelinating disease. It is caused by the ubiquitous John 
Cunningham virus (JCV), a human polyoma virus. The incidence has decreased following the 
introduction of HAART.  
The clinical presentation depends on the area of the brain that is affected. The disease should 
be suspected in patients with: 
 Focal signs and symptoms  
o Develop over weeks to months 
 Progressive dementia which may lead to coma and death 
 Low CD4 counts (less than 100 cells/µL); may be normal 
The diagnosis is based on: 
 Clinical presentation 
 CSF analysis 
o PCR assay for JCV has a high sensitivity and specificity; except in 
patients on HAART 
 Neuroimaging 
o MRI is more sensitive and shows hypo intensities on T1 images and 
hyper intensities on T2 images 
 Brain biopsy 
o The characteristic features are bizarre astrocytes; lipid-laden 
macrophages and myelin loss 
There is no definitive therapy but HAART can improve the clinical deficits and prolong 
survival and should therefore be initiated or augmented. 
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1.7.4 Opportunistic Malignancies of the Central Nervous System 
 
Primary CNS Lymphoma (PCNSL) 
This is a primary non-Hodgkins lymphoma that is limited to the CNS. The disease normally 
occurs in patients with advanced immune dysfunction i.e. CD4 cell counts less than 
50cells/µL. The incidence has decreased in regions where HAART use is widespread but the 
decline has not been as expected. The vast majority of cases are linked to infection with 
Epstein-Barr virus (EBV).  B cells that are infected with EBV undergo monoclonal 
proliferation in patients with severe immune dysfunction.  
The clinical presentation includes: 
 B symptoms  
o Nightsweats; unexplained pyrexia and weight loss 
 Focal and non-focal signs 
o Aphasia; confusion; headache; hemiparesis; memory loss and seizures 
The diagnosis is dependent on: 
 CSF analysis 
o Cytology  
o PCR assay for EBV has a high sensitivity and specificity 
 Neuroimaging 
o MRI is more sensitive 
o Lesions are irregular;  single and usually enhance with contrast, 
 Brain biopsy 
o Stereotactic biopsy is useful to establish a definitive diagnosis 
HAART confers a longer survival and should be initiated upon diagnosis of PCNSL.  High 
dose methotrexate and whole brain radiation have shown promising results in clinical trials.  
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1.7.5 Treatment Related Neurological Disease 
 
Antiretroviral toxic neuropathy 
 
In the pre-HAART era the distal symmetric polyneuropathy (HIV-DSP) was linked to severe 
immunosuppression. In developing regions peak HIV viral load and the nadir CD4 cell count 
are still risk factors for the development of the condition. In areas of widespread HAART 
availability HIV-DSP continues to be highly prevalent due to: 
 Chronic inflammation  
 Continued low levels of viral replication 
 Possible nerve damage secondary to immune reconstitution 
 Risk factors associated with an increased life expectancy 
o Drug-induced neurotoxicity (other medications including illicit drugs) 
o Co-morbid medical disorders e.g. diabetes mellitus 
 
The clinical features are typical of those commonly associated with a small fibre sensory 
neuropathy and include: 
 Absent ankle reflexes 
 Painless numbness or painful paresthesiae in the feet 
 Progressive symptoms over weeks to months 
 Symptoms confined to the lower limbs, below the knees 
 
 
The diagnosis is based on a combination of: 
 Clinical features 
 Electromyography and nerve conduction studies 
o May be normal 
 Skin biopsy 
o Can provide a definitive diagnosis 
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The therapy is two-fold: 
 Stop reverse transcriptase inhibitors which have been implicated 
o Didanosine; stavudine and zalcitabine 
 
 Symptomatic therapy for the pain 
o  Lamotrigine may be effective 
o Topical capsaicin and recombinant human nerve growth factor may be 
beneficial (limited evidence) 
o Traditional drugs used for neuropathic pain have not been proven to be 
useful in HIV-DSP e.g. amitriptyline; gabapentin and pregabalin 
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Immune Reconstitution Inflammatory Syndrome (IRIS) 
 
In this syndrome the patient undergoes clinical deterioration in the face of immune recovery. 
Neurological IRIS is an uncommon phenomenon in well-resourced regions. In resource-
limited regions it is more prevalent. The well identified risk factors are: 
 Rapid immune recovery, evidenced by a precipitous decrease in the viral load  
 Severe immunosuppression at HAART initiation, reflected by a low nadir 
CD4 cell count 
 Underlying opportunistic infections 
Genetic factors may also influence the development of IRIS: 
 Cytokine polymorphisms 
 Expression of pro-inflammatory cytokines e.g. IL 6 
 
The clinical syndromes associated with the diagnosis of IRIS are not uniform. There are 
numerous clinical, immunologic and radiologic features which are encompassed by the 
diagnosis of IRIS. The specific presentation depends on the underlying opportunistic 
infection. The organisms commonly associated with IRIS include:  
 Bacterial pathogens  
o Mycobacterium tuberculosis 
 Neurological IRIS occurs later than IRIS in other organs 
 Clinical deterioration may be due to: 
 Development/ recrudescence of TBM 
 Expansion of intracranial tuberculomas 
 Fungal pathogens 
o Cryptococcus neoformans 
 Most significant fungal pathogen in CNS-IRIS 
 Occurs 3 to 20 months after initiation of HAART 
 Clinical features are non-specific and the condition may be 
difficult to diagnose 
 Consider if: 
 CSF shows sterile inflammation and organism is not 
cultured 
 New enhancement becomes evident on neuroimaging 
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 Parasitic pathogens  
o Toxoplasma gondii 
 Commonly presents as an encephalitis 
 Viral pathogens 
o Herpes viruses 
 Varicella Zoster Virus 
 Can present as a painful dermatomal rash; 
encephalitis; transverse myelitis or a vasculitis which 
can cause cerebral infarcts 
 Cytomegalovirus 
 Typical presentation in IRIS is that of a retinopathy 
o JC Virus 
 Usually develops 4 to 8 weeks after the initiation of HAART 
 Diagnosis is difficult 
 The prognosis is poor and mortality is high 
 
There is no single therapeutic regimen to manage CNS-IRIS. Prevention, which requires 
early initiation of HAART, is the best option. There are certain guidelines which can assist in 
the optimum management of IRIS: 
 Delaying the initiation of HAART by 1 month in patients with diagnosed 
opportunistic infections 
 Immunomodulatory therapy 
o High dose steroids are indicated when there is a risk of herniation, due 
to inflammation 
o The use of steroids in other scenarios  is controversial  
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Toxic Myopathy  
This condition was initially recognized following the introduction of azidothymidine (AZT). 
Numerous other anti-retrovirals have subsequently been associated with the disease and 
include didanosine; etravarine; raltegravir and tenofovir.   
The clinical features are non-specific: 
 Hip and shoulder girdle weakness 
 Mildly elevated creatine kinase (CK) levels 
The diagnosis can be confirmed by: 
 Blood levels for CK 
 Electrophysiology (non-specific) 
 Muscle biopsy 
o Abnormal mitochondria 
o Ragged red fibres  
The symptoms tend to improve following withdrawal of the offending drug.  
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1.8 Epilepsy 
1.8.1 Definitions 
Epileptic seizures are defined as a “transient occurrence of signs and or symptoms due to 
abnormal, excessive or synchronous neuronal activity in the brain”. Seizure activities include: 
 Alterations in level of consciousness 
 Involuntary autonomic; motor; psychic or sensory events  
Seizure activity usually lasts only a few seconds to minutes. Seizures can occur in anyone if 
the appropriate pathophysiological conditions exist.  
Seizures due to acute and transient conditions have been described as provoked or acute 
symptomatic epileptic seizures. 
Epilepsy refers to the condition in which a persistent alteration of brain function leads to a 
risk of recurrent epileptic seizures. Not everyone who has had a seizure has epilepsy. 
Epilepsy is not a single disease; it refers to a group of disorders that reflect underlying brain 
abnormalities secondary to a variety of causes.  
 
1.8.2 New onset versus newly diagnosed  
The time from onset to diagnosis may vary significantly and is dependent on many factors 
including: 
 Access to medical facilities 
 Seizure type 
 Socio-economic background 
The extent of the incidence of new onset epilepsy and the incidence of newly diagnosed 
epilepsy may fluctuate. In new onset epilepsy the numerator comprises patients identified at 
their second unprovoked seizure. Newly diagnosed epilepsy includes both new onset epilepsy 
and people with more than two unprovoked seizures (initial diagnosis occurs during the study 
period, Beghi et al, 2010)
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1.8.3 Classification of Seizures 
The pathogenesis of seizures and epilepsy are currently better understood due to improved 
techniques in neuroimaging, genetics and molecular biology. The International League 
Against Epilepsy (ILAE) Commission on Classification and Terminology has accordingly 
revised the seizure and epilepsy classification systems (Berg et al, 2010).The clinically 
significant classifications are based on the mode of seizure onset and underlying aetiology. 
 Generalized  
o The seizures may originate at a specific locus but rapidly involve bilateral 
networks. The seizures can be asymmetric.  
o Cortical and subcortical structures may be involved.  
o The onset may appear focal but the origin and lateralization are not consistent 
with subsequent seizures.  
 Focal 
o The seizures originate within the networks of one hemisphere.  
o They can begin in subcortical structures.  
o The onset of seizures is consistent in subsequent events.  
 Unclassified 
o Seizures that cannot be categorised are referred to as unclassified.   
o New information may lead to accurate diagnosis at a later stage.  
 Genetic 
o In these patients the epilepsy is directly attributable to known or presumed 
genetic defects with resultant seizures 
 Structural or metabolic  
o Specific structural and metabolic disorders carry an increased propensity for 
epilepsy.  
o The disorder may be either congenital (e.g. cortical dysplasia) or acquired (e.g. 
stroke).  
 Unknown  
o The underlying cause in these patients is not currently known.  
o All types of epilepsies with normal imaging and no documented genetic, 
metabolic or immune etiology are included in this category. 
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CHAPTER TWO 
LITERATURE  REVIEW 
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2.1 New onset seizures (NOS) in HIV infected Individuals 
2.1.1 Introduction 
New onset seizures have been well documented in HIV infected individuals. The first 
comprehensive description of the neurological complications of AIDS by Levy, Bredesen  
and Rosenblum in 1985 included two patients with presumed sub-acute encephalitis in who 
the only clinical feature identified was seizures. Holtzman , Kaku  and So in 1989 published 
the first study looking specifically at new onset seizures in HIV. Multiple studies since then 
have described the occurrence. The study by Kellinghaus et al, published in 2008 was 
conducted in the HAART era.   
In some individuals seizures may be the initial presenting symptom signalling an underlying 
neurological disorder.  Seizures occur at any stage of the disease. They have been described 
during the sero-conversion stage, but they occur with greater frequency in patients with 
advanced disease. In the majority of patients a definitive cause can be found for the seizure 
occurrence. The most common causes can be divided into five categories: 
 Focal Brain Lesions (FBLs) 
 HIV-Associated Neurocognitive Disorder (HAND) 
 Meningitis 
 Metabolic Dysfunction 
 No Identifiable Cause (NIC) 
The patients in whom no cause has been identified account for up to 46% of patients 
presenting with NOS (Wong; Suite and Labarl, 1990). The interest in this group lies in the 
fact that there is no data on their course and outcome. The seizures may be a forerunner of 
established causes or it may denote a primary manifestation of the HIV itself. 
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The seizure patterns described include focal; focal with secondary generalization and 
generalized seizures. In the studies published to date generalized seizures predominate. The 
presence of focal seizures does not necessarily imply an underlying focal lesion. Status 
epilepticus has been documented in up to one fifth of patients. The significance of 
electroencephalographic (EEG) abnormalities is uncertain as non-specific abnormalities have 
been documented in asymptomatic HIV-infected people.  
The use of anti-epileptic drugs (AEDs) for a prolonged period is recommended except when 
the seizure can be attributed to a reversible metabolic cause. The concurrent use of enzyme 
inducing AEDs and HAART can lead to significant drug interactions.    
 
 
2.1.2 Incidence  
The published data on seizures in HIV-infected patients is largely derived from retrospective, 
hospital based studies that were done prior to the availability of HAART (see Table 2.1 page 
51). The incidence amongst HIV-infected patients ranged from 2-20%. In the 2005 study by 
Sinha et al, 20% of patients presented with NOS. This study was conducted at a specialist 
neurology referral centre with a resultant selection bias. In the most recent study, Kellinghaus 
et al, 2008 identified new onset seizures in 6% of their HIV infected patients, the majority of 
who were on HAART. This figure is probably an accurate reflection of the frequency of 
seizures in developed countries where HAART is widely accessed. The information available 
from developing countries is limited, especially in the current age of increasing availability of 
anti-retroviral therapy. 
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Table 2.1 Summary of Studies on New Onset Seizures in HIV 
 
 
Holtzman 
et al 
Wong 
et al 
Van 
Paeschen 
et al 
Dore et 
al 
Pesola 
et al 
Pascual 
et al 
Chadha 
et al 
Modi 
et al 
Sinhaet 
al 
Kellinghaus 
et al 
Country USA USA USA Australia USA SPAIN INDIA 
South 
Africa 
INDIA GERMANY 
Year 1989 1990 1995 1996 1998 1999 2000 2000 2005 2008 
Study 
Design 
RS RS RS RS RS PS PS PS RS RS 
Sample 
Size 
5604 630 1574 519 N/A 550 455 N/A 500 831 
No with 
NOS (%) 
100 
(2) 
70 
(11) 
68 
(4) 
50 
(10) 
26 
17 
(3) 
23 
(5) 
60 
99 
(20) 
51 
(6) 
Seizure 
Type(%) 
 
GTC 65 80 63 84 100 71 65 62 63 78 
Focal 35 20 19 10 0 11 35 28 34 22 
SE  14 18 0 0 19 0 10 8 0 
Aetiology(%)  
FBL 32 33 37 30 35 35 48 53 48 40 
Toxo 28 16 12 22 19 29 30 2 23 14 
TB 0 0 0 0 0 0 13 28 N/A 0 
PML 1 0 0 6 8 6 4 0 1 14 
PCNSL 4 11 0 2 4 0 0 0 1 0 
Other 0 6 25 0 4 0 0 23 0 0 
Meningitis 16 10 12 14 12 0 17 22 N/A N/A 
CM 13 10 4 8 4 0 N/A 7 41 N/A 
TBM 0 0 1 0 0 0 N/A 8 N/A N/A 
Other 3 0 7 6 8 0 N/A 7 N/A N/A 
HIVE/ HAD 24 7 2 16 31 0 4 N/A 5 22 
Metabolic 3 11 N/A N/A 15 12 0 0 N/A N/A 
NIC 23 46 44 42 27 6 0 25 N/A 49 
Px on 
HAART(%) 
0 0 0 0 0 0 0 0 0 84 
 
Legend 
RS=Retrospective; PS=Prospective; N/A=Not Available; SE= Status Epilepticus  
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2.1.3 Aetiology 
The causes for seizures in HIV-infected individuals can be categorized into five main groups:  
 Focal brain lesions (FBLs) 
o Infections 
o Toxoplasma encephalitis (TE) 
o Tuberculomas 
o Progressive multifocal leukoencehalopathy (PML) 
 Neoplasms  
o Primary CNS Lymphoma (PCNSL) 
 Meningitis 
o Cryptococcal Meningitis (CM) 
o Tuberculous Meningitis (TBM) 
 HIV-associated Neurocognitive Disorder (HAND)  
 Metabolic Abnormalities  
 No Identifiable Cause (NIC)                                                                                
There is a significant disparity in aetiologies between cohorts from developed and developing 
countries. Infectious diseases occur more commonly in developing regions.  
53 
 
Focal Brain Lesions 
The characteristics of the four most common causes of FBLs are detailed below. 
 
Toxoplasmosis 
Seizures are a well-recognized clinical manifestation in patients with TE and are a common 
early presentation. In the pre-HAART era toxoplasmosis was the commonest cause of HIV-
associated FBLs and responsible for up to 30% of NOS in the pre-HAART era (see Table 2.1 
page 51). Cerebral toxoplasmosis has decreased in incidence in developed countries since 
HAART has become commonplace, it remains however the commonest opportunistic 
infection of the CNS. In developing countries the decrease has not been as significant, 
possibly due to low nadir CD4 counts. The incidence of toxoplasmosis in HIV-infected 
patients is closely aligned to the CD4 cell count. In the recent study by Kellinghaus et al, 
2008 toxoplasmosis accounted for 14% of patients with NOS.  
 
Tuberculomas 
Tuberculomas as a cause of NOS were only described in studies from developing countries 
(India and South Africa).  In the 2000 study by Modi et al, the FBLs were more commonly 
due to TB than toxoplasmosis, an indication of the underlying disease prevalence. South 
Africa has the highest prevalence of TB in the world (Churchyard et al, 2014).  
In developing countries HIV infected patients with focal seizures and tuberculous abscesses 
have been described. The abscesses can present as FBLs.  They are usually solitary lesions, 
which are larger and progress more swiftly than tuberculomas. The abscess cavity contains 
pus and culture may yield M. tuberculosis. Surgical drainage of the pus improves the long 
term prognosis.   
  
54 
 
Progressive Multi-focal leukoencephalopathy (PML)  
Seizures occur in approximately one tenth of patients and occur early during the course of the 
disease. Focal and generalized seizures have been described. The pathogenesis of seizures in 
PML, a white matter disease is complex and includes: 
 Presence of lesions adjacent to the cortex, which act as excitatory foci 
 Cortical lesions have also been described 
  Axonal conduction abnormalities 
 Disturbances in neuron-glia balance 
PML has been implicated in patients presenting with new onset seizures (NOS) in up to 14% 
of patients. The Kellinghaus study, 2008 conducted in the HAART-era had the highest 
proportion of patients with PML.  It is possible that PML in some patients was a clinical 
presentation of IRIS.  
 
Primary CNS Lymphoma (PCNSL) 
This is the commonest neurological malignancy in the setting of HIV. The incidence has 
declined since HAART has become readily available.  It occurs in up to 11% of patients (see 
Table 2.1 page 51) presenting with NOS and is more common in patients with advanced 
disease. Epstein-Barr virus is implicated in almost all cases of PCNSL.  In HIV infected 
patients with PCNSL seizures occur in approximately one third of patients.  
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Table 2.2 Characteristics of FBLs 
 
 Toxoplasmosis TB PML PCNSL 
CD4 count 
(cells/ µL) 
<200 Variable <100 <100 
Other Findings 
IgG antibodies in 
serum 
and urine to T. Gondii 
 
Evidence of pulmonary 
or non-neurological TB 
  
CSF 
Characteristics 
    
Glucose Normal/ decreased Normal/ decreased Normal Normal 
Protein Normal/ increased Increased 
Normal/ 
increased 
Normal 
White cell count 
Normal/ increased 
lymphocytes 
Increased lymphocytes Normal 
Normal/ increased 
lymphocytes 
Other Findings T. gondii PCR 
Microscopy for AFBs 
Culture for 
Mycobacterium 
Tuberculosis 
NAAT 
JC Virus PCR EBV PCR 
Neuroimaging     
Lesion numbers Usually multiple Solitary/ multiple 
Solitary/ 
multiple 
Solitary/ multiple 
Common  locations 
Basal ganglia; frontal 
and parietal 
Basal ganglia; 
brainstem; 
cerebellum and 
cerebral 
hemispheres 
 
Brainstem; 
cerebellum 
and 
subcortical 
white 
matter 
Corpus callosum; 
periepndymal, 
periventricular and 
temporal 
Enhancement Ring-enhancing 
Basal meningeal and 
ring-enhancement 
Bright rim may be seen 
on MRI pre-contrast 
Occurs in 
25% 
(↑ in IRIS) 
Common, 
heterogenous 
enhancement 
Other Findings 
Usually 1-2cm 
Mass effect 
Hydrocephalus if 
lesion causes 
obstruction 
Mass effect 
Cortical 
ribbon sparing 
Usually >3cm 
Adapted from Tan et al, 2012 
Legend: AFB = Acid Fast Bacilli 
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Meningitis 
Meningitis is an important cause of NOS in HIV-infected individuals. The incidence is higher 
in cohorts from developing regions.  
Cryptoccal Meningitis (CM) 
Cryptococcal neoformans is responsible for most of the cryptococcal infections in HIV 
infected individuals. The majority of patients with meningitis have an associated systemic 
cryptococcal infection.  The incidence of CM has decreased in the western world following 
the introduction of HAART. CM remains a significant problem in resource-limited countries 
where HIV prevalence is high and access to healthcare is limited. Most cryptococcal 
meningitis cases occur in sub-Saharan Africa where it is one of the leading causes of death. 
Seizures are more frequent in patients from Africa. This probably reflects delayed 
presentation in the region (Antinori, 2013).  In studies from developing regions it is a notable 
cause of NOS. In the 2005 study by Sinha et al, 41% of patients with NOS had underlying 
CM. The occurrence of CM in the study by Kellinghaus et al, 2008 is unfortunately not 
documented.  
 
Tuberculous Meningitis (TBM) 
The organism associated with meningitis is typically Mycobacterium tuberculosis. 
Tuberculous meningitis (TBM) is not a common cause of NOS except in regions of high TB 
prevalence (see Table 2.1 page 51). In the South African study by Modi et al, 2000 it was 
slightly more common than CM and accounted for 8% of all patients presenting with NOS.  
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Table 2.3 Characteristics of CM and TBM 
 
 
 CM TBM 
CD4 count 
(cells/ µL) 
<100 Variable 
Other Findings Evidence of systemic infection 
Evidence of pulmonary 
or non-neurological TB 
CSF 
Characteristics 
 
Glucose Normal/ Decreased Decreased 
Protein Normal/ Increased Normal/ Increased 
White cell count 
Normal/ Increased 
lymphocytes 
Increased lymphocytes 
Other Findings 
Opening pressures ↑ 
Cryptococcal Antigen is sensitive and 
specific 
Microscopy for AFBs 
Culture for Mycobacterium 
Tuberculosis 
NAAT 
Neuroimaging  
Lesion numbers Usually multiple Ill-defined exudates 
Common  locations Basal ganglia Not applicable 
Enhancement 
Leptomeningeal, especially in patients 
with IRIS 
Basilar enhancement 
 
Other Findings 
Communicating hydrocephalus with 
↑intra-cranial pressure 
Punched-out cystic lesions 
Hydrocephalus possible 
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HIV-associated Neurocognitive Disorder (HAND) 
 
There are three stages of neurocognitive impairment recognized: 
 Asymptomatic Neurocognitive Impairment (ANI) 
 Mild Neurocognitive disorder (MND) 
 HIV-associated Dementia (HAD) 
Seizures are well described in patients with HAD (see Table 2.1 page 51). The nomenclature 
describing neurocognitive dysfunction has undergone numerous changes. The number of 
patients presenting with NOS due to this is difficult to fully elucidate. In the first study of 
NOS by Holtzman , Kaku  and So in 1989 almost a quarter of their patients were believed to 
have neurocognitive dysfunction, accounting for their seizures. Kellinghaus et al, 2008 found 
neurocognitive dysfunction in one fifth. This was unexpected as the majority of their patients 
were on anti-retroviral therapy. HAND was not a significant cause in the studies from 
developing countries (India and South Africa). The condition may have been under-
diagnosed in their resource limited settings in the early days. 
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Metabolic Disorders 
The prevalence of metabolic disorders amongst patients with NOS varies from none recorded 
to 15% (see Table 2.1 page 51). The 1996 study by Dore, Law and Brew was the only case-
controlled study and they found that metabolic abnormalities occurred with the same 
frequency in HIV-infected patients with and without seizures. The study by Van Paesschen, 
Bodian and Maker in 1995 included very ill patients. In their cohort renal failure and 
hypomagnesemia were found to be risk factors for NOS, especially status epilepticus. Drug 
toxicity has been implicated in up to half of patients with NOS. In the small study (17 
patients) of Pascual-Sedano et al, 1999 8 (47%) patients had a drug-related cause. The drugs 
implicated include the anti-viral foscarnet sodium and illicit drugs like cocaine and heroin.  
 
No Identifiable Cause (NIC) 
See section 2.2 page 63 for details 
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2.1.4 Seizure Patterns  
Focal; generalized; secondary generalized; epilepsy partialis continuum and status epilepticus 
have been well documented in HIV-infected individuals. Generalized seizures occur most 
commonly in all the major studies to date (see Table 2.1 page 51). Pesola and Westfal, 1998 
only recruited patients with generalized seizures. Secondary generalized seizures may be 
under-reported as generalization may occur rapidly and eyewitness reports may be inaccurate.  
Presentation with focal seizures was not necessarily indicative of an underlying focal lesion 
in the majority of studies.  Diffuse neurological disease as in HAD can cause focal seizures.  
In a small study of seventeen patients Pascual-Sedono et al, 1999 documented status 
epilepticus in 19% of patients. In 1995 Van Paesschen, Bodian  and Maker diagnosed status 
epilepticus in 18% of their patients. The authors postulated that in HIV-infected patients’ 
renal failure and hypomagnesaemia may be risk factors for the development of status 
epilepticus. Lee, Garcia and Alldredge, 2005 looked specifically at 42 HIV-infected patients 
with status epilepticus. The majority of their patients had advanced disease.  Opportunistic 
neurological disease (infections and malignancies) were identified in half their patients.  
There have been isolated reports of epilepsy partialis continua in the setting of HIV.  
 
2.1.5 EEG Changes 
Non-specific EEG abnormalities, the most common of which is generalized slowing have 
been documented in new onset seizures associated with HIV infection (Holtzman et al, 1989; 
Wong et al, 1990 and Kellinghaus et al, 2008). The significance of these findings is not 
readily apparent as similar findings have been reported in asymptomatic HIV-infected 
individuals.  Epileptiform discharges are an uncommon finding and in the recent study by 
Kellinghaus et al, 2008 only one patient had epileptiform discharges. Similar findings were 
reported by Wong et al, 1990 and Chadha et al, 2000. The only study in which epileptiform 
discharges were detected in the majority of patients was by Modi et al in 2000. Normal 
readings have been documented in 20-60% of patients with documented seizures (see table 
2.1 page 51). EEGs are an insensitive tool in the diagnosis of new onset seizures associated 
with HIV infection (Holtzman et al, 1989; Wong et al, 1990 and Kellinghaus et al, 2008). 
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2.1.6 Anti-Epileptic Drug (AED) Use 
The International League Against Epilepsy (ILAE) and American Academy of Neurology 
(AAN) issued guidelines in 2012 for antiepileptic drug selection in people with HIV/ AIDS 
(Birbeck et al, 2012). 
They concluded that it may be important to avoid enzyme-inducing AEDs in patients on 
HAART regimens that included protease inhibitors (PIs) or nonnucleoside reverse 
transcriptase inhibitors (NNRTIs). Drug interactions in these patients could lead to virologic 
failure. The efficacy of the HAART regimen needs to be closely monitored if patients require 
enzyme-inducing AEDs for optimum seizure control.   
Acute seizure management in HIV-infected individuals is not different to that in non-HIV 
infected individuals. Normal protocols should be adhered to and the foremost requirement is 
termination of the seizure.  
The drug levetiracetam has been recommended for use in HIV
-
infected individuals.  
Levetiracetam has: 
 A broad spectrum of activity  
 Favorable side-effect profile  
 Minimal drug interactions  
Unfortunately the drug is not widely available in resource-limited settings. Valproic acid is 
recommended in these instances. Valproic acid does not cause enzyme-induced virologic 
failure but there are other well recognized side effects with this drug. There has been 
evidence to indicate that dose adjustments may be required in patients on lopinavir/ritonavir 
and zidovudine.   
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2.1.7 Conclusion 
The studies reviewed indicate that NOS are a significant occurrence in HIV-infected 
individuals both in South Africa and internationally. The risk is higher in patients with 
advanced disease. Important etiologies include: 
 Focal brain lesions 
 Meningitis 
 HIV-associated Neurocognitive Disorder 
 Metabolic abnormalities and  
 No Identifiable Cause  
The majority of studies delineating NOS were done in the pre-HAART era. The only 
significant study done in the HAART-era was published in 2008 by Kellinghaus et al. It was 
based in Germany, a developed country where HAART is readily available and accessible. 
Data from developing regions in the current era of increasing HAART availability is 
deficient. 
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2.2 New onset seizures in HIV infected Individuals with 
No Identifiable Cause 
 
2.2.1 Incidence  
Up to half of patients presenting with NOS have no identifiable cause for their seizures. In 
the 1989 study by Holtzman , Kaku  and So,  23 patients (23%) had NIC for their seizures, 
despite extensive investigations being performed. The mean follow-up period for these 
patients was 6.5 months. During this period none of the patients developed an obvious cause 
for their seizures. Three patients subsequently developed dementia. It is possible that HIV 
encephalopathy, as it was known at that stage was underdiagnosed initially. The authors 
inferred that seizures may be a symptom of primary CNS involvement in HIV.  Wong, Suite 
and Labar did a similar study in 1990 and found NIC in 32 patients (46%). They performed 
autopsies in 7 of their patients in whom there was no readily apparent cause. The histological 
findings in these patients were typical of HIV encephalitis i.e. microglial nodules; 
multinucleated cells and inclusion-bearing cells. A significant finding in their study was that 
their CT scans were both sensitive (90%) and specific (100%) in the detection of FBLs. They 
reached a similar conclusion to Holtzman et al i.e. HIV infection of the brain was the most 
likely cause for seizures in the group with NIC.  In the 1996 study by Dore, Law and Brew 
42% of the patients had NIC. This may be an inflated figure as 18% were on the anti-viral 
Foscarnet, which has been reported to cause seizures (AIDS Research Group, 1995). Pascual-
Sedano et al, 1999 had only 1 patient (6%) in whom they did not identify a cause for the 
seizures. A significant proportion of their patients (47%) had toxic-metabolic causes 
identified but as mentioned above the significance of metabolic abnormalities is uncertain.  
The 2002 study by Modi et al looked specifically at a cohort of 15 patients in whom there 
was NIC.  The majority of their patients had advanced disease.  None of their patients were 
on HAART.  A significant finding in their patients was an absence of white matter lesions 
(WML) on MRI scans, a common finding in patients with HAD.  
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Their patients had focal hypoperfusion defects on Technetium Exametazime 
hexamethylpropyleneamine oxime (
99m
Tc-HMPAO) Single-photon emission computed 
tomography (SPECT) scans. The authors postulated that the SPECT abnormalities were 
indicative of either a focal metabolic encephalopathy or an encephalopathy due to HIV 
infection.   
Kellinghaus et al, 2008 found no apparent cause in almost half their patients. The significant 
drawbacks in this study were the lack of CSF analysis as a routine in the patients evaluated 
and the lack of imaging in some individuals. The unavailability of these investigations may 
account for the high frequency of patients in who no cause was readily identifiable.   
 
2.2.2 Pathogenesis 
Primary HIV infection probably has a role in the pathogenesis of epilepsy in this sub-group 
An autopsy study in 1986 by Navia, Jordan and Price described nine patients with new-onset 
seizures in whom the autopsies did not reveal any opportunistic disease. The authors 
concluded that direct infection of the brain by HIV was responsible for the seizures. Their 
findings are supported by the autopsy findings of findings of Wong, Suite and Labar,1990 
who performed autopsies on seventeen HIV-infected patients with NOS in whom no cause 
had been identified. In six of their patients the pathology was consistent with primary HIV 
infection.  There are many processes believed to contribute to the development of seizures: 
 HIV-mediated neuronal cell death 
 Neurotoxic substances 
o Cytokines 
o Eicosanoids 
o Free radicals 
These substances enhance glutamate availability and activate voltage-gated calcium channels 
and N-methyl-D-aspartate (NMDA) receptors. 
It is likely that the underlying process causing seizures is similar to that causing HIV-
associated Dementia. 
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2.2.3 SPECT scans in HIV Neurology 
 
SPECT scans qualitatively estimate regional cerebral blood flow (rCBF). The technique of 
brain perfusion imaging with SPECT has contributed to the understanding of the 
pathophysiology of disorders in both neurology and psychiatry (Nicola’s et al 1993; Catafau 
et al 1994; Parellada et al 1998 and Catafau et al 1999). The SPECT scan offers the ability to 
detect regional cerebral blood flow in both the normal and the abnormal brain. The normal 
perfusion in the brain of an adult individual shows bilaterally symmetrical tracer distribution. 
Usually there is higher activity in temporal, parietal, and occipital regions/ cortices, basal 
ganglia, thalami, and cingulate gyrus (Camargo, 2001). Abnormal findings include focal or 
regional areas of either decreased or increased tracer uptake. The tracer HMPAO has few 
side-effects (Henderson, 2012).    
 
Brain SPECT scans have long been used to study HIV infected individuals. Perfusion defects 
have been well described in patients with HIV-related neurocognitive dysfunction (Holman et 
al, 1992 and Sacktor et al 1995{a}). It has been suggested that the number of perfusion 
defects may correspond to the severity of the dysfunction (Pohl et al, 1988 and Ajmani et al, 
1991). Pohl et al studied 12 HIV infected individuals with varying degrees of neurocognitive 
dysfunction. The SPECT scans in most of their patients were abnormal. They did follow-up 
scans in some patients which revealed increased numbers of defects, equivalent to the 
increase in clinical symptoms. The sites most commonly affected are the frontal; parietal; 
temporal and thalamic regions (Maini et al, in 1990; Schwartz et al, 1994 and Kramer and 
Sanger, 1990).   
There has been some evidence to suggest that perfusion abnormalities on SPECT may 
precede the clinical features of dementia in HIV-infected individuals (Schielke et al, 1990 
and Sacktor et al 1995{b}). A technical sub-committee of the AAN concluded, that SPECT 
scans could be used in the early diagnosis of HIV encephalopathy (Assessment of Brain 
SPECT. Report of the Therapeutics and Technology Assessment Subcommittee of the 
American Academy of Neurology, 1996).
 
 In 2009 the European Association of Nuclear 
Medicine Neuroimaging Committee also suggested that SPECT scans were useful in the 
diagnosis of HIV encephalopathy (Kapucu et al, 2009).  
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The study by Modi et al, in 2002 specifically studied the SPECT scans in HIV infected 
individuals presenting with NOS. They performed SPECT scans on 15 HAART-naïve 
patients with NOS. None of their patients had evidence of any other neurological disease or 
clinical features suggestive of a dementia. The patients were extensively investigated 
including CSF evaluations and MRI scans all of which were normal. The only consistent 
abnormality in their patients was the presence of temporal lobe perfusion defects on SPECT 
scans. On the basis of their SPECT results, the authors postulated that there was a causal 
relationship between cerebral infection and the HIV itself. They believed that the infection 
could be accounting for the abnormalities documented on the SPECT scans and therefore the 
epilepsy itself. 
 
2.2.4 Quantification of SPECT scans 
The use of visual evaluation of SPECT images on its own may be limited in the assessment 
of subtle variations in regional perfusion. This is the main indication for the use of 
quantification in clinical research (Catafau, 2001).The quantification of the ratios of tracer 
uptake in different regions of the brain assists in the estimation of the relative rCBF 
distribution within the brain. Regional counts can be obtained from the average counts per 
pixel of regions of interest (ROIs) drawn and placed on different cerebral areas. Ratios are 
obtained by comparing the regional count to a specific region which is presumed to be 
uninvolved in the pathological process e.g. the cerebellum. The left-to-right ratio of the same 
cerebral region or asymmetry indices are used to enhance left/right rCBF differences (Catafau 
et al, 1996). The process is simple but labour-intensive and lengthy if a high number of ROIs 
and ratios is to be generated. There can be complications relating to ROI design and selection 
of an appropriate reference region. Geometric or regular ROIs can be generated and placed 
on specific cerebral territories or they can be created to fit anatomic structures (irregular 
ROIs). They can also be created to fit particular cerebrovascular territories. However, 
drawing the same ROIs and placing them in exactly the same cerebral areas is a time-
consuming process and requires special dedication. Results may not be accurate if the process 
is not carefully adhered to. The selection of the reference region is decisive in the 
determination of region-to-reference uptake ratios. The differences in ratios and the 
generation of the ROIs usually vary. In the search for more standardized and objective 
alternatives for brain perfusion SPECT quantification, circumferential profiles and polar 
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maps have been proposed with limited success (Spreafico et al, 1988; Ichise et al, 1995). 
Software programs have been developed to allow statistical comparison of different groups of 
subjects.  These automated assessments of the perfusion defects improve the consistency of 
image interpretation (Van Laere et al, 2002). Quantification has been shown to be accurate 
with minimal errors in the clinical setting (Ritt et al, 2011). Bailey and Willowson in 2013 
reported that quantification was accurate within 5% of the true radionuclide concentration.  
The study by Tran Dinh et al, 1990 assessed the disturbances in the cerebral perfusion of 18 
asymptomatic HIV-positive individuals compared to 9 control subjects. They used 
quantitative SPECT measurements to detect changes in cerebral blood flow. The majority of 
their patients (16) had areas of hypo perfusion compared to the controls. The regions affected 
were: 
 Frontal     77% 
 Cerebellum, Thalamus, Occipital 61% 
 Temporal    55% 
 Parietal    44%    
They concluded that quantitative measurement of cerebral blood flow can be used to detect 
early changes in neurologically asymptomatic HIV infected individuals.   
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2.3 Study Objectives 
The aims of the current study were to document the current Profile of South African Patients 
with New Onset Seizures and to complete a longitudinal evaluation of the group of HIV-
infected patients with NOS where at the outset and at initial evaluation no cause is found. The 
profile of NOS in South Africa has not been documented in the current era of an anti-
retroviral treatment program. There are no longitudinal studies and no published data 
evaluating patients with NIC. All studies to date are cross-sectional. 
The study will: 
 Profile HIV-infected patients presenting with NOS in South Africa. 
 Attempt to address the important question of the significance of the presence 
of NIC in some HIV-infected individuals  
The patients with NOS who have NIC at the outset will presumably follow 
one of the following courses: 
o Remain without a cause i.e. The epilepsy is a primary HIV-related 
manifestation 
o Develop an HIV-related neurological illness e.g. intra-cranial mass 
lesion; meningitis 
o Develop HIV-associated dementia  
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CHAPTER THREE 
New Onset Seizures in HIV Infected Individuals;  
Current Profile Of South African Patients   
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3.1 Methods 
 
3.1.1 Study Design 
Cross-sectional; descriptive-analytic study.  
The protocol was granted approval by the Human Research Ethics Committee (Medical), 
University of the Witwatersrand, Johannesburg. (Appendix C).  
Patients were recruited over an eighteen month period i.e. January 2013 to June 2014.  
3.1.2 Study Population 
All individuals presenting with new onset seizures at the following sites: 
 Charlotte Maxeke Johannesburg Academic Hospital, Parktown, Johannesburg, 
Gauteng 
 Chris Hani Baragwanath Academic Hospital, Soweto, Johannesburg, Gauteng 
 Helen Joseph Hospital, Auckland Park, Johannesburg, Gauteng 
The three hospitals are tertiary-level public sector referral hospitals, affiliated to the 
University of the Witwatersrand.  
 
3.1.3 Study Criteria 
Inclusion 
 New onset seizures diagnosed clinically at admission; at the neurology out-
patient department or via the neurology consult service.  
 Documented HIV positivity, either at the time of the NOS or within 12 months 
of the NOS 
 Age greater than 18 years 
Exclusion 
 Patients unwilling to sign consent for participation in the study 
 Previously diagnosed epilepsy ( more than one month prior to recruitment into 
the study) 
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We screened 246 patients consecutively over the eighteen month period.  200 patients were 
evaluated for the cross-sectional component of the study.  
The reasons for exclusions from the cross-sectional study were as follows:   
 Patients refused consent  18  
 Incorrect diagnosis    12 
 Patients absconded    16  
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3.1.4 Measurements 
 
Semi-structured interview and clinical examination (see Appendix D) 
The following information was obtained:  
Demographic data:   Age; gender; sexual orientation and level of education 
Seizure data:  Date of initial seizure; type of seizure and previous history of 
seizures 
Risks and possible triggers:  Family history; alcohol intake; drug use (herbal; illicit and 
prescription) 
Previous medical history:  Neurological and non-neurological illnesses were documented 
HAART:  Date of initiation; compliance and specific regimen being used 
was obtained 
General Information:  An open-ended question requesting any information that the 
patient wished to share was posed at the end of the interview 
 
A clinical examination was performed on all patients. 
General examination:  Assessment of stigmata of chronic disease and immune 
suppression; cardiovascular system examination; respiratory 
and abdominal examinations. 
Neurological examination:  Assessment of the level of consciousness; higher functions; the 
presence of meningism; cranial nerve examination; evaluation 
for the presence of primitive reflexes; cranial nerve 
examination; gait evaluation; cerebellar examination and 
assessment of the motor and sensory systems.  
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Seizure characteristics  
The classification of the predominant seizure type was documented for each patient. The 
classification used was elucidated by Berg et al (2010). See table below 
 
Table 3.1. Classification of Seizures 
 
 Generalized seizures 
o Tonic-clonic (in any combination) 
o Absence 
 Typical 
 Atypical 
 Absence with special features 
 Myoclonic 
o Clonic 
o Tonic 
o Atonic 
 Focal seizures 
 Unknown* 
          
*Seizures that cannot be clearly diagnosed should be considered  
unclassified until further information allows accurate diagnosis.  
This is not a specific category. 
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HIV Stage  
The HIV staging was determined for each patient. The staging was adapted from the Centers 
for Disease Control (CDC) revised classification as described by Schneider et al in 2008.  
The staging was based on CD4 T-lymphocyte counts only. A summary of the staging system 
used is tabulated below. 
 
Table 3.2 Stages of HIV Infection 
 Stage 1 
o CD4+ T-lymphocyte count ≥ 500 cells/µL 
 Stage 2 
o CD4+ T-lymphocyte count 200-499 cells/µL 
 Stage 3 
o CD4+ T-lymphocyte count <200 cells/µL 
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Laboratory Investigations  
Routine investigations were performed on all patients. These were submitted to the National 
Health Laboratory Service (NHLS) branches at each of the hospitals. The investigations 
included: Full Blood Count (FBC); Urea and Electrolytes (U&E); Erythrocyte Sedimentation 
Rate (ESR); Blood Glucose; Liver Function Test (LFT) and Calcium, Magnesium and 
Phosphate (CMP) levels. 
In all patients the HIV serology was confirmed via an enzyme-linked immunosorbent assay 
(ELISA) test. The CD4 count was determined via flow cytometry on serum samples.  
Further blood laboratory tests investigations were performed to specifically identify 
recognized causes of seizures. These investigations included syphilis serology; complement 
fixation tests (CFTs) for cysticercosis and toxoplasmosis; IgM and IgG tests for CMV and 
polymerase chain reaction for HTLV-1.   
Lumbar punctures were performed in patients unless contra-indicated (based on brain scan 
findings). The CSF samples were sent for routine investigations i.e. chemistry, microscopy 
and cell count; and specific studies including Veneral Disease Research Laboratory (VDRL) 
studies for syphilis; cryptococcal antigen and india ink stain; PCR studies for JC Virus; EBV 
and herpes viruses and adenosine deaminase levels (ADA). The samples were sent for 
bacterial culture and culture for mycobacterium tuberculosis.  
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Electroencephalogram (EEG)  
Standard 12-lead EEGs recordings were performed when possible. The length of the 
recording was 20 minutes. The recording machine used was a Nihon Kohden Model EEG-
9100K 
The EEGs were reported on by registrars in the Neurology departments at the respective 
hospitals and reviewed by consultant neurologists. The EEGs were reviewed by the 
researcher to ensure consistency in reporting. The results were recorded as follows: 
 Normal 
 Focal slowing  
 Generalized slowing  
 Epileptiform discharges present 
 Not done 
 
Radiology 
 Chest X-ray (CXR) 
This was done routinely on all patients.  
 Computer Tomography Brain (CTB) 
Scans were done on all patients. The scans were reported on by registrars in 
the Radiology departments at the respective hospitals and reviewed by 
consultant radiologists. The scans were reviewed by the researcher to ensure 
consistency in reporting. The recording machines used were: 
o Charlotte Maxeke Johannesburg Academic Hospital 
 Philips Brilliance 64 slice 
 Philips Brilliance 128 slice 
o Chris Hani Baragwanath Academic Hospital 
 Toshiba Aquiliom 64 slice 
o Helen Joseph Hospital 
 Philips Brilliance 64 slice 
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 Magnetic Resonance Image (MRI) Scans Brain  
These were done on patients in whom laboratory investigations and CTBs 
were normal. The scans were reviewed by the researcher and a senior 
radiologist to ensure consistency in reporting. The machines used were: 
o Charlotte Maxeke Johannesburg Academic Hospital 
 Siemens 1.5 Tesla 
o Chris Hani Baragwanath Academic Hospital 
 General Electric 1.5 Tesla 
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3.1.5 Criteria for Diagnosis 
 
Metabolic Disorders 
They were the presumed cause of the seizures if  
 Serum sodium was less than 115mmol/l  
 Serum calcium was less than 1.2mmo/l 
 Serum magnesium was less than 0.8mmol/l  
 Urea nitrogen was greater than 35.7mmol/l 
 Creatinine was greater than 884µmol/l 
These values are based on the criteria outlined by Beghi et al, 2010 for the identification of 
acute symptomatic seizures.  
 
Meningitis  
The diagnosis of meningitis was based on a combination of clinical features and CSF 
analysis.
 
The clinical features included: 
 Altered mental status 
 Fever 
 Neck stiffness 
 Photophobia 
 Vomiting 
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The CSF results were interpreted as follows:  
 Bacterial meningitis: 
o Abnormal cell count (elevated white cells with >50% neutrophils) and  
o Positive Gram stain or  
o Positive bacterial culture  
 Cryptococcal meningitis (described by Antinori, 2013): 
o Direct identification of the organism by India ink stain or 
o Positive cryptococcal antigen in CSF (latex agglutination method) 
o Positive culture for Cryptococcus neoformans 
 Tuberculous meningitis (described by Marx and Chan, 2011): 
o Acid-fast bacilli on stain 
o Positive culture for mycobacterium tuberculosis 
o Lymohocyte-predominant pleocytosis 
 Total white cell counts usually between 100-500 cells/µL 
 In the very early stage there may be a neutrophil predominance 
and lower cell count 
o Elevated protein levels 
Typically between 1 and 5g/L 
o Low glucose 
Usually < 0.45g/L or CSF: plasma ratio <0.5 
o Adenosine deaminase level >10U/L 
 
Neuroimaging features suggestive of TBM included 
o Basal meningeal enhancement 
o Hydrocephalus 
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Focal Brain Lesions (FBLs) 
We were unable to obtain histopathological diagnoses. We therefore presumed the aetiology 
of FBLs by collating information obtained from clinical, biochemical and radiological 
findings in conjunction with non-neurological illness and response to therapy. The algorithm 
used to identify presumed diagnoses was based on the approach outlined by Modi M, 
Mochan and Modi G, 2004. This was used in conjunction with a response to therapy.  
 
Figure 3.1 Approach to FBLs in HIV+ individuals 
(Adapted from Modi M, Mochan and Modi G, 2004)   
Legend 
NCC=Neurocysticercosis; Toxo=Toxoplasmosis 
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The additional information utilized to make a presumptive diagnosis was based on the table 
below  
Table 3.3 Characteristics of FBLs 
 
 
 
Toxoplasmosis TB PML PCNSL NCC 
CD4 
count  
(cells/ 
µL) 
<200 Variable <100 <100 Variable 
Other 
Findings 
IgG antibodies in 
serum and urine 
to 
T. Gondii 
 
Evidence of 
pulmonary or 
non-
neurological 
TB 
  
Concomitant 
neurological 
infections 
CSF 
Features 
 
Glucose Normal/ 
decreased 
Decreased Normal Normal 
Normal/ 
decreased 
Protein Normal/ 
increased 
Increased 
Normal/ 
increased 
Normal Increased 
White 
cell 
count 
Normal/ 
increased 
lymphocytes 
Increased 
lymphocytes 
Normal 
Normal/ 
increased 
lymphocytes 
Increased 
lymphocytes 
Other 
Findings 
T. gondii PCR 
Microscopy for 
AFBs 
Culture for 
Mycobacterium 
Tuberculosis 
 
JC Virus 
PCR 
EBV PCR 
CSF and 
serum 
ELISA for 
NCC 
Neuro-
imaging 
 
Lesion 
numbers 
Usually multiple 
Solitary/ 
multiple 
Solitary/ 
multiple 
Solitary/ 
multiple 
Multiple 
 
Common  
locations 
Basal ganglia; 
frontal 
and parietal 
Basal ganglia; 
brainstem; 
cerebellum and 
cerebral 
hemispheres 
 
Brainstem; 
cerebellum 
and 
subcortical 
white 
matter 
Corpus 
callosum; 
periepndymal, 
periventricular 
and temporal 
 
 (Adapted from Tan et al, 2012 and Serpa et al, 2007) 
Legend:  
NCC= Neurocysticercosis 
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HIV-associated Dementia (HAD) 
The International HIV Dementia Scale (IHDS) described by Sacktor et al, 2005 was used as a 
screening tool to test for the presence of HIV-related cognitive abnormalities. They showed 
that the IHDS has good sensitivity and adequate specificity in screening for HIV dementia in 
both the industrialized and developing world. See table 3.4 on page 83. 
 
Patients with a score of < 10 on the IHDS were evaluated further for possible dementia. 
The diagnosis of HAD was based on a combination of: 
 Clinical features outlined above 
 CSF analysis 
o Normal or non-specific abnormalities 
 Radiology (CT and or MRI Brain) 
o Normal or 
o Age-inappropriate cerebral atrophy with corresponding ventricular 
enlargement  
o Patchy confluent high-intensity white matter signal changes on T2-
weighted MRI scans 
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Table 3.4 International HIV Dementia Scale (IHDS) 
Memory Registration 
Give the patient four words to recall. Give the patient 1 second to say each 
word. Tell the patient that you will ask for recall of the words later. 
 
Motor Speed 
Have the patient tap the first two fingers of the non-dominant hand as widely 
and as quickly as possible 
o 4 = 15 in 5 seconds 
o 3 = 11-14 in 5 seconds 
o 2 = 7-10 in 5 seconds 
o 1 = 3-6 in 5 seconds 
o 0 = 0-2 in 5 seconds 
Psychomotor Speed 
Have the patient perform the following movements with the non-dominant 
hand as quickly as possible 
o Clench hand in fist on flat surface 
o Put hand flat on surface with palm down 
o Put hand perpendicular to flat surface on the side of the 
5
th
 digit 
 4 = 4 sequences in 10 seconds 
 3 = 3 sequences in 10 seconds 
 2 = 2 sequences in 10 seconds 
 1 = 1 sequences in 10 seconds 
 0 = unable to perform 
Memory-Recall 
Ask the patient to recall the four words. If the words are not recalled, then you 
can prompt with a clue 
o Give 1 point for each word recalled spontaneously 
o Give 0.5 point for each correct answer after prompting 
o Maximum = 4 points 
 
The maximum possible score is 12 points.  
A patient with a score of < 10 should be evaluated further for possible 
dementia. 
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3.1.6 Data Management and Analysis 
 
The patients clinical and laboratory data was captured on an Excel spreadsheet by the 
researcher Kapila Hari.  
Some of the detailed data was analysed with the assistance of Lusendo Matondo 
(Quantitative analyst). The analyses were carried out using Statistical Packages for Social 
Sciences (SPSS) version 13.  
 
The specific analyses performed include: 
 The Kolmogotov Smirnov test to demonstrate the skewed nature of the CD4 
count data (Figure 3.2 page 86) 
 The Mann Whitney test was used to calculate the difference in the mean CD4 
count between the CM and TBM groups (Table 3.6 page 92) 
 The Chi square test of independence was used to determine whether there was 
a significant relationship between FBLs and:  
o Seizure type (Table 3.7 page 93) 
o EEG abnormalities (Table 3.9 page 94) 
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3.2  Results  
 
3.2.1 Demography of Study Sample 
Two hundred patients were analysed.  
In the study sample 115 patients (57.5%) were male and 85 (42.5%) were female. The ratio 
of males to females was 1.4: 1.  
The mean age of the patients was 37.9 years.  The patients ranged in age from 19 to 66 years. 
All the patients were Black African. 
All the patients were heterosexual.   
 
3.2.2 HAART  
Eighty-five patients (42.5%) were receiving HAART at the time their first seizure occurred. 
The mean duration of HAART was 20 months. 
In the group there were 47 (55.3%) males and 38 (44.7%) females. The ratio of males to 
females was 1.2 to 1.  
The degree of coverage amongst our group was 43.4%, based on current WHO guidelines i.e. 
HAART to be prescribed if the patients’ CD4 count is <500 cells/µL (World Health 
Organisation consolidated Guidelines on the use of Antiretroviral drugs, June 2013). 
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3.2.3 CD4 Count 
All study participants had at least one CD4 count recorded. The CD4 count at the time of baseline was 
used for analysis purposes.  
The mean CD4 count for the entire group was 167cells/ µL. The mean CD4 count in the HAART 
sub-group was 191.5cells/µL, and in the HAART-naïve group it was 149cells/µL.  The CD4 
counts ranged from <1 to 1090 cells/ µL.  The CD4 count distribution is displayed in a histogram 
below. The data was skewed.  
 
Figure 3.2 The Kolmogotov Smirnov test of the CD4 count  
 
3.2.4 HIV Stage 
The HIV stage was determined for each patient. The classification as outlined previously 
(table 3.2 page 74) was used.  
Table 3.5 HIV Stages in Study Population 
Stage No. of patients Percentage 
1 11 5.5 
2 49 24.5 
3 140 70 
 
The majority of patients (70%) were in stage 3.  
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3.2.5 Aetiology 
The aetiologies identified were  
 Meningitis   58 patients  
 FBLs     55 patients  
 Strokes    30 patients  
 HAD     25 patients  
 NIC     22 patients  
 Trauma   9 patients  
 Metabolic dysfunction  5 patients  
 
 
Figure 3.3 Seizure Aetiologies 
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3.2.6 Aetiology within HIV Stages 
Patients in stages 1, 2 and 3 were analysed to determine the relative frequency of the 
aetiologies within each stage.  
 
 
Figure 3.4 Aetiologies in HIV Stage 1 
 
There were 11 patients in stage 1.    
 NIC    7 patients 
 Stroke    2 patients 
 HAD    2 patients 
There were no patients with meningitis, FBLs or metabolic dysfunction. 
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Figure 3.5 Aetiologies in HIV Stage 2 
 
There were 49 patients in stage 2.  
 FBLs    16 patients 
 Strokes   14 patients 
 NIC    10 patients 
 Meningitis   5 patients 
 Trauma   3 patients 
 HAD    2 patients 
 
There was1 patient with dual pathology (stroke and meningitis).   
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Figure 3.6 Aetiologies in HIV Stage 3 
 
 
There were 140 patients in stage 3.  
 Meningitis   53 patients 
 FBLs    39 patients 
 HAD    21 patients 
 Stroke    14 patients 
 Trauma   6 patients 
 NIC    5 patients 
 Metabolic dysfunction 5 patients 
 
Three patients had dual pathology (2 had meningitis and FBLs and 1 patient had meningitis 
and stroke).   
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The meningitis, FBLs and metabolic sub-groups were further analysed to determine the 
frequency of individual conditions.   
 
 Meningitis 
There were 58 patients  
o Cryptococcal Meningitis  30  
o Tuberculous Meningitis  21 
(Culture positive in CSF: 16) 
o Bacterial meningitis   3  
o Viral meningo-encephalitis  4 
 
 FBLs 
There were 55 patients   
o Tuberculomas    31 
(Culture positive: 22) 
o Toxoplasmosis   9  
o Neurocysticercosis    8 
o Aneurysms    3 
o PML      2 
o Pituitary adenoma    1 
o Meningioma    1 
 
 Metabolic 
There were 5 patients 
o Renal failure    5 
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Profile of patients with CM versus TBM 
The sub-group of patients with meningitis was analysed further to distinguish between 
patients with CM and TBM. 
There were 30 patients with CM, all of whom were in HIV stage 3; the majority of patients 
with TBM (81%) were in HIV stage 3.   
The mean CD4 count in patients with CM (60.5) was lower than in the TBM group (140). 
The mean CD4 count difference between the two groups was statistically significant as the P-
value was <0.001. The difference in the mean CD4 count between the CM and TBM groups 
was analysed using the nonparametric version the t test i.e. the Mann Whitney test as the CD4 
data was not normally distributed. 
 
Table 3.6 Mean CD4 count (CM versus TBM) 
 
  
 
 No. Minimum Maximum Mean Standard  
Deviation 
Median P  
value 
CD4 count TBM 21 9 416 140.04 107.34 111 0.000 
CM 30 5 165 60.53 50.14 46 
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3.2.7 Seizure Classification 
One hundred and seventy patients (85%) had generalized tonic-clonic seizures.  
Thirty patients (15%) had focal seizures.  
We did not identify any patients with status epilepticus. 
 
FBLs and Seizure Type 
The sub-group of patients’ with FBLs was analysed determine whether there was a 
correlation with focal seizures. The chi square test of independence was used to test the two 
categorical variables.The relationship is statistically significant (p-value = 0.003). This 
evidence suggests that FBLs are associated with focal seizures (see Table 3.7 below).  
 
Table 3.7 FBLs and Seizure Type 
 
Chi-square; p-value: 8.962; 0.003 
Focal seizures Total 
Yes No 
Focal brain lesion 
Yes 15 40 55 
No 15 130 145 
Total 30 170 200 
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3.2.8 EEG Results 
Standard EEG recordings were performed on 161 patients (80.5%). 
Table 3.8 EEG Findings 
EEG Finding No. of Patients Percentage (%) 
Generalized slowing 84 52.2 
Normal recording 37 23 
Focal slowing  30 18.6 
Epileptiform discharges 10 6.2 
 
 
 
Focal Brain Lesions and EEG Abnormalities 
The sub-group of patients’ with FBLs was analysed to assess whether there was an 
association with focal slowing on EEG. The chi square test of independence was used to test 
the two categorical variables. The relationship between FBLs and focal abnormalities was 
significant (p value = 0.000).  
 
Table 3.9 FBLs and EEG Abnormalities 
 
Chi-square; p-value: 25.536; 0.000 
Focal brain lesion Total 
Yes No 
EEG 
EEG Normal 7 32 39 
EEG Focal Abnormality 20 11 31 
EEG Generalised Abnormality 18 73 91 
Total 45 116 161 
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3.2.9 CTB Results 
Eight patients (4%) with cryptococcal meningitis and no focal deficits did not have brain 
scans. One hundred and ninety-two patients (96%) had CT scans of their brains done. 
The scans were abnormal in 169 patients (85%). The specific findings are listed below. 
 
Table 3.10 CTB Findings 
CTB Finding  No. of Patients Percentage (%) 
FBL 55 28.6 
Atrophy 54 28.1 
Basal enhancement 34 17.7 
Infarct 28 14.6 
Normal 24 12.5 
Haemorrhage 5 2.6 
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3.2.10 Summary of Results 
In this study there were 200 HIV-infected patients with NOS 
 All were Black African 
 115 males; 85 females 
 Mean age was approximately 38 years 
 HAART coverage was inadequate at 42.5% 
 Mean CD4 count was 167 cells/µL 
 Majority (70%) were in HIV stage 3 
 The most common underlying aetiologies were meningitis and FBLs 
o Tuberculosis and cryptococcal infection predominated 
 Generalized tonic-clonic seizures (85%) occurred more often than focal 
seizures 
 More than half (52%) of the patients had generalized slowing on their EEG 
 The majority (88%) had abnormal  CTB results 
3.2.11 Limitations 
 HIV viral load measurements were not obtained (cost constraints) 
 There were no biopsies performed on patients with focal brain lesions (this is 
not routine clinical practice at our institutions) 
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3.3 Descriptive Analysis of New Onset Seizures in HIV in 
South African patients  
 
3.3.1 Demography 
In this study sample the majority (57.5%) of patients were male. The ratio of males to 
females was 1.4 to 1. This is an unexpected finding as the prevalence of HIV in South Africa 
is higher amongst females than males. Recent figures show that the overall prevalence was 
9.9% in males and 14.4% in females (South African National HIV Prevalence, Incidence and 
Behaviour Survey, 2012). The higher proportion of males in this study subjects could be 
explained by the Gauteng provincial demographics: 
 In Gauteng, the site of this study the male to female ratio is higher in the age 
group 20-54 years. (Mid-year population estimates, 2013, Statistics South 
Africa). 
 The majority of our cohort (90%) was between the ages of 20 and 54 years.  
 
 
The mean age of 37.9 years is consistent with the national HIV prevalence data.   
See table 3.11 below (South African National HIV Prevalence, Incidence and Behaviour 
Survey, 2012).  
 
Table 3.11 HIV Prevalence by Age, South Africa 
Age Group (years) % 
0-14 2.4 
15-24 7.1 
25-49 25.2 
50+ 7.6 
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All patients were Black African, which is not unexpected.  In South Africa the vast majority 
of the population (79.8%) are Black African.  The teaching hospitals at which the studies 
were conducted serve a predominantly Black African population. The prevalence of HIV is 
highest amongst this race group.  
See table 3.12 below (South African National HIV Prevalence, Incidence and Behaviour 
Survey, 2012).  
 
Table 3.12 HIV Prevalence by Race, South Africa 
Race % 
Black African 15.0 
White 0.3 
Coloured 3.1 
Indian/ Asian 0.8 
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3.3.2 HAART 
In our cohort there were 85 patients (42.5%) receiving HAART.  
One hundred and ten patients (95.7%) of the 115 patients in the HAART-naïve group were 
eligible for therapy based on their CD4 count alone i.e. <500 cells/µL (WHO Consolidated 
guidelines on the use of Antiretroviral drugs, June 2013). The guidelines further recommend 
that priority should be given to patients with CD4 counts <350 cells/µL. In our cohort of 
HAART-naïve patients there were 101 (87.8%) with CD4 counts <350 cells/µL.  
Our figures indicate sub-optimal HAART coverage amongst our patients. The coverage in 
our group was 43.4% based on the current WHO guidelines. Johnson, 2012 estimated that 
adult HAART coverage in South Africa was 52% if the criterion of CD4 counts <350 
cells/µL was used. If we used this criterion then our coverage was 45.7%. Our lower than 
expected figure may be due to: 
 The high proportion of males in our cohort.  
Johnson, 2012 showed that there is a significant difference in coverage 
between males (41%) and females (60%). This is borne out in the study. The 
overall ratio of males to females was 1.4:1 but in the HAART group it was 
1.2:1.  
 The inherent bias of this study population (Urban, hospital-based). 
It has been hypothesized that patients with advanced HIV migrate to urban 
regions in Gauteng and the Western Cape in the belief that the health-care 
services may be superior (Johnson, 2012). Cleary et al, 2012 showed that there 
were numerous factors in rural regions which contributed to the urban 
migration of individuals seeking HAART: 
o High healthcare costs in rural regions 
o Stigma associated with accessing HAART in a local setting 
o Perceptions about quality of services 
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3.3.3 CD4 count 
Seizures in HIV-infected individuals are more common in patients with advanced disease. This was 
well documented in the pre-HAART era and also in recent studies conducted in the HAART-era. 
 The overall mean CD4 count in this study was 167cells/µL.  
This is consistent with the findings of Potchen et al, 2014. Their study was 
similar in that it was conducted at a teaching hospital in Lusaka, Zambia. They 
evaluated 43 HIV-positive individuals with first onset seizures. The study was 
done in the HAART era but the coverage was low at 37%. The mean CD4 count in 
their cohort was 187cells/µL. In the study by Kellinghaus et al, 2008 the mean CD4 
count was not calculated but 18/ 33 patients (54.5%) had CD4 counts below 
200cells/µL. This was despite the majority of patients (84.1%) being on HAART.  
 
 In our patients on HAART the mean CD4 count (194.5cells/µL) was low. 
This value reflects the low counts at initiation of anti-retroviral therapy in this 
country. A recent meta-analysis by Siedner et al, 2015 reviewed the CD4 counts of 
>96 000 South Africans prior to commencement of anti-retroviral therapy. The mean 
count in their group was 123cells/µL.  
This low figure is consistent with the findings of Olajumoke et al, 2013. They studied 
20 Nigerian patients presenting with NOS. All their patients were on HAART for a 
mean period of 19.5 months. Despite this the mean CD4 count was low at 
165cells/µL. 
 
 In the HAART-naïve group the mean count was 149cells/µL.  
The low mean count is to be expected.  Numerous hospital-based studies conducted 
prior to the widespread availability of HAART (Pesola and Wesrfal, 1998; Pascual-
Sedono et al, 1999 and Modi et al, 2000) showed similar low mean CD4 counts 
amongst their patients.  The study by Modi et al was done at one of the sites of the 
current study. They studied 37 patients who were HAART-naïve and the mean CD4 
count in their group was 239.  
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3.3.4 Seizure Classification and EEG Results 
 The majority of our patients (85%) had GTC seizures.  
This is consistent with the published studies (see table 2.1, page 51 for details) 
where GTC seizures account for between 62 and 100% of seizures. A review 
of seizures in HIV-seropositive individuals documented that generalized 
seizures were more common (Satishchandra and Sinha, 2008).  
The reporting of generalized seizures may be falsely elevated: 
o There may be rapid secondary generalization  
o History is inadequate.  
 
 Non-specific EEG abnormalities occurred commonly and were present in the 
majority of patients (52%). Epileptiform discharges were rare (10 patients i.e. 5%).  
This is consistent with previous studies where EEGs were found to be an insensitive 
tool in the diagnosis of seizures in HIV-infected populations (Wong, Suite and Labar 
1990; Chadha et al, 2000 and Kellinghaus et al, 2007).  
An interesting finding in this study was the significant correlation between focal EEG 
abnormalities and focal brain lesions. Siddiqui et al, 2015 concluded that EEG 
abnormalities were common in patients with imaging abnormalities and suggested 
that EEGs may assist in prioritising patients for neuroimaging in resource-limited 
settings.  
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3.3.5 CT Brain Results 
 The majority of brain scans (88%) were abnormal in this cohort.  
Neuroimaging abnormalities were documented in 70% of patients in a 
Zambian cohort of HIV infected patients with first seizure (Potchen et al, 
2014) whilst Kellinghaus et al found abnormalities in only 45.5% of the 
patients in their German study. The high proportion of neuroimaging 
abnormalities in studies from the Sub-Saharan region are likely due to: 
o Increased presence of opportunistic infections 
In developed countries HIV-related opportunistic neurological 
infections have decreased following the widespread use of HAART. 
Two prospective multi-centre trials reviewing more than thirty 
thousand patients have confirmed this finding (Monforte et al, 2004 
and Garvery et al, 2011).
  
In South Africa the experience has not been similar.
 
Asselman et al, 
2010 evaluated 75 patients on HAART presenting with neurological 
disorders. Their study was based at a public sector referral hospital in 
Cape Town, South Africa. The majority (60%) of their patients had 
either tuberculosis or cryptococcal infection.  
 
o Low mean CD4 count 
Almost one third of patients in this study had cerebral atrophy 
documented on imaging. Kim et al, 1996 reviewed the neuroimaging 
findings in AIDS Dementia and concluded that atrophy is more 
common in patients with advanced HIV disease. In the current 
HAART era low nadir CD4 count has been identified as the greatest 
risk factor for the development of cerebral atrophy (Cohen et al, 2010).  
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3.3.6 Aetiology 
The majority of our patients (89%) had an identifiable cause for their seizures. This is 
consistent with the published literature (see table 2.1, page 51 for details). The aetiologies in 
the specific HIV stages are discussed below. 
HIV Stage 1 
There were 11 patients in stage 1.    
 NIC    7 patients 
 Stroke    2 patients 
 HAD    2 patients 
There were no patients with meningitis, FBLs or metabolic dysfunction. 
The category of patients with NIC had extensive investigations to exclude opportunistic 
infections and is therefore better represented in this stage i.e. CD4 count >500 cells/µL. This 
sub-group was part of the longitudinal study and the results are analysed further in section 4.3 
page 156. 
The diagnosis of HAD in patients in stage 1 is uncommon. Both patients with HAD were on 
HAART at baseline.  Joska et al, 2010 reviewed 15 studies in an attempt to determine 
whether HAART improved neurocognitive function. They concluded that although HAART 
improved cognition it did not completely resolve neurocognitive deficits.   
Several reasons for this apparent treatment failure have been postulated and include:  
 The “legacy effect” of HIV infection:  permanent damage predating the initiation of 
HAART  
 Ongoing CNS disease activity resulting from lack of viral suppression due to poor 
CNS penetration effectiveness (CPE) of antiretrovirals (ARVs) 
 Potential neurotoxicity of HAART 
 Confounding comorbidities like psychiatric illness, substance abuse, cerebrovascular 
disease 
 Ageing  
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The nadir CD4 counts of the patients with HAD were not available; but it is likely that the 
counts were low, thus predisposing them to the development of HAD (Heaton et al, 2011). 
Siedner et al, 2015 showed that the mean CD4 count in South Africans prior to commencement of 
anti-retroviral therapy was 123cells/µL.  
 
The occurrence of stroke amongst patients with high CD4 counts is not uncommon. Mochan, 
Modi M. and Modi Gl, 2003 studied 35 Black South African patients at the Chris Hani 
Baragwanath hospital (a site of the current study). Their patients were all HAART-naïve. 
Almost one quarter (23%) of the patients in their study was in CDC stage 1. Chow, 2014 
reviewed the association between stroke and HIV. She concluded that there was sufficient 
evidence to support an increased risk of ischaemic stroke in individuals with HIV infection. 
The factors which increased the stroke risk include: 
 Traditional Risk Factors 
o Hypertension 
o Dyslipidaemia 
o Diabetes Mellitus 
o Smoking 
 Impaired fibrinolysis with consequent hyper-coagulable state 
The absence of patients with meningitis in stage 1 is consistent with the findings of Jarvis et 
al, 2010. They identified 492 HIV-infected individuals with meningitis in South Africa. None 
of their patients were in CDC stage 1. The highest CD4 count documented amongst their 
patients was 467cells/µL. See table 3.13 below for details.  
 
Table 3.13 Meningitis in HIV+ individuals, South Africa 
Diagnosis No. of Patients Mean CD4 (cells/µL) CD4 Range (cells/µL) 
CM 337 39 18-85 
TBM 126 126 61-201 
Bacterial 
Meningitis 
29 287 155-467 
Adapted from Jarvis et al, 2010 
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In developing countries focal brain lesions are associated with infections. Three studies have 
evaluated FBLs in South Africa (Bhigjee et al, 1998; Modi M., Mochan and Modi G., 2004 
and Smego, Orlovic and Wadula, 2006). Bhigjee et al evaluated 38 patients with FBLs. They 
measured the CD4 count in 27 patients, none of who had counts >500cells/µL. Modi et al 
reviewed 32 patients with FBLs. In their study there were only 4 patients in CDC stage 1. 
Smego et al, 2006 evaluated 26 patients with FBLs. None of their patients were in CDC stage 
1. The studies by Modi et al and Smego et al studies were performed at sites included in the 
current study in the pre-HAART era. In our setting, FBLs are unusual in patients in CDC 
stage 1.  
All the patients in this study with metabolic dysfunction had renal failure. The absence of 
patients with renal failure amongst the stage 1 sub-group is unsurprising as it has been shown 
that a CD4 count < 200cells/µL is a major risk factor for the development of renal disease 
(Naicker and Fabian, 2010).   
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CDC Stage 2 
There were 49 patients in stage 2. One patient had dual pathology (stroke and meningitis). 
 FBLs    16 patients 
 Strokes   14 patients 
 NIC    10 patients 
 Meningitis   5 patients 
 Trauma   3 patients 
 HAD    2 patients 
Almost one third (16) of the patients in stage 2 had FBLs. Amongst the patients with FBLs most had 
either TB (8) or NCC (3). Modi M., Mochan and Modi G., 2004 studied 22 patients with presumed 
tuberculomas. Their patients were HAART-naive and even though the mean CD4 count was 188, the 
range of CD4 counts extended to 610cells/µL.  
Neurocysticercosis is well described in the context of HIV infection. Serpa et al, 2007 reviewed the 
literature on the co-infection and identified 27 patients. Unfortunately individual CD4 counts were 
only available for 6 patients. Four of the patients were in HIV stage 2. Modi M., Mochan and Modi 
G., 2004 identified 9 patients with NCC, in their patients the mean CD4 count was 509cells/µL. It 
has been postulated that symptomatic neurocysticercosis is more likely at higher CD4 counts. A 
possible reason for this is that lower CD4 counts are associated with decreased host inflammatory 
responses (Prasad et al, 2006).  
Ba-Diop et al, 2014 reviewed the epidemiology, causes and treatment of epilepsy in sub-
Saharan Africa. Traumatic brain injury was identified as a risk factor in the region. The 
causes include: 
 Road accidents 
 Assaults 
 Violent sports 
Amongst our patients 2 had been involved in road accidents and one had been assaulted. 
 
There were 5 patients with meningitis; 4 of who had TBM and 1 had a bacterial meningitis. 
TBM is more common in patients with advanced disease but can present at higher CD4 
counts, especially in regions of high TB prevalence (Tan et al, 2012).   
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HIV Stage 3 
There were 140 patients in stage 3.  
 Meningitis   53 patients 
 FBLs    39 patients 
 HAD    21 patients 
 Stroke    14 patients 
 Trauma   6 patients 
 NIC    5 patients 
 Metabolic dysfunction 5 patients 
 
 
Meningitis 
This was the most common aetiology identified and was present in 53 patients. Meningitis is 
a prominent cause of NOS and been described in >40% of patients (Sinha et al, 2005). The 
common causes of meningitis in this stage were cryptococcal infection and tuberculosis.  
Cryptococcal meningitis was diagnosed in 30 patients. Jarvis and Harrison, 2007 have shown 
that in developing countries cryptococcal neoformans remains an important opportunistic 
pathogen and that in sub-Saharan Africa it is the leading cause of meningitis in adults. The 
HAART era has led to a decrease in incidence of CM in the developed world. This effect has 
not been replicated in the developing world. The burden of cryptococcal disease has remained 
high in this country even in the current HAART era. The most likely reasons for this are: 
 The large number of patients with low CD4 counts that are not accessing 
HAART 
 The low mean CD4 count of patients at initiation of HAART  
(Jarvis et al, 2007). 
The relatively high incidence of CM in our cohort could also be explained by the findings of 
Antinori, 2013 who showed that seizures are more common in HIV-infected individuals from 
Africa, compared to the rest of the world.  In African patients with CM seizures occur in 
9.1% of patients whilst in developed countries they occur in 6.1% of patients. This increase 
could be a consequence of late presentation.  
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The risk of CM in HIV-infected patients is highest amongst patients with advanced disease 
(CD4 count below 100cells/µL). All the patients with CM (even those on HAART) had a 
CD4 count below 200cells/µL and the majority (76.7%) had counts below 100 cells/µL.  
Tuberculous meningitis was identified in 17 patients. TBM has not been documented as a 
frequent cause of seizures in other studies to date. The relatively high incidence in this cohort 
is probably due to: 
 The high TB prevalence in South Africa. 
 The high proportion of TBM in South African patients with meningitis  
 The low mean CD4 count  
The WHO has identified 22 countries which are high burden countries and account for 81% 
of the global cases of TB (see Figure 3.7 below). South Africa is one of these countries and 
has the highest incidence and prevalence of TB within the group (WHO Report on Global 
Tuberculosis Control, 2012).  
 
 
Figure 3.7 High Burden TB countries 
(From Kaiser Family Foundation, www.GlobalHealthFacts.org, based on WHO, Global tuberculosis control 
2010, reprinted with permission from the Henry J. Kaiser Family Foundation, California, USA). 
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TBM has been identified as a significant cause of meningitis in HIV-infected individuals in 
South Africa (Jarvis et al, 2010). In their patients the mean CD4 count was 126 cells/ µL. 
Pettit et al, 2011 have also shown that the risk of TB is higher among HIV-infected patients 
with low CD4 counts.  
 
There were only 3 patients with bacterial meningitis. This is consistent with the findings of 
Jarvis et al, 2010 who found low numbers of bacterial meningitis. All our patients had 
Pneumococcus which was also the dominant organism identified in their patients with 
bacterial meningitis.  
 
Focal Brain Lesions 
Focal brain lesions occur frequently in HIV-infected individuals and have been described in 
up to 53% of patients presenting with NOS (see table 2.1, page 51 for details). In stage 3 we 
identified FBLs in 39 patients. FBLs in our setting have been shown to occur in patients with 
advanced disease. In the 2009 study by Modi M., Mochan and Modi G patients with FBLs 
had a mean CD4 count of 181cells/µL. 
The majority of patients (23) had tuberculomas. The high proportion of tuberculomas in this 
study is consistent with the findings of Modi M., Mochan and Modi G, 2004. Their case 
series on HIV-associated FBLs was conducted at the Chris Hani Baragwanath Hospital, one 
of the sites of the current study. TB was the presumed cause in >50% of their patients with 
FBLs. Their patients were all HAART-naïve. In the Cape Town-based study by Asselman et 
al, 2010 there were 25 patients with focal brain lesions, 6 of whom had tuberculomas and a 
further 8 received antitubercular therapy despite no definitive diagnosis. 
Seizures are a characteristic finding in adult patients with tuberculomas and occur in 11% of 
patients (DeLance et al, 2013). They are however not well documented in HIV positive 
patients with NOS except in the studies by Chadha et al, 2000 (India) and Modi et al, 2000 
(South Africa). Both these studies are from high TB burden countries.  
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Toxoplasmosis has been identified as the commonest cause of FBLs in most of the published 
studies on NOS in HIV (see table 2.1, page 51 for details) and in the 1999 study on FBLs by 
Bhigjee et al. The study by Bhigjee et al was done in KwaZulu Natal, South Africa. In the 
current study only 9 patients, all of who were in stage 3 had FBLs that were attributed to 
toxoplasmosis. This comparatively low proportion is probably due to: 
 Low sero-prevalence of T. gondii in this study population 
The sero-prevalence of T. gondii in immunocompromised patients reflects that 
of the background population. A study in Gauteng, South Africa found 
prevalence in the HIV-positive population to be 8% (Hari et al, 2007). In the 
studies by Pascual-Sedono et al, 1999 (Spain), and Chadha et al, 2000 (India) 
almost a third of patients had toxoplasmosis implicated as the cause for their 
seizures. In Spain the seroprevalence of T. gondii has been shown to be 43.8% 
and in India it was 41.7% (Pappas, Roussos and Falagas 2009). The 
seroprevalence in Kwazulu Natal, the site of the study by Bhigjee et al was 
31.3% (Schneider, Schutte and Bromner 1992).  
We identified 8 patients (4%) with neurocysticercosis. The only other study in which NCC 
featured as a cause of seizures amongst HIV-positive individuals was the 2009 study by Modi 
M., Mochan and Modi G. In their study there were 3 patients (14%) with NCC. The 
occurrence of NCC in the South African setting is to be expected. Cysticercosis is endemic in 
South Africa (WHO report on neglected tropical diseases, 2010). Thirty per cent of epilepsy 
in endemic regions is due to NCC (Ndimubanzi et al, 2010). In the setting of HIV Modi M., 
Mochan and Modi G, 2004 have shown that NCC is responsible for almost one third of FBLs.  
 
There were 3 patients with fusiform intra-cranial aneurysms, suggestive of HIV 
vasculopathy. Intra-cranial aneurysms in HIV-positive adults are rare.  There have been only 
two cases previously reported in the literature with the combination of HIV infection, 
intracranial aneurysms and seizures, one of whom was an adult South African (Modi et al, 
2008).  
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Metabolic Dysfunction 
In this study there were 5 patients (2.5%) with seizures due to metabolic dysfunction.  This 
figure is consistent with published data (see table 2.1, page 51 for details). The 5 patients all 
had renal failure. Renal failure has been identified as a potential risk factor for NOS (Van 
Paesschen et al, 1995). Unfortunately CD4 counts were not available for their patients but of 
their group of 68 patients, 91% had AIDS, suggesting advanced disease (Revision of the 
CDC surveillance case definition for acquired immunodeficiency syndrome. 1987). NOS 
were described as a presenting feature in 2 patients with end-stage renal failure (Olatinwo and 
Hewitt, 2002).  
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3.3.7 Conclusion 
In the current era of an anti-retroviral program the majority of HIV infected South African 
Patients with New Onset Seizures  
 Have an underlying cause  
 The most common causes are 
 Meningitis and 
 Focal Brain Lesions 
 Infectious aetiologies predominate; especially in patients with 
advanced disease i.e. HIV stages 2 and 3. 
 The most commonly identified infections are tuberculosis and 
cryptococcal infection; which is consistent with the prevalent 
infections in our region. 
 Have advanced immune-suppression 
 Low mean CD4 count (167 cells/µL) 
 Are not on HAART 
 The majority of HAART-eligible patients are not accessing therapy 
 Present with generalized tonic-clonic seizures 
 Have neuroimaging abnormalities 
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CHAPTER FOUR 
 
New Onset Seizures In HIV Infected Individuals  
with No Identifiable Cause 
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4.1 Methods 
4.1.1 Study Design 
A longitudinal study (clinical and SPECT scan).  
The protocol was granted approval by the Human Research Ethics Committee (Medical), 
University of the Witwatersrand, Johannesburg. (Appendix C).  
Patients were recruited over an eighteen month period i.e. January 2013 to June 2014. 
 
4.1.2 Study Population 
All patients recruited for the cross-sectional study (see 3.1.2page 70) 
 
4.1.3 Study Criteria 
Inclusion 
Patients with new onset seizures in who there was no identifiable cause i.e. 
 Blood laboratory tests investigations were normal 
 CSF analysis was normal 
 CT Brain was normal  
 MRI brain normal (no specific abnormalities) 
 
Exclusion  
 Patients unwilling to sign a request for participation in the longitudinal study 
which included a separate consent sheet for the performance of SPECT scans 
(Appendix F) 
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4.1.4 Measurements 
 
Semi-structured interview and clinical examination (see Appendix E) 
The procedure outlined earlier (3.1.4 page 77) was followed for each patient.  
This was repeated at 6-monthly intervals for the duration of the patients’ inclusion in the 
study.  
Seizure characteristics  
The classification of the predominant seizure type was documented for each patient. The 
classification used was elucidated by Berg et al (2010). See table 3.1 page 73 for details. 
HIV Staging 
This information was determined for all patients at baseline. The methods utilized have been 
discussed previously. See table 3.2 page 74. 
The International HIV Dementia Scale (IHDS) 
This information was determined for all patients at baseline and each visit. The details of this 
tool have been discussed previously.  See table 3.4 page 86. 
Laboratory Investigations 
The investigations listed previously (page 75), including the CSF analysis were performed on 
each patient and repeated at 6-monthly intervals for the duration of their inclusion in the 
study. 
 Blood HIV-1 RNA viral loads were requested on all patients and repeated at 
6-monthly intervals for the duration of the patients’ inclusion in the study.   
Electroencephalogram (EEG)      
Standard 12-lead EEGs recordings were performed on all patients at baseline. 
The EEGs were reviewed by the researcher to ensure consistency in reporting. The results 
were recorded as detailed previously (page 76). 
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Radiology 
 Chest X-ray (CXR) 
This was done routinely on all patients.  
 Computer Tomography Brain (CTB) 
Scans were done on all patients. The scans were reviewed by the researcher 
and Professor. M. Modi (MBBCH MMed {WITS} FC Rad) to ensure 
consistency in reporting.  
 Magnetic Resonance Image (MRI) Scans Brain  
Scans were done on all patients. The scans were reviewed by the researcher 
and Professor. M. Modi to ensure consistency in reporting. They were 
repeated at 6-monthly intervals for the duration of the patients’ inclusion in the 
study.  
 The unexplained white matter abnormalities on scans were documented using 
the well-established Fazekas Scale (Fazekas et al, 1987). See table 4.1 below 
for details 
 
Table 4.1 Fazekas Scale of White Matter Hyperintensities 
 
 Periventricular Hyperintensities 
0 Absent 
1 “Caps” or pencil-thin lining 
2 Smooth “halo 
3 Irregular; extending into deep white matter 
 
 Deep White Matter Hyperintensities 
0 Absent 
1 Punctate foci 
2 Beginning confluence of foci 
3 Large confluent areas 
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Nuclear Medicine 
Radionuclide SPECT scans using 99mTc-HMPAO were done in all of the patients in whom 
no identifiable cause was found.  Several radiopharmaceuticals have been used to image the 
brain for brain perfusion SPECT scans (Bonte , Devous and Holman 1996). HMPAO has 
been one of the most widely used and successful radiopharmaceutical in brain perfusion 
imaging. Once administered, its peak activity in the brain is reached within 2 minutes of 
injection but more importantly there is no redistribution. Consequently, both the initial tracer 
uptake and distribution are proportional to rCBF at the time of injection and also remain 
unaltered for a relatively long time (at least 2 hours) to allow imaging (Catafau, 2001).  
They scans were repeated at 6-monthly intervals for the duration of the patients’ inclusion in 
the study.  
 The patients were in a quiet and dimmed room with their eyes open and ears 
unplugged for approximately 30 min before the administration of the 99mTc-
HMPAO injection. Patient interaction was minimized during this stage.  
 The patients received an intravenous injection of 740 Megabecquerel (MBq) 
of 99mTc-HMPAO through a line already placed in the cubital fossa. The 
room conditions during the injection and tracer uptake were similar. 
 They were placed in a supine position on the Gamma camera bed, with the 
head immobilized on a head rest and secured with Velcro (front and/or chin) 
straps to minimize head movement.  
 Imaging was done with a dual head Gamma camera (Infinia  Haweye, GE 
Medical). A low energy high-resolution collimator was used to scan all the 
patients.  
 SPECT imaging was recorded on step and shoot mode using a 128 X 128 
matrix; one projection for each 3° in a 360° orbit for a total of 120 projections. 
We processed the data after normalization and back projection using a 
butterworth (0.5 frequencies) and power 10. 
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Visual Assessments 
 
The scans were analysed by 2 experienced nuclear medicine physicians. The senior physician 
has vast experience (>20 years) with a special interest in neuroimaging. 
The appropriate brain perfusion SPECT interpretation was made using a step-by-step 
approach.  
 Firstly, a set of slices was selected as a basis for identification of the SPECT 
perfusion patterns. The transaxial slices were the starting point and then the 
other sets of slices were used for confirmation, localization, and to assess the 
extension of findings. 
 For standardisation and reproducibility, the same regional order of perfusion 
assessment was followed and included all cerebral regions, such as assessing 
at first the cortical regions from bottom to top which are: cerebellum, temporal 
lobes, frontal lobes (orbitofrontal, prefrontal, and superior frontal areas), 
occipital lobes, and parietal lobes.  
 The mesial and lateral aspects of the above-mentioned cerebral regions were 
also evaluated separately.  
 The global and regional tracer uptake and distribution were assessed to 
identify areas of normal distribution and those with clear perfusion 
abnormalities.  
 Whenever perfusion was considered to be abnormal, symmetry between the 
two cerebral hemispheres was checked. 
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Quantification 
 
In this study we used the software program PMOD Base Functionality version 3.6 (PBAS, 
version 3.6).  A well- established way of obtaining brain volumes of interest automatically is 
by leveraging the most likely localization of brain areas as encoded in the maximum 
probability atlas constructed by Hammers et al, 2003. This software package offers much 
improved batch processing which encompasses the automatic generation of brain volume of 
interest/ regions of interest (VOI/ROI). As previously stated, many types of quantitative 
analyses are based on the average signal within tissue structures. The PBAS includes a large 
and flexible set of tools for defining VOI. The definition types include contour outlines, 
regular geometric objects, object maps, linear VOIs and VOIs with holes. The VOIs can be 
created using many versatile tools and the calculation of their common pixels can be done.  
SPECT brain data were transferred as DICOM for recognition and we used automatic VOIs 
from the adapted brain atlas. Regional counts per pixel were automatically generated for 
analysis. The brain atlas allows for the selection of 63 brain ROI. We however selected 30 
regions; left and right) based on previous literature describing SPECT scan abnormalities in 
HIV infected individuals (Tran Dinh et al, 1990; Tatsch et al 1990; Modi et al 2002).  The 
ROI/ VOI were grouped as dominant cerebral regions to facilitate analysis. The VOIs used 
are listed in table 4.2 page 120.  
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Table 4.2 Volumes/ Regions of Interest 
 
Frontal Superior  
Frontal Middle 
Frontal Inferior  
Cingulate Anterior 
Cingulate Middle 
Cingulate Posterior  
Hippocampus  
Occipital 
Caudate 
Putamen 
Pallidum 
Thalamus  
Parietal  
Temporal  
Cerebellum 
 
  
121 
 
 
Figure 4.1 
 
Figure 4.2 
 
 
 
 
 
 
 
Figure 4.3 
 
ROI/ VOI Selection 
Figures 4.1- 4.3 show the automatic 
creation of VOI. These regions 
were created using the probability 
atlas available on the PBAS 
software. The contour VOIs were 
interactively adjusted using the 
VOI features of PBAS, which are 
described in the User’s Guide, 
2014. A reduced set of VOI tools 
was utilized, based on the 
configuration. (User’s Guide)  
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4.1.5  Data Management and Analysis 
The quantification generated copious amounts of data. These data were analysed by the 
researcher in conjunction with Professor Mboyo-Di-Tamba Vangu and the assistance of 
Lusendo Matondo. The analyses were carried out using Statistical Packages for Social 
Sciences (SPSS) version 13 and Excel. The specific analyses included: 
 
 The Kolmogorov-Smirnov test of normality to assess the distribution of the 
data 
 Analysis of Variance (ANOVA) tests to test the null hypothesis that: 
o The means of the dominant cerebral regions for all patients were equal 
at 
 Baseline 
 Follow-up 
o The means of patients in the different HIV stages at recruitment are 
equal 
 Paired sample t tests to compare baseline data: 
o The left and right cerebral hemispheres in individual patients  
o The dominant cerebral regions in the left and right cerebral 
hemispheres for all patients 
o The differences between individual cerebral regions for all patients 
o The differences between HIV stages  
 Paired sample t tests to compare the differences between individual cerebral 
regions at follow-up 
 Paired sample t tests to compare baseline and follow-up data 
o All regions grouped together for individual patients 
o The left and right cerebral hemispheres in individual patients  
o The dominant cerebral regions for all patients 
o The dominant cerebral regions for patient 1 
 Paired sample t tests to compare the pre and post-HAART data for patients 1; 
3; 7 and 8 
o The left and right cerebral hemispheres 
o The dominant cerebral regions 
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4.2 Results 
 
4.2.1 Study Population 
There were 22 patients eligible for the study i.e. 
 HIV Infection 
 New onset Seizures 
 No Identifiable Cause 
o Normal laboratory investigations 
o CT and MRI scans of the brain did not reveal any specific abnormality 
that could account for the seizures 
Fifteen patients were enrolled, 7 patients were unwilling to participate in a longitudinal study. 
 
4.2.2 Demography of Study Sample 
 There were 10 females and 5 males in our sample at baseline. 
 The average age was 36.9 years.  
 The ages ranged from 20 to 55 years. 
 
4.2.3 HAART 
There were 5 patients on HAART at baseline. Amongst the remaining 10 patients there were 
9 patients eligible for HAART. 
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4.2.4 CD4 Count and HIV-1 RNA Viral loads  
 The mean CD4 count was 414.4cells/µL.  
 The range was from 49 to 1090 cells/µL. 
There were 4 patients in whom the viral load was undetectable 
 All were on HAART.  
 
4.2.5 HIV Stage  
 Stage 1    6 patients 
 Stage 2    5 patients 
 Stage 3    4 patients 
 
4.2.6 Seizure Classification 
All the patients had generalized tonic-clonic seizures. 
 
4.2.7  EEG Results 
 Normal recordings   13 patients  
 Generalized slowing   2 patients 
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4.2.8 MRI Brain Results 
The most common abnormality detected on the scans was unexplained white matter lesions. 
The white matter abnormalities were graded according to the Fazekas Scale (Fazekas et al, 
1987), an established and validated method of reporting white matter hyper intensities (Gouw 
et al, 2008). This visual scale has been shown to correlate closely with quantitative 
assessments of white matter lesions (Valdés Hernández Mdel et al, 2013) and has previously 
been used to assess unexplained white matter lesions in HIV Positive individuals (Haddow et 
al, 2014). A summary of the grading scale is detailed below (Table 4.3).  
 
Table 4.3 Fazekas Scale of Scoring WML 
 
Fazekas Score MRI Finding 
0 None or a single punctate WML 
1 Multiple punctate lesions 
2 Beginning confluence of lesions (bridging) 
3 Large confluent lesions 
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Table 4.4 Summary of Laboratory Investigations and MRI Results  
(Baseline) 
 
Patient 
Number 
Age Sex 
HAART 
(Duration 
In 
months) 
CD4 
HIV-1 
RNA VL 
Hepatitis 
C 
MRI 
Score 
(Fazekas) 
1 33 F Nil 340 356 Positive 2 
2 20 F 12 606 Undetectable Negative 1 
3  50 M Nil 156 113743 Negative 1 
4 37 F 18 272 13488 Negative 1 
5 46 F 60 1090 Undetectable Negative 1 
6 55 F 180 997 Undetectable Negative 1 
7 41 M Nil 182 11358 Negative 0 
8 30 F Nil 99 29110 Negative 1 
9 30 F Nil 523 17927 N/D 1 
10 40 F Nil 920 2430 N/D 1 
11 32 F Nil 442 22698 N/D 0 
12 50 M Nil 314 2537 N/D 1 
13 33 M Nil 49 75635 N/D 1 
14 28 M Nil 310 7405 Positive 1 
15 29 F 14 172 Undetectable Negative 0 
N/D= Not Done 
 
There were 3 patients in whom the MRI scans were normal i.e. the Fazekas score was 0.  
  
127 
 
4.2.9 SPECT Scans at Baseline 
The SPECT scans were performed in the inter-ictal phase.  
 The SPECT scans were initially reported on visually  
 The perfusion in the brain images was then quantified.  
 We used the software program PBAS, version 3.6 (Referenced as Users’ 
Guide). 
 
  
Quantitative Assessment of the SPECT scans  
 “Quantitative SPECT” refers to SPECT images reconstructed in units of 
radioactivity concentration per pixel. The count/ pixel is calculated and then 
averaged out for each ROI.  We used thirty ROI (see details in the Methods 
section page 119) and the initial data for each ROI is documented in Table 4.7 
(page 130). These regions are based on the probabilistic atlas of the PBAS 
program. 
 The quantification data generated was then analysed to compare differences 
between: 
o Left and right cerebral hemispheres in terms of: 
 Individual patients 
 Corresponding dominant cerebral regions 
o The individual dominant cerebral regions 
o Patients at baseline and follow-up in terms of: 
 Individual patients 
 Corresponding dominant cerebral regions 
 CDC Stages 
o Patients pre and post-HAART 
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Table 4.5 SPECT scans at Baseline (Visual Assessment) 
 
Patient 
Number 
Visual Assessment 
1 
Perfusion defects in inferior parts of temporal lobes. 
R>L. 
2 
Perfusion defects in anterior and mesial parts of temporal lobes. 
L>R. 
3 Perfusion defects in temporal lobes; R>L. and L. basal ganglia 
4 Perfusion defects in anterior and inferior parts of temporal lobes 
5 Perfusion defects in temporal lobes 
6 Normal 
7 Normal 
8 Perfusion defects in anterior and mesial parts of both temporal 
lobes and R. basal ganglia 
9 
Perfusion defects in anterior temporal lobes (L>R) and L. parietal 
lobe. 
10 Perfusion defects both temporal lobes and basal ganglia. 
11 
Perfusion defects in mesial parts of both temporal lobes and L. 
parietal lobe. 
12 
Perfusion defects in anterior and mesial parts of both temporal 
lobes (R>L). 
13 
Perfusion defects in anterior and mesial parts of both temporal 
lobes and parietal lobes. 
14 Normal 
15 
Perfusion defects in inferior parts of both temporal lobes (L>R) 
and L. parietal lobe. 
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Table 4.6 SPECT scans at Baseline (Visual Assessment) 
 
  
Patient 
Number 
Temporal 
 
Parietal 
Basal Ganglia 
 
Frontal 
 Left Right Left Right Left Right Left Right 
1 + ++       
2 ++ +       
3  ++   +    
4 ++ ++       
5 ++ ++       
6 Normal 
7 Normal 
8 ++ ++    +   
9 ++ + +      
10 + +   + +   
11 + + +      
12 + ++       
13 + + + +     
14 Normal 
15 ++ + +      
Key 
+: <2 Deficits present 
++: >2 Deficits present  
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Table 4.7 Quantitative SPECT Data at Baseline (30 ROI) 
NB! There were no quantitative SPECT data for patients 9 and 10 due to technical difficulties 
Legend 
L=Left; R=Right; FS= Frontal Superior; F M= Frontal Middle; FI= Frontal Inferior; CiA= Cingulate Anterior; 
CiM= Cingulate Middle; CiP= Cingulate Posterior; HP= Hippocampus; O= Occipital; Ca= Caudate; Pu= 
Putamen; Pa= Pallidum; Th= Thalamus; Par= Parietal; Tem= Temporal; Cb= Cerebellum 
SPECT images reconstructed in units of radioactivity concentration per pixel and averaged per region 
  
Patients 1 2 3 4 5 6 7 8 11 12 13 14 15 Mean 
Region  
FS L 51.07 48.16 27.70 56.06 105.23 60.13 41.24 35.73 119.57 63.44 55.47 75.92 32.36 65.75 
FS R 51.47 49.26 26.84 55.69 106.53 59.34 47.32 35.50 120.25 65.46 56.12 73.86 38.12 66.61 
FM L 54.59 46.82 29.29 55.84 102.41 59.57 37.42 36.89 117.29 62.49 56.99 75.09 20.62 65.64 
FM R 55.49 51.42 29.26 60.39 108.21 62.89 51.93 39.01 125.19 66.83 58.92 72.96 28.81 69.94 
FI L 52.31 48.45 30.37 55.48 109.00 61.57 35.70 37.03 108.43 64.02 55.73 78.59 22.10 67.27 
FI R 55.13 48.63 29.66 55.26 113.57 64.27 50.40 37.59 117.71 65.96 56.05 75.54 25.45 69.14 
CiA L 56.23 49.24 31.08 55.59 114.69 62.94 50.01 37.55 113.09 68.83 62.31 76.13 35.70 70.42 
CiA R 58.28 52.96 30.55 58.23 118.94 62.83 49.61 40.15 120.48 67.45 61.45 75.46 39.89 72.18 
CiM L 53.64 51.60 31.81 53.80 123.02 60.91 53.31 36.19 115.33 60.74 56.96 75.23 40.56 69.06 
CiM R 55.64 51.74 30.72 56.45 126.30 60.31 52.55 36.47 115.22 64.55 58.61 72.95 43.29 70.42 
CiP L 50.59 47.35 27.83 46.19 115.10 51.74 49.50 32.61 103.55 52.38 52.43 75.33 40.28 62.83 
CiP R 45.50 46.24 26.40 41.08 109.11 50.60 44.67 32.48 98.84 49.08 54.38 62.87 43.30 60.44 
HP L 47.88 42.85 27.02 49.47 116.58 57.79 44.73 30.75 98.82 59.35 51.09 60.39 32.01 61.88 
HP R 45.28 42.38 26.75 50.01 114.96 56.32 46.05 32.78 98.96 56.97 51.81 68.70 28.39 61.52 
O L 57.53 51.91 34.03 60.29 114.18 67.66 53.56 36.01 131.46 71.73 62.12 68.58 46.89 73.96 
O R 54.87 52.23 34.21 58.01 120.70 70.31 35.28 37.08 125.79 68.70 59.21 79.81 45.82 72.63 
Ca L 45.98 43.32 26.60 42.81 101.63 50.74 40.56 32.11 96.79 51.21 53.87 81.81 30.47 57.49 
Ca R 47.08 42.61 25.97 40.26 111.19 48.19 46.67 32.38 92.06 45.52 49.82 58.96 33.98 58.09 
Pu L 54.61 53.76 31.69 61.26 126.53 69.45 50.48 39.22 121.82 69.23 72.08 54.11 24.09 74.53 
Pu R 54.43 52.58 32.00 57.52 137.23 68.25 55.76 38.69 123.64 69.84 67.00 77.62 29.36 75.05 
Pa L 54.10 52.51 31.35 60.06 135.47 69.33 54.32 38.52 122.84 68.02 74.70 79.40 24.46 75.26 
Pa R 54.76 52.67 31.39 58.29 138.62 65.43 52.42 36.76 116.65 69.75 63.11 81.08 31.27 73.17 
Th L 49.34 47.95 31.36 53.99 126.97 61.56 51.96 36.36 114.91 63.68 61.72 77.57 29.86 68.98 
Th R 54.09 50.32 32.64 52.80 126.37 58.59 48.88 33.05 121.91 62.81 56.16 68.15 31.08 69.40 
Par L 54.29 51.73 32.23 54.91 108.42 60.70 45.75 35.98 119.94 65.21 57.70 71.61 39.12 69.41 
Par R 50.67 52.28 30.15 52.76 108.09 60.11 35.05 33.78 120.29 61.27 54.73 76.30 34.32 66.83 
Tem L 52.40 47.83 29.99 55.66 110.16 61.44 40.60 34.60 107.50 63.66 57.21 75.56 42.03 67.04 
Tem R 53.98 49.51 29.81 55.92 116.33 64.52 37.58 34.82 115.67 64.85 58.03 74.06 42.29 68.91 
Cb L 59.35 55.93 32.78 59.33 132.88 68.70 51.14 38.52 128.83 70.84 66.02 76.72 44.38 77.25 
Cb R 58.61 55.51 33.00 60.61 135.06 68.95 46.24 38.69 132.86 69.44 66.19 81.64 47.43 76.72 
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The individual ROI were grouped together to represent the dominant cerebral regions. These 
groupings are based on the brain probabilistic atlas of the PMOD software program 
(Referenced as Users guide). 
 Frontal Superior; Middle and Inferior Frontal region 
 Cingulate Anterior; Middle and Posterior Cingulate 
 Caudate; Thalamus; Putamen and Pallidum Central region 
 Temporal and Hippocampus   Temporal region 
 Parietal     Parietal region    
 Occipital     Occipital region 
 Cerebellum     Cerebellum 
 
 
The quantitative data, at baseline according to dominant cerebral regions is documented 
below. 
Table 4.8 Cerebral Regions  
 
Patient 
Number 
Frontal Cingulate 
Central 
Region 
Temporal 
Region 
Parietal 
Region 
Occipital 
Region 
Cerebellum 
1 320.06 319.88 414.39 199.54 104.96 112.4 117.96 
2 292.74 299.13 395.72 182.57 104.01 104.14 111.44 
3 173.12 178.39 243 113.57 62.38 68.24 65.78 
4 338.72 311.34 426.99 211.06 107.67 118.3 119.94 
5 644.95 707.16 1004.01 458.03 216.51 234.88 267.94 
6 367.77 349.33 491.54 240.07 120.81 137.97 137.65 
7 264.01 299.65 401.05 168.96 80.8 88.84 97.38 
8 221.75 215.45 287.09 132.95 69.76 73.09 77.21 
11 708.44 666.51 910.62 420.95 240.23 257.25 261.69 
12 388.2 363.03 500.06 244.83 126.48 140.43 140.28 
13 339.28 346.14 498.46 218.14 112.43 121.33 132.21 
14 451.96 437.97 578.7 278.71 147.91 148.39 158.36 
15 167.46 243.02 234.57 144.72 73.44 92.71 91.81 
SPECT images reconstructed in units of radioactivity concentration per pixel and averaged per region for each 
patient 
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4.2.10 Statistical Analysis of Quantitative SPECT Data at Baseline 
  
The details of the statistical analyses are documented in Appendix G. 
A significance level of 5% was assumed. 
The data of the 30 ROI was normally distributed, enabling parametric tests. 
The following findings were relevant: 
 There was symmetrical perfusion between the left and right cerebral 
hemispheres for: 
o Individual patients 
o Dominant cerebral regions (all patients grouped together) 
 
 There were significant regional differences between the cerebellum (reference 
region) and the: 
o Frontal region 
o Cingulate 
o Central region 
o Temporal region 
 
 There were significant regional differences between the patients in HIV stage 
3 and: 
o Stage 1 
o Stage 2  
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4.2.11 Follow-up Data 
Follow-up data is available for 8 patients (patients 1-8 according to table 4.4 page 126). 
The data is recorded in tables 4.11 to 4.18 (pages 136-152) 
 One patient was pregnant during the study and did not have some of the 
investigations done at her 6 month visit. She did however continue to follow 
up and her investigations were completed later (Patient 1).   
 One patient did not attend her 6-month follow-up but did come to the 12 
month follow-up (Patient 3).  
Demography 
The average follow-up period for females was 10.2 months and males were 6.6 months. 
HAART 
Four patients initiated HAART during the study. All patients were on HAART at their last 
visit.  NB! Patient 1 was eligible for HAART from her initial visit but declined therapy on 
numerous occasions. She only initiated HAART after discovering that she was pregnant.  
CD4 Count and HIV-1 RNA Viral Loads  
There were 8 patients who had repeat CD4 counts and HIV-1 RNA Viral Loads measured. 
A significant change in the CD4 count is defined as a 30% change in the absolute count 
(Panel on Antiretroviral Guidelines for Adults and Adolescents, 2015). Four patients had 
significant changes in their CD4 counts during the study period. In 3 of the patients there was 
an improvement. Three of these patients initiated HAART during the study.  
 
HIV Stages 
At final visits: 
 There were 4 patients in stage 1 
 There were 4 patients in stage 2 
 There were no patients in stage 3 
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Table 4.9 Summary of Laboratory Investigations and MRI Results 
(6 Months) 
Patient 
Number 
HAART 
(Duration 
In 
months) 
CD4 
HIV-1 
RNA VL 
MRI 
Score 
(Fazekas) 
SPECT 
(Visual) 
1 Nil 255 295 2 
Perfusion defects 
in temporal 
lobes. R>L. 
2 18 383 35030 1 
Perfusion defects 
temporal lobes. 
L>R. Additional 
perfusion defects 
in L. parietal 
lobe 
3  6 338 70237 1 
Perfusion defects 
in L. temporal; 
parietal and 
frontal lobes 
4 Did not attend 
5 66 1066 Undetectable 1 
Perfusion defects 
in temporal lobes 
L>R 
6 186 572 200 2 
Perfusion defects 
in temporal and 
parietal lobes. 
L>R. 
7 3 251 4878 0 Normal 
8 5 280 7430 1 
Perfusion defects 
both temporal 
lobes 
 
NB! The lumbar punctures at this stage did not reveal any significant abnormalities  
135 
 
Table 4.10 Summary of Laboratory Investigations and MRI Results 
(12 Months) 
Patient 
Number 
HAART 
(Duration 
In 
months) 
CD4 
HIV-1 
RNA VL 
MRI 
Score 
(Fazekas) 
SPECT 
(Visual) 
1 7 299 Undetectable 2 Normal                    
2 18 598 14465 0 
Perfusion defects 
in both temporal 
lobes 
3  12 546 10658 1 
Perfusion defects 
in both temporal 
lobes 
4 30 539 13488 1 
Perfusion defects 
in inferior parts 
of temporal lobes 
NB!! The data for patient 1 was done at 18 months; she was pregnant at the 12 month visit 
 
Follow-up Data for Individual Patients 
The clinical; laboratory; radiology and nuclear medicine data for each of the 8 patients that 
followed up for a minimum period of 6 months is detailed in the following 8 tables. 
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Table 4.11 Baseline and Follow-up Data Patient 1 
 
Investigation Visit 1 Visit 2  
(6 Months) 
Visit 3  
(12 Months) 
Visit 4  
(18 Months) 
Clinical 
Examination 
Normal Normal Normal 
(Pregnant) 
Normal 
Seizure 
Control 
2 GTC seizures 
prior to her 
visit 
Inadequate 
(2 events) 
Good 
(0 events) 
Good 
(0 events) 
AED None 
Sodium 
Valproate 
started 
Sub-therapeutic 
Dose adjusted 
No adjustment 
Patient already 
in 2
nd
 trimester 
No adjustment 
 
IHDS 12 12 11 12 
CD4 count 340 255 198 299 
Viral Load 356 295 423 Undetectable 
HAART No No Yes Yes 
HAART 
Duration 
Nil Nil 1 Month 7 Months 
MRI Scan 
(Fazekas 
Score) 
2 2 Not done 
(Patient 
pregnant) 
 
 
2 
Qualitative 
SPECT 
Perfusion 
defects in 
inferior parts of 
temporal lobes. 
R>L. 
No change Normal 
Quantitative 
SPECT 
comparisons 
P=0.88 
P=0.012 
(between visit 2 
and 3) 
p=0.005 
(between visit 1 
and 3) 
 
Frontal 320.06 314.53 510.27 
Cingulate 319.88 310.88 487.52 
Central 
Region 
414.39 409.23 660.03 
Temporal 
Region 
199.54 102.15 301.87 
Parietal 
Region 
104.96 105.11 166.54 
Occipital 
Region 
112.4 198.92 168.76 
Cerebellum 117.96 111.36 172.65 
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Patient 1 Baseline and Follow-up Data 
 
Baseline 
She was clinically stable. 
She had 2 generalized tonic-clonic seizures prior to her presentation. She was not on anti-
epileptic medication. Sodium valproate was started at an appropriate dose. 
She was not on HAART; despite having being referred previously. 
Her CD4 count was within the range at which therapy would have been recommended i.e. her 
CD4 count was < 350 cells/µL (South African antiretroviral therapy guidelines, 2013). 
Her MRI scan revealed some unexplained WML. 
The visual assessment of her SPECT scan showed asymmetrical temporal lobe defects.  
6 Month Visit 
She was clinically well but reported 2 seizures during the intervening period. Laboratory 
investigations revealed that her sodium valproate level was sub-therapeutic and her dose was 
adjusted accordingly.  
She remained reluctant to initiate HAART; despite the decrease in her CD4 count. 
Her MRI and visual assessments of her SPECT scan remained unchanged. 
The quantitative data for her first and second SPECT scans were compared and the difference 
was insignificant (p=0.88). 
12 Month Visit 
She was stable; she had not experienced any seizures since her previous visit. 
She was pregnant (4 months). Her anti-epileptic medication was not changed as she was in 
the second trimester already. She did not have any radiological investigations during this 
period 
She initiated HAART 1 month prior to her visit. 
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18 Month Visit 
She was stable; she had not experienced any seizures since her previous visit. 
There was a significant increase in her CD4 count (> 50%) and her serum viral load was 
undetectable.  
The visual assessment of her SPECT scans also improved. 
The quantitative SPECT data were compared (see appendix G for statistical analysis) 
 No improvement between scans 1 and 2 (p=0.94).  
 Improvement between scans 
o 1 and 3 (p=0.005) 
o 2 and 3 (p=0.012) 
 
In this patient the initiation of HAART corresponded with: 
 Adequate seizure control 
 Significant increase in her CD4 count 
 Decrease in her serum viral load 
 Improvement in the visual and quantitative assessments of her SPECT scans 
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Table 4.12 Baseline and Follow-up Data Patient 2 
 
Investigation Visit 1 
Visit 2 
(6 Months) 
Visit 3 
(12 Months) 
Clinical 
Examination 
Normal 
Lower respiratory 
tract infection 
Normal 
Seizure 
Control 
Good 
(0 events) 
Good 
(0 events) 
Good 
(0 events) 
AED Sodium Valproate Sodium Valproate Sodium Valproate 
IHDS Score 12 11 12 
CD4 count 606 383 598 
Viral Load Undetectable 35030 14465 
HAART Yes Yes Yes 
HAART 
Duration 
12 Months 18 Months 24 Months 
MRI Scan 
(Fazekas 
Score) 
1 1 0 
Qualitative 
SPECT 
Perfusion defects 
in anterior and 
mesial parts of 
temporal lobes. 
L>R. 
Additional perfusion 
defects in L. parietal 
lobe 
Perfusion defects in 
both temporal lobes 
Quantitative 
SPECT 
comparisons 
P=0.44 P=0.04 
Frontal 
Region 
292.74 364.81 754.21 
Cingulate 299.13 379.77 796.3 
Central 
Region 
395.72 507.56 1079.72 
Temporal 
Region 
182.57 125.16 492.73 
Parietal 104.01 237.63 269.96 
Occipital 104.14 129.85 286.85 
Cerebellum 111.44 147.92 309.73 
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Patient 2 Baseline and Follow-up Data 
 
Baseline 
She was clinically stable. 
She had 1 generalized tonic-clonic seizure prior to her presentation. She was on sodium 
valproate which had been started at her local clinic. 
She was stable on HAART. 
Her MRI scan revealed some unexplained WML. 
The visual assessment of her SPECT scan showed asymmetrical temporal lobe defects.  
6 Month Visit 
She was unwell and had symptoms and signs of a lower respiratory tract infection. She 
received antibiotics and had improved when seen a week later. Her CXR did not reveal 
evidence of TB and her sputum samples were negative for AFBs. 
Her laboratory investigations revealed that her immune control had deteriorated. 
There were no significant changes in her MRI scan. 
The visual assessment of her SPECT scan revealed additional defects in the left parietal lobe. 
The difference in the quantitative assessments between her initial and repeat SPECT scans 
was insignificant (p=0.44). 
12 Month Visit 
She was stable and her seizure control remained good.  
Her immune markers improved. 
Her MRI scan and the visual assessment of her SPECT scan also improved. 
The quantitative assessment of her SPECT scans revealed a significant improvement in 
comparison to her previous scan (p=0.04). 
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Table 4.13 Baseline and Follow-up Data Patient 3 
 
Investigation Visit 1 Visit 2  
(6 Months) 
Visit 3  
(12 Months) 
Clinical 
Examination 
Normal Normal Normal 
Seizure 
Control 
Good 
(0 events) 
Good 
(0 events) 
Good 
(0 events) 
AED Sodium Valproate Sodium Valproate Sodium Valproate 
IHDS Score 10 10 12 
CD4 count 156 338 546 
Viral Load 113743 70237 10658 
HAART No Yes Yes 
HAART 
Duration 
Nil 6 Months 12 Months 
MRI Scan 
(Fazekas 
Score) 
2 1 1 
Qualitative 
SPECT 
Perfusion defects 
in temporal lobes; 
R>L. and L. basal 
ganglia 
Perfusion defects in 
L. temporal; parietal 
and frontal lobes 
Perfusion defects in 
both temporal lobes 
Quantitative 
SPECT 
comparisons 
P=0.03 (between visit 1 and 3) 
 
Frontal 
Region 
173.12 
Not Available 
693.18 
Cingulate 178.39 645.75 
Central 
Region 
243 863.6 
Temporal 
Region 
113.57 400.75 
Parietal 62.38 235.57 
Occipital 68.24 245.67 
Cerebellum 65.78 245.26 
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Patient 3 Baseline and Follow-up Data 
Baseline 
He was clinically stable. 
He had 3 generalized tonic-clonic seizures prior to his presentation. He was on sodium 
valproate which had been started during his admission to the medical ward one week 
previously. 
He had begun counselling at his local clinic and was due to begin anti-retroviral therapy a 
week later. 
His MRI scan revealed WML. 
The visual assessment of his SPECT scan showed asymmetrical temporal lobe and basal 
ganglia defects.  
6 Month Visit 
He was clinically stable and had initiated HAART 6 months previously. 
His immune control had improved as evidenced by the significant increase in his CD4 count 
and a decrease in his serum viral load.  
His MRI scan and the visual assessment of his SPECT scan also improved.  
Unfortunately due to technical difficulties there were no quantitative data for the SPECT. 
12 Month Visit 
He had clinical improvement and continued his immune recovery. 
The visual assessment of his SPECT revealed improvements and his quantitative data was 
significantly improved when compared to the initial scan (p=0.03).  
In this patient the initiation of HAART corresponded with: 
 Significant increase in his CD4 count over 12 months 
 Decrease in his serum viral load 
 Improvement in his MRI scan 
 Improvement in the quantitative assessments of his SPECT scans (p=0.03) 
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Table 4.14 Baseline and Follow-up Data Patient 4 
 
Investigation 
Visit 1 Visit 2  
(6 Months) 
Visit 3  
(12 Months) 
Clinical 
Examination 
Normal 
Patient did not 
attend 
Normal 
Seizure 
Control 
Good 
(0 events) 
Good 
(0 events) 
AED Sodium Valproate Sodium Valproate 
IHDS Score 12 11 
CD4 count 272 539 
Viral Load 35396 13488 
HAART Yes Yes 
HAART 
Duration 
18 Months 30 Months 
MRI Scan 
(Fazekas 
Score) 
1 1 
Qualitative 
SPECT 
Perfusion defects 
in anterior and 
inferior parts of 
temporal lobes 
Perfusion defects in 
inferior parts of 
temporal lobes 
Quantitative 
SPECT 
P=0.002 
Frontal 
Region 
338.72 
 
452.17 
Cingulate 311.34 422.23 
Central 
Region 
426.99 568.51 
Temporal 
Region 
211.06 288.06 
Parietal 107.67 151.85 
Occipital 118.3 161.62 
Cerebellum 119.94 164.31 
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Patient 4 Baseline and Follow-up Data 
 
Baseline 
She was clinically stable. 
She had 1 generalized tonic-clonic seizure prior to her presentation. She was on sodium 
valproate which had been started by her general practitioner. 
She was on HAART for 18 months but her virologic control was inadequate and she was 
referred for review of her therapy. 
Her MRI scan revealed WML. 
The visual assessment of her SPECT scan showed symmetrical temporal lobe defects.  
 
6 Month Visit 
She did not attend as she was away taking care of her ill mother. 
 
12 Month Visit 
She was clinically stable and had not experienced any further seizures. 
Her immune control had improved following a change in her antiretroviral therapy. 
The visual assessment of her SPECT scan also improved.  
The quantitative assessment of her SPECT scans revealed a significant improvement in 
comparison to her previous scan (p=0.002). 
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Table 4.15 Baseline and Follow-up Data Patient 5 
 
Investigation Visit 1 Visit 2  
(6 Months) 
Visit 3  
(12 Months) 
Clinical 
Examination 
Normal Normal 
Patient did not 
return 
Seizure 
Control 
2 GTC seizures 
prior to her visit 
Good 
(0 events) 
AED 
None 
Sodium Valproate 
started 
Sodium Valproate 
IHDS Score 11 11 
CD4 count 1090 1066 
Viral Load Undetectable Undetectable 
HAART Yes Yes 
HAART 
Duration 
60 Months 66 Months 
MRI Scan 
(Fazekas 
Score) 
1 1 
Qualitative 
SPECT 
Perfusion defects 
in temporal lobes 
Perfusion defects in 
temporal lobes.  
L>R 
Quantitative 
SPECT 
P=0.32 
Frontal 
Region 
367.77 406.78 
Cingulate 349.33 399.28 
Central 
Region 
491.54 577.3 
Temporal 
Region 
240.07 271.07 
Parietal 120.81 136.68 
Occipital 137.97 164.82 
Cerebellum 137.65 160.52 
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Patient 5 Baseline and Follow-up Data 
Baseline 
She was clinically stable. 
She had 2 generalized tonic-clonic seizure prior to her presentation. She was started on 
sodium valproate.  
She was on HAART for 60 months and her virologic control was good. 
Her MRI scan revealed WML. 
The visual assessment of her SPECT scan showed asymmetrical temporal lobe and basal 
ganglia defects.  
 
6 Month Visit 
She remained stable and her seizure control was good. 
She maintained her virologic suppression. 
The visual and quantitative assessment of her SPECT scans improved,  but the improvement 
in the quantitative data was not significant (p=0.32). 
In this patient her clinical stability coincided with: 
 An insignificant decrease in her CD4 count  
 Maintenance of virologic suppression 
 An insignificant increase in cerebral perfusion on quantitative SPECT 
measurements (p=0.32) 
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Table 4.16 Baseline and Follow-up Data Patient 6 
 
Investigation Visit 1 Visit 2  
(6 Months) 
Visit 3  
(12 Months) 
Clinical 
Examination 
Normal Features of HAD 
Patient did not 
return 
Seizure 
Control 
Good 
Fair 
(1 event) 
AED Sodium Valproate Sodium Valproate 
IHDS Score 11 8 
CD4 count 997 572 
Viral Load <40 200 
HAART Yes Yes 
HAART 
Duration 
180 Months 186 Months 
MRI Scan 
(Fazekas 
Score) 
1 2 
Qualitative 
SPECT Normal 
Perfusion defects in 
temporal and 
parietal lobes.  
L>R. 
Quantitative 
SPECT 
P=0.007 
Frontal 
Region 
644.95 456.5 
Cingulate 707.16 445.85 
Central 
Region 
1004.01 610 
Temporal 
Region 
458.03 294.26 
Parietal 216.51 152.35 
Occipital 234.88 160.87 
Cerebellum 267.94 170.49 
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Patient 6 Baseline and Follow-up Data 
 
Baseline 
She was clinically stable. 
She had 1 generalized tonic-clonic seizure prior to her presentation. She was on sodium 
valproate which had been started by her general practitioner. 
She was on HAART for 18 months but her virologic control was inadequate and she was 
referred for review of her therapy. She did not follow up on this referral. 
Her MRI scan revealed WML. 
The visual assessment of her SPECT scan showed symmetrical temporal lobe defects.  
6 Month Visit 
She had clinical features of HAD; and her IHDS score deteriorated. 
She had 1 seizure; despite her AED level being normal. 
Her immunological control deteriorated and she was referred for review of her antiretroviral 
regimen. The patient claimed that she was compliant on her anti-retrovirals and had proof of 
regular clinic visits to collect her medication. 
Her MRI scan and visual assessments of her SPECT scans were worse. 
The quantitative data revealed a significant deterioration (p=0.007) between her initial and 
repeat scans. 
In this patient her neurocognitive deterioration coincided with: 
 A decrease in her CD4 count  
 An increase in her viral load  
 An increase in the quantity of WML on her MRI scan 
 An increase in perfusion defects 
 A significant decrease in cerebral perfusion on quantitative SPECT 
measurements (p=0.007). 
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Table 4.17 Baseline and Follow-up Data Patient 7 
 
Investigation Visit 1 
Visit 2  
(6 Months) 
Visit 3  
(12 Months) 
Clinical 
Examination 
Normal Normal 
Patient did not 
return 
Seizure 
Control 
Good 
(0 events) 
Good 
(0 events) 
AED Sodium Valproate Sodium Valproate 
IHDS Score 11 12 
CD4 count 182 251 
Viral Load 11358 4878 
HAART No Yes 
HAART 
Duration 
Nil 3 Months 
MRI Scan 
(Fazekas 
Score) 
0 0 
Qualitative 
SPECT 
Normal Normal 
Quantitative 
SPECT 
P=0.001 
Frontal 
Region 
264.01 535.64 
Cingulate 299.65 503.91 
Central 
Region 
401.05 679.38 
Temporal 
Region 
168.96 325.8 
Parietal 80.8 177.22 
Occipital 88.84 197.83 
Cerebellum 97.38 196.37 
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Patient 7 Baseline and Follow-up Data  
 
Baseline 
He was clinically stable. 
He had 2 generalized tonic-clonic seizures prior to his presentation. He was on sodium 
valproate which had been started during his admission to the medical ward three weeks 
previously. 
His MRI scan and the visual assessment of his SPECT scan were normal. 
He was referred to the hospital clinic for counselling and initiation of HAART. 
 
6 Month Visit 
He was clinically stable and had initiated HAART 3 months previously. 
His immune control had improved as evidenced by the significant increase in his CD4 count 
and a decrease in his serum viral load.  
His MRI scan and the visual assessment of his SPECT scan remained normal.  
The quantitative SPECT data showed a significant improvement (p=0.001). 
 
In this patient the initiation of HAART corresponded with: 
 Significant increase in his CD4 count 
 Decrease in his serum viral load 
 Improvement in the quantitative assessments of his SPECT scans (p=0.001). 
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Table 4.18 Baseline and Follow-up Data Patient 8 
 
Investigation Visit 1 Visit 2  
(6 Months) 
Visit 3  
(12 Months) 
Clinical 
Examination 
Stable Stable 
Patient did not 
return 
Seizure 
Control 
Fair 
(1 event) 
Good 
AED None None 
IHDS Score 11 12 
CD4 count 99 280 
Viral Load 29110 7430 
HAART No Yes 
HAART 
Duration 
Nil 5 months 
MRI Scan 
(Fazekas 
Score) 
1 1 
Qualitative 
SPECT 
Perfusion defects 
in anterior and 
mesial parts of 
both temporal 
lobes and R. basal 
ganglia 
 
Perfusion defects in 
anterior, mesial and 
inferior parts of both 
temporal lobes 
Quantitative 
SPECT 
P=0.004 
Frontal 
Region 
221.75 698.01 
Cingulate 215.45 700.28 
Central 
Region 
287.09 909.22 
Temporal 
Region 
132.95 415.51 
Parietal 69.76 221.73 
Occipital 73.09 228.92 
Cerebellum 77.21 246.81 
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Patient 8 Baseline and Follow-up Data 
 
Baseline 
She was clinically stable. 
She had 1 generalized tonic-clonic seizure prior to her presentation. She was not on anti-
epileptic therapy and unwilling to start. 
She was referred to her local clinic for counselling and to initiate HAART. 
Her MRI scan revealed WML. 
The visual assessment of her SPECT scan showed symmetrical temporal lobe defects and 
defects in the right basal ganglia.  
 
6 Month Visit 
She remained stable and did not experience any further seizures. 
She was on HAART and did not experience any significant side-effects. 
The visual assessment of her SPECT scans revealed a marginal improvement. 
The quantitative SPECT data showed a significant improvement (p=0.004). 
 
In this patient the initiation of HAART corresponded with: 
 Good seizure control 
 Significant increase in her CD4 count 
 Decrease in her serum viral load 
 Improvement in the visual and quantitative assessments of her SPECT scans 
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Pre- and Post-HAART Sub-group 
Four patients (patients 1; 3; 7 and 8) initiated HAART during the study. Their data was 
analysed separately.  
Table 4.19 Pre and Post-HAART Clinical Data 
 
Patient 
Number 
HAART 
Duration 
(months) 
CD4 Count Viral Load 
MRI 
Fazekas 
Score 
 Pre-
HAART 
Post-
HAART 
Pre-
HAART 
Post-
HAART 
Pre-
HAART 
Post-
HAART 
1 7 255 299 295 Undetectable 2 2 
3 12 156 546* 113743 10658 2 1 
7 3 182 251* 11358 4878 0 0 
8 5 99 280* 29110 7430 1 1 
*These patients had a significant increase in their CD4 counts 
 
The SPECT Quantitative data for each of the 4 patients’ pre and post-HAART were analysed 
(see Appendix G for details): 
 There was a significant increase in both left and right cerebral perfusion for 
each patient 
 There was a significant increase in the overall perfusion for each patient as 
indicated by the assessments of the dominant cerebral regions 
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4.2.12 Summary of Results 
 
There were twenty-two patients were eligible for the study but only 15 patients consented to 
inclusion in the longitudinal study (10 females and 5 males).  
At baseline: 
 All patients presented with generalized tonic clonic seizures. 
 Most patients (14) were either on sodium valproate or initiated it at that visit 
 Only 5 patients were on HAART 
 Six patients were in HIV stage 1 and 5 in stage 2 
 The majority (13) had normal EEG recordings. 
 The most common MRI finding was unexplained WML (12 patients). 
 The most common abnormality on visual SPECT assessment was in the 
temporal region (12 patients). 
 Quantitative SPECT revealed regional abnormalities between the cerebellum 
and Frontal; cingulate; central and temporal regions 
Follow-up: 
 There was a high rate of attrition i.e. there were 7 patients at the 6 month visit 
and 4 patients at the 12 month visit. 
 Seizure control was adequate except in 1 patient who required a dose 
adjustment. 
 HAART was initiated in 4 patients. 
 Unexplained WML persisted; except in : 
o Patient 3 the lesions ↓ 
o Patient 6 the lesions ↑ 
 Visual SPECT assessments: 
o Improved in patients 1; 2; 3; 4 and 7 
o Deteriorated in patient 6 
 There was an improvement in the cerebral perfusion as measured by the 
quantitative SPECT in all patients except patient 6 
 
Pre and post-HAART 
 Four patients initiated HAART during the study 
 All had improvements in their 
o CD4 counts 
o Viral loads 
o Quantitative SPECT data 
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4.3 Descriptive Analysis at Baseline and Follow-up 
4.3.1 Attrition 
There was a high rate of attrition in the longitudinal study. Numerous factors have previously 
been recognized which contribute to decreased recruitment and high attrition in longitudinal 
studies (Patel, Doku and Rennakoon 2003 and Booker, Harding and Benzeval 2011).  
The following were important factors in this study: 
 Male gender 
 “Non-White” race 
 Underprivileged socio-economic individuals i.e. unemployed or low 
occupational status 
 Low educational status 
 Low family income 
 People at increased risk of ill-health/ recent illness/ poor present health 
 Misgiving about  researchers and studies 
 Apprehensions about the research and consent processes 
 Differences in perceptions between lay belief and medical teaching 
 Additional demands of this trial 
o Length of time to complete investigations 
This was crucial in this context as patients had investigations (CTB; 
MRI and SPECT scans) which are subject to long waiting lists at the 
research sites 
o Stigma and reluctance to seek care amongst HIV-positive individuals 
 
 
  
156 
 
4.3.2 Demography at baseline and follow-up 
The higher proportion of females (66.6%) in this cohort was unexpected because in the larger 
study population there was a preponderance of males (57.5%). A possible explanation for this 
is that of the 7 patients at baseline who refused to be included in the study 6 were males, thus 
skewing the proportions. It has been shown that females are more likely than males to 
participate in longitudinal studies (Post et al, 2012).  
The average follow-up period for females was 10.2 months and males were 6.6 months. Mein 
et al, 2012 analysed factors which contributed to attrition in longitudinal health studies. They 
showed that “men are considerably more likely to drop out, all other factors being equal.” 
 
4.3.3 HAART at baseline and follow-up 
HAART penetration at baseline was 33.3%%, which is lower than that of the study 
population (42.5%). This finding is consistent with that of Siedner et al, 2015 who showed 
that despite the availability of HAART in South Africa the number of patients accessing 
therapy was sub-optimal due in part to: 
 Poverty 
 Transportation-related barriers 
 HIV-associated stigma 
All patients were on HAART at the end of the study.  Possible explanations include: 
 Provision of transport money  
 Decreased stigma as patients were dealing with the same doctor and staff at 
each visit 
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4.3.4 CD4 Count and HIV-1 RNA Viral loads at baseline and during  
follow-up 
The mean CD4 count at baseline (414.4cells/µL) was much higher than that of the broader 
study (167cells/µL). This is most likely due to the exclusion of patients with identifiable causes. The 
majority of our patients with identifiable causes had opportunistic infections, suggesting immune-
suppression.  Our findings are consistent with those of Modi et al, 2009. In their study patients 
with NIC for their seizures were analysed separately. The mean CD4 count in their patients 
with NIC, all of whom were HAART-naive was 323cells/µL. This was higher than their 
overall mean CD4 count which was 239cells/µL.  
During the follow-up period 3 patients registered significant improvements (>30%) in their 
CD4 counts. All of these patients initiated HAART during the study period.  The CD4 count 
increase in the patients initiating HAART is expected. Smith et al, 2004 studied the long term 
effects of HAART in 397 patients. The median CD4 count increased by: 
 114cells/µL at 6 months  
 181cells/µL at 12 months.  
The mean RNA viral load in our group was 26971.5copies/mL. This was much lower than the mean 
value in the 2009 study by Modi et al (>410678.9 copies/mL). The use of HAART in our patients 
was the most likely reason for the lower mean RNA viral loads.  
 
4.3.5 HIV Stages at baseline  
 There were 6 patients in stage 1; the majority (4) were on HAART. 
 There were 4 patients in stage 3; all were HAART-naive 
The use of HAART in some patients was associated with the obvious benefits of lower RNA viral 
loads and higher CDC stages. Moore and Bartlett, 2011 showed that HAART usage linked to: 
 Increased CD4 counts  
 Decline in RNA viral loads  
Their study population was similar to ours i.e.  an urban HIV-infected population, some of whom 
were receiving HAART. 
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4.3.6 Seizure Classification and EEG Results at baseline 
All 15 patients had generalized tonic-clonic seizures. This finding is consistent with other 
studies in which patients with NIC for their seizures have been analysed separately. In the 
2002 study by Modi et al, thirteen of their 15 patients with NIC had GTC seizures. In the 
1990 study by Wong, Suite and Labar they identified 32 patients in whom there was no 
presumed cause for the seizures except HIV. In the sub-group 22 patients had GTC seizures 
only and 14 had a combination of GTC and focal seizures. 
The EEG recordings were normal in 13 patients and in 2 patients there was generalized 
slowing. No patients had specific abnormalities of epileptic dysfunction. This correlates with 
the findings of Siddiqi et al, 2015 who showed that abnormal EEG findings in HIV-infected 
adults with NOS were associated with abnormal imaging findings. They found a link between 
white matter abnormalities on MRI and EEG slowing.  
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4.3.7 MRI scans at baseline and during follow-up 
Two thirds (10) of patients at baseline had white matter lesions on their MRI scans.  
The significance of these lesions in the clinical setting of HIV infection is unclear. It is likely 
that the white matter abnormalities observed in our patients are multi-factorial in origin. These 
lesions have been associated with numerous clinical variables:   
 Neurocognitive dysfunction 
None of the patients in this component of the study had evidence of 
neurocognitive dysfunction at baseline. The presence of abnormal white 
matter in asymptomatic HIV-infected individuals has been documented 
previously. Gray et al, 1996 showed pathological evidence of white matter 
disease in asymptomatic HIV infected individuals. A South African study 
(Hoare et al, 2011) used diffusion tensor imaging to study the relationship 
between white matter damage and cognitive impairment. They compared the 
findings in 46 Clade C HIV-positive subjects to healthy non-HIV controls. 
They detected white matter abnormalities in HIV+ cognitively normal 
individuals as well as those with HAND. The changes were more extensive in 
patients with dementia.  
 A low nadir CD4 count 
Cohen et al, 2010 examined the patterns of brain volume loss in HIV-infected 
neuroasymtomatic individuals. They found lower nadir CD4 counts were 
associated with white matter abnormalities. This has been confirmed by 
Jernigan et al, 2011.  As part of the CHARTER study they reviewed the 
clinical factors which contributed to abnormal brain structure in HIV. They 
found a low nadir CD4 count was the most consistent predictor of white 
matter abnormalities on MRI scans. In this study four patients had CD4 counts 
<200cells/µL and six were on HAART at baseline. We did not have the nadir 
CD4 counts of the patients on HAART.  As discussed previously, a recent 
meta-analysis by Siedner et al, 2015 showed that mean CD4 counts of 
>96 000 South Africans prior to commencement of anti-retroviral therapy was 
123cells/µL.   
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 Black race 
Haddow et al, 2013 retrospectively reviewed the brain MRI studies of 254 
HIV-positive patients. The images were independently reviewed for white 
matter lesions. They identified black race as the only risk factor for the 
development of diffuse white matter abnormalities.  In this study all patients 
were Black African. The significance of race in the occurrence of white matter 
lesions has also been shown in the setting of subclinical cerebrovascular 
disease associated with cardiovascular disease (Nyquist et al, 2014).   
 
 Older age 
McMurtray et al, 2007 assessed the relationship between age and white matter 
lesions in HIV-infected individuals. This study was part of the ongoing Hawaii 
aging with HIV cohort study. They concluded that in the HAART-era the 
extent of white matter lesions correlated with age and systolic blood pressure.  
Gongvatana et al, 2011 examined 85 HIV-infected individuals to determine 
the clinical factors which contribute to white matter abnormalities. Older age 
was significantly associated with white matter injury in their HIV-infected 
patients, most of who were on HAART. In our group of 15 patients there were 
3 patients who were 50years and older. 
 
 Hepatitis C co-infection 
Co-infection with Hepatitis C virus was a notable factor in patients HIV-
infected individuals with white matter injury (Gongvatana et al, 2011).  In this 
study 2 of the 10 people tested were positive for Hepatitis C. Co-infection 
rates in South Africa are <5% as reported by Rao et al, 2015.    
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4.3.8 SPECT scans  
Visual Data 
The perfusion defects documented visually at baseline in our patients were: 
 Temporal lobe abnormalities  11 patients 
 Parietal lobe abnormalities  4 patients 
 Basal ganglia abnormalities  3 patients  
 Normal    3 patients 
Temporal lobe abnormalities were detected in all our patients with abnormal scans. The 
defects were bilateral but asymmetrical. The presence of temporal lobe abnormalities in HIV-
infected patients with no discernible cause for their NOS has been documented previously 
(Modi et al, 2002). In their cohort of 15 patients (none of whom were on HAART) all had 
temporal lobe perfusion defects. They surmised that the defects were indicative of a focal 
HIV-related encephalopathy.  
Ajmani et al, 1991 performed SPECT scans on a small number (5) of patients with varying 
stages of HIV-related dementia. They documented temporal defects in all their patients; and 
found that the extent of the defects corresponded to the severity of the dementia. Their 
findings were confirmed by Schwartz et al in 1994. They detected temporal and frontal lobe 
abnormalities in their HIV infected individuals with dementia. None of our patients had 
dementia (as assessed by their IHDS score and clinical examination) at baseline; one patient 
did develop an HIV-associated dementia during the study period.  
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Quantitative Data 
In epilepsy, brain perfusion SPECT is used to localize the seizure. It is preferable that the 
patient be imaged both during the inter-ictal period as well as in the ictal state. At present 
brain SPECT is the only imaging modality able to capture the rCBF changes associated with 
seizures. Cerebral blood flow abnormalities in patients with idiopathic generalized epilepsy 
have been documented (Joo, Tae and Hong 2008): 
 Anterior and posterior cingulate gyri 
 Anterior nucleus of the thalamus Left = Right 
 Dorsolateral nucleus of the thalamus Right 
 Superior colliculus of the midbrain Right 
 Cerebellum 
 
Regional Abnormalities 
The regional abnormalities in our patients, based on the quantitative data did not correspond 
to the regions described above in patients with epilepsy. We detected multiple regions which 
had significant hypo perfusion when compared to the cerebellum (reference region): 
 Frontal Region 
 Cingulate 
 Central Region 
 Temporal Region 
[The cerebellum has previously been suggested as an optimum reference region in studies 
using 
99m
Tc-HMPAO (Syed et al, 1992)] 
The regional abnormalities which we have documented may indicate that the patients with 
NOS in who no cause has been identified: 
 May represent an early phase in the spectrum of neurocognitive dysfunction 
seen in HIV infection 
 May be a precursor for dementia in some patients 
In this study one patient (patient 11) developed features consistent with a 
diagnosis of HIV-associated dementia. 
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Pohl et al, 1988 studied 12 HIV infected individuals with varying degrees of neurocognitive 
dysfunction. The SPECT scans in most of their patients were abnormal. They did follow-up 
scans in some patients which revealed increased numbers of defects, equivalent to the 
increase in clinical symptoms. 
Schielke et al, 1990 studied 20 patients with HIV infection and no significant neurological 
dysfunction. Their findings suggested: 
 Perfusion abnormalities on SPECT may occur prior to clinical features of 
dementia  
Holman et al, 1992 compared the brain SPECT scans of 20 HIV-infected individuals with 
dementia and 20 normal control subjects.  They found increased cortical defects in patients 
with dementia. The regions most affected were similar to the regions affected in our patients: 
 Frontal  
 Temporal 
 Parietal 
In 1995 (b) Sacktor et al compared SPECT abnormalities in HIV-infected individuals with 
and without cognitive impairment. They found no difference in the number of abnormalities 
observed between the two groups. They postulated:  
 SPECT abnormalities may precede the development of cognitive impairment 
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The regional abnormalities in our patients with early dementia were analogous to the findings 
of Maini et al, 1990. They performed SPECT scans on 26 patients with either early or late 
AIDS dementia. In their 21 patients with early dementia the following areas were affected (in 
decreasing frequency): 
 Frontal region 
 Anterior temporal and posterior parietal lobes 
 Anterior parietal lobe 
Schwartz et al, 1994 compared the SPECT findings in 27 patients with HIV related dementia 
to 38 healthy controls. The abnormalities detected in their patients were similar to those in 
ours. The patients with dementia had significantly increased defects in: 
 Medial and lateral frontal region 
 Medial and lateral temporal regions 
Chang et al, 2000 used perfusion MRI to document decreased regional cerebral blood flow in 
19 HIV infected patients with HIV-minor cognitive motor disorder and HIV associated 
dementia. They found significantly decreased blood flow in: 
 Inferior, lateral frontal cortex   Right > Left 
 Inferior medial parietal region  Left = Right 
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Individual patients at baseline: Left versus Right analysis 
 
In our patients there were no significant differences 
 Between the left and right hemispheres overall 
 Between the left and right corresponding dominant cerebral regions  
This is consistent with the findings of Harris et al, 1994. They attempted to quantitatively 
demonstrate cerebral perfusion abnormalities in HIV-1 infected individuals. They compared 
3 groups of patients: 
 9 HIV infected individuals with mild dementia 
 10 neurologically asymptomatic HIV infected individuals 
 8 HIV uninfected individuals 
They did not identify any region that had significantly increased asymmetry compared to 
controls and concluded that  
 HIV-positive individuals have diffuse and variable abnormalities which could 
be regional; hemispheric or global.  
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SPECT scans Pre- and Post-HAART 
The four patients who initiated HAART during the study showed significant improvements in 
cerebral perfusion in all regions between the scans done pre- and post-HAART (see 
Appendix G for calculation).  
 Patient 15 had 2 SPECT scans prior to HAART initiation and there was no 
significant difference between the two scans.  
 She had a significant improvement in cerebral perfusion in the third scan; this 
was done 6 months after she initiated HAART.  
 The results for this patient suggest that the significant changes seen were 
linked in these 4 patients to the initiation of HAART.   
 
In 2013 Bailey and Willowson conducted an evidence based review of quantitative SPECT 
imaging and potential clinical applications. Amongst the potential uses listed was to: 
 Assess disease progression or response to treatment 
Several studies have shown the benefit of SPECT scans in the monitoring of response to 
therapy in neurological disorders: 
 Cerebral blood flow during long-term treatment of elderly patients with 
nootropic drugs (Dormehl et al, 1999) 
 Brain Perfusion and Cognitive Function changes in Hypertensive Patients 
(Efimova et al, 2007) 
 Chronic Lyme disease (Donta, Noto and Vento, 2012) 
 Traumatic brain injury (Raji et al, 2014) 
 Cerebral autoimmune vasculitis (Mauro et al, 2015) 
 
 
  
167 
 
There have been reports of improvements (documented on brain SPECT scans) in patients 
receiving anti-retroviral therapy. All the reports have been in patients with cognitive 
dysfunction.  
 In 1990 Tatsch et al documented randomly distributed focal or regional areas 
of hypo perfusion on brain SPECT scans of 40 HIV infected individuals. They 
concluded that perfusion abnormalities may precede the symptoms of 
dementia and correlate better with cognitive improvement after therapy than 
other structural imaging modalities like CT and MRI.  
 In 1991 Masdeu et al evaluated HIV-infected patients with dementia. Their 
investigations included SPECT scans. Four of their patients received AZT, and 
in these patients there were documented improvements noted on their SPECT 
scans.  
 Tran Dinh et al, 1990 advocated the use of quantitative cerebral SPECT scan 
imaging as a suitable method for monitoring the effects of therapy in early 
HIV infection.  
 In 1998, Szeto et al studied 10 patients with early AIDS dementia. Their 
patients had brain SPECT scans done at entry into the study and 12 weeks 
later. In the interim the patients were given Atevirdine mesylate, a non-
nucleoside reverse transcriptase inhibitor. Four patients completed the study 
and had repeat SPECT scans at week 12. Two patients responded clinically to 
the therapy and in these patients the SPECT images improved on both 
qualitative and quantitative analyses.  
 Tozzi et al, 1999 performed SPECT scans on13 HIV infected patients with 
neuropsychological abnormalities. The scans were repeated 6 months later 
(they received HAART in the interim). Ten patients showed improvement in 
the deficits, with half of them showing complete reversal of their defects.  
 More recently Sprinz et al, 2008 described improvements in the brain SPECT 
images of a HIV positive patient with cognitive dysfunction. Her initial 
images showed multiple areas of hypo perfusion on quantitative analysis; the 
most prominent of which was in the frontal region.  She received HAART for 
6 months. Her repeat SPECT images showed improvement in areas of hypo 
perfusion.  The authors suggested that the technique could be used as a marker 
of clinical improvement.  
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4.3.9 Summary 
In our patients with HIV and NOS: 
 All had generalized tonic-clonic seizures 
 EEG recordings were often normal 
 Unexplained WML on MRI were common 
 Temporal lobe abnormalities on visual SPECT assessment were common 
 Regional cerebral hypo perfusion as documented on quantitative SPECT 
analysis was present 
 
During the longitudinal follow-up: 
 Seizure control was not difficult to achieve with sodium valproate 
 
 One patient developed a HIV-associated dementia 
o Patient 6 
The patient developed clinical features consistent with a diagnosis of 
HIV-associated dementia 
Her CD4 count decreased and her serum viral load increased 
The visual and quantitative SPECT scan assessments deteriorated. 
 
 The improvements in patients initiating HAART was significant in terms of: 
o CD4 count 
o Serum viral load 
o Cerebral perfusion as evidenced by the quantitative SPECT data 
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4.3.9 Conclusion 
New Onset Seizures in HIV infected individuals in who no cause is identifiable may 
represent: 
 Early stages of the spectrum of neurocognitive dysfunction seen in HIV 
infection 
 May be a precursor for dementia in some patients 
In this study only one patient developed features consistent with a diagnosis 
of HIV-associated dementia. 
These patients are likely to benefit from the initiation of anti-retroviral therapy.  
Quantitative SPECT imaging of the brain may play a role in the assessment of HAART 
related cognitive improvement.  
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4.3.11 Study Limitations 
 
 The small number of patients recruited for the longitudinal component of the 
study. The patients were recruited at 3 sites over an eighteen month period. 
Two hundred patients were recruited in to the first section of the study, 
making this the largest study of NOS in HIV infected individuals but: 
o Only 22 patients were eligible for the longitudinal component  
o 7 patients refused permission to be included in the longitudinal study 
 High rate of attrition in the longitudinal component of the study. 
The possible reasons for this are discussed in the data analysis section 
 The duration of follow-up. It would have been preferable to assess the patients 
over a minimum period of 2 years. This was impractical as the study needed to 
be completed within the stipulated 2 years. 
 The lack of extensive neuropsychological tests on patients in the longitudinal 
study. The patients in this study, although all South African did not share a 
common language. Harvey et al, 2003 showed that there are performance 
differences across English and other languages in executive functions, 
vigilance, and psychomotor speed.  
 Discrepancy between visual assessment and quantitative analysis 
o The presence of deficits in the temporal regions may have been over-
estimated. Visual assessment of the temporal region is difficult because 
of its intrinsically low uptake (Tanaka et al, 2000). 
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 Appendix D Patient Data Sheet Page 1 
Demographic Data  
Name  
Hospital Number  
Age  
Sex  
Sexual Orientation  
Telephone Number  
Seizure History  
Date of 1
st
 seizure  
Previous Epilepsy  
Seizure Type  
Risks/Triggers  
Family History  
Trauma  
Alcohol  
Drugs  
Herbal  
Medicinal  
Recreational  
Previous Medical History  
Medication  
Current  
HAART  
Clinical Examination  
Stigmata of Immune-suppression  
Vitals (PR/BP/T°)  
General Medical Examination  
CNS Examination  
Level of Consciousness  
HIVDS Score  
Meningism  
Cranial Nerves  
Primitive Reflexes  
Motor  
Sensory  
Reflexes  
Cerebellum  
Other  
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Investigations  
Blood laboratory tests  
FBC  
ESR  
U&E & Glucose  
CPM  
LFT  
T Cell Subsets  
Syphilis Serology  
Cysticercosis CFT  
Toxoplasma CFT  
CMV  
HTLV-1  
CSF  
Cell count  
Chemistry  
ADA  
EBV  
HSV  
JCV  
Syphilis  
Other  
EEG  
CT Brain  
MRI Brain  
  
 
 
 
 
 
  
 Appendix E Patient Data Sheet (Longitudinal Study) Page 1 
Demographic Data Visit 1 Visit 2 Visit 3 
Name    
Hospital Number    
Age    
Sex    
Sexual Orientation    
Telephone Number    
Seizure History    
Date of 1
st
 seizure    
Previous Epilepsy    
Seizure Type    
Risks/Triggers    
Family History    
Trauma    
Alcohol    
Drugs    
Herbal    
Medicinal    
Recreational    
Previous Medical History    
Medication    
Current    
HAART    
Clinical Examination    
Stigmata of Immune-
suppression 
   
Vitals (PR/BP/T°)    
General Medical Examination    
CNS Examination    
Level of Consciousness    
HIVDS Score    
Meningism    
Cranial Nerves    
Primitive Reflexes    
Motor    
Sensory    
Reflexes    
Cerebellum    
Other    
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Investigations Visit 1 Visit 2 Visit 3 
Blood laboratory tests    
FBC    
ESR    
U&E & Glucose    
CPM    
LFT    
T Cell Subsets    
Syphilis Serology    
Cysticercosis CFT    
Toxoplasma CFT    
CMV    
HTLV-1    
CSF    
Cell count    
Chemistry    
ADA    
EBV    
HSV    
JCV    
Syphilis    
Other    
EEG    
CT Brain    
MRI Brain    
Brain SPECT Scan    
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I,________________________________________ being 18 years or older,  
 
consent to participating in a research project entitled:  
A LONGITUDINAL CLINICAL AND SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY 
(SPECT) SCAN STUDY ON HUMAN IMMUNO-DEFICIENCY VIRUS (HIV) INFECTED PATIENTS 
WITH NEW ONSET EPILEPSY AND NO IDENTIFIABLE CAUSE 
The procedures / questionnaires have been explained to me and I understand and 
appreciate their purpose, any risks involved, and the extent of my involvement. I have 
read and understand the information. 
I understand that radioactive investigations will be carried out on myself, and that they are 
not necessary for the diagnosis/ treatment of my condition. 
I understand that the procedures form part of a research project, and may not provide any 
direct benefit to me. 
 
I understand that all experimental procedures have been reviewed and approved by the 
Human Research Ethics Committee, University of the Witwatersrand, Johannesburg. If you 
have any questions regarding your rights as a participant in this study or any complaints 
please contact Ms Anisa Keshav from the Ethics Committee on 011 717 1234. 
I understand that my participation is voluntary, and that I am free to withdraw from the 
project at any time without prejudice. 
 
____________________________                       _____________________ 
Subject name and signature        Date 
 
____________________________               ______________________ 
Dr. Kapila R. Hari and signature   Date 
0832593480 
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Statistical Analysis of Quantitative SPECT Data for ROI at Baseline  
The data was analysed to determine normalcy of the variables. A significance level of 5% 
was assumed. The results detailed below show a normal distribution, enabling parametric 
tests.   
Kolmogorov-Smirnov Test of Normality 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Legend 
L=Left; R=Right; FS= Frontal Superior; F M= Frontal Middle; FI= Frontal Inferior; CiA= Cingulate Anterior; 
CiM= Cingulate Middle; CiP= Cingulate Posterior; HP= Hippocampus; O= Occipital; Ca= Caudate; Pu= 
Putamen; Pa= Pallidum; Th= Thalamus; Par= Parietal; Tem= Temporal; Cb= Cerebellum 
SPECT images reconstructed in units of radioactivity concentration per pixel and averaged per region 
 
 
 
N 
Normal Parameters Kolmogorov- 
Smirnov Z 
P-value 
Mean Std. Deviation 
FS L 13 58,01 26,71 0,958 ,318 
FS R 13 59,32 26,42 0,970 ,304 
FM L 13 56,68 26,96 0,941 ,339 
FM R 13 61,52 27,566 0,973 ,300 
FI L 13 56,68 26,29 0,852 ,462 
FI R 13 59,97 27,61 0,939 ,342 
CiA L 12 60,76 26,96 1,043 ,226 
CiA R 13 63,40 27,21 1,035 ,234 
CiM L 13 61,48 27,31 1,248 ,089 
CiM R 13 62,65 27,73 1,150 ,142 
CiP L 13 55,79 25,21 1,248 ,089 
CiP R 13 53,47 23,81 1,193 ,116 
HP L 13 54,86 25,79 0,999 ,271 
HP R 13 54,22 25,64 1,094 ,182 
O L 13 65,61 27,98 0,936 ,344 
O R 13 63,51 29,06 0,915 ,372 
Ca L 13 51,34 22,91 1,090 ,186 
Ca R 13 51,31 23,85 1,248 ,089 
Pu L 13 64,51 30,28 0,892 ,403 
Pu R 13 65,52 31,81 1,054 ,217 
Pa L 13 65,47 32,04 0,839 ,482 
Pa R 13 64,26 31,13 0,996 ,275 
Th L 13 60,80 29,09 1,106 ,173 
Th R 13 60,72 30,09 1,149 ,143 
Par L 13 60,49 25,95 0,989 ,283 
Par R 13 57,79 27,35 1,065 ,206 
Tem L 13 58,59 24,56 0,953 ,323 
Tem R 13 60,27 27,14 1,007 ,263 
Cb L 13 67,39 30,50 1,086 ,189 
Cb R 13 67,71 31,60 1,169 ,130 
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Statistical Analysis of Quantitative SPECT Data for cerebral regions at Baseline  
The quantitative data, at baseline according to dominant cerebral regions is documented 
below. 
Cerebral Regions  
Patient 
Number 
Frontal Cingulate 
Central 
Region 
Temporal 
Region 
Parietal 
Region 
Occipital 
Region 
Cerebellum 
1 320.06 319.88 414.39 199.54 104.96 112.4 117.96 
2 292.74 299.13 395.72 182.57 104.01 104.14 111.44 
3 173.12 178.39 243 113.57 62.38 68.24 65.78 
4 338.72 311.34 426.99 211.06 107.67 118.3 119.94 
5 644.95 707.16 1004.01 458.03 216.51 234.88 267.94 
6 367.77 349.33 491.54 240.07 120.81 137.97 137.65 
7 264.01 299.65 401.05 168.96 80.8 88.84 97.38 
8 221.75 215.45 287.09 132.95 69.76 73.09 77.21 
11 708.44 666.51 910.62 420.95 240.23 257.25 261.69 
12 388.2 363.03 500.06 244.83 126.48 140.43 140.28 
13 339.28 346.14 498.46 218.14 112.43 121.33 132.21 
14 451.96 437.97 578.7 278.71 147.91 148.39 158.36 
15 167.46 243.02 234.57 144.72 73.44 92.71 91.81 
 
SPECT images reconstructed in units of radioactivity concentration per pixel and averaged per region for each 
patient 
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A paired sample T test was done to compare the left and right hemispheres for individual 
patients.  
 
Left versus Right Cerebral Hemispheres  
(individual patients at baseline) 
 
Patient Number p Value 
1 0.99 
2 0.96 
3 0.96 
4 0.97 
5 0.92 
6 0.99 
7 0.10 
8 0.99 
11 0.47 
12 0.10 
13 0.98 
14 0.90 
15 0.89 
  
 
There were no significant differences detected, indicating symmetrical perfusion for 
individual patients. 
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Paired sample T tests were used to determine the difference between the left and right 
hemispheres for the dominant cerebral regions (all patients) at baseline.  
 
Cerebral Regions (Left vs Right) 
 
Region Left Right P 
Value 
Frontal Region 2484.83 2597.98 0.80 
Cingulate 2573.68 2568.67 0.99 
Central 
Region 
3474.8 3463.37 0.99 
Temporal 
Region 
1626.29 1647.16 0.94 
Parietal 
Region 
865.7 866.76 0.99 
Occipital 
Region 
1840.44 1761.06 0.30 
Cerebellum 1803.62 1860.04 0.55 
 
There were no significant differences between the left and right cerebral regions. 
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A single factor Analysis of Variance (ANOVA) test was done to test the null hypothesis that 
the means of the dominant cerebral regions are equal.  
 
Table 4.15 Cerebral Regions 
 
Anova: Single Factor 
SUMMARY  
Groups Count Sum Average Variance   
Frontal 
Region 
25 4333.17 173.3268 5512.666 
  
Cingulate 25 4405.03 176.2012 5276.164 
  
Central 
Region 
25 2807.78 112.3112 2331.844 
  
Temporal 
Region 
25 1447.45 57.898 575.7495 
  
Parietal 
Region 
25 1566.51 62.6604 635.3733 
  
Occipital 
Region 
25 1650.82 66.0328 817.6745 
  
Cerebellum 25 5929.84 237.1936 11511.8 
  
 
ANOVA       
Source of 
Variation 
SS df MS F P-
value 
F crit 
Between 
Groups 
738884.1 6 123147.3 32.33272 
1.06E-
25 
2.152911 
Within 
Groups 
639870.4 168 3808.753 
   
 
Total 1378755 174         
 
Conclusion: the F > F crit, we therefore rejected the null hypothesis.  
 The means of the different regions are not all equal. At least one of the means 
is different.  
Paired sample T-tests were performed to test each pair of means to determine the source of 
the difference. 
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Paired sample T tests were used to determine the difference between individual regions. The 
p-values in red, in the table below indicate regions between which there are significant 
differences.   
 
Individual regions 
 
 
There were significant differences between most regions. The notable exceptions were 
between: 
 The frontal region and the cingulate 
 The occipital and parietal regions 
 The cerebellum and 
o The parietal region 
o The occipital region 
  
Region 
Frontal 
Region 
Cingulate Central 
Region 
Temporal 
Region 
Parietal 
Region 
Occipital 
Cingulate 0.92  
 
 
 
 
Central 
Region 
0.02 0.02 
Temporal 
Region 
0.00 0.00 0.00 
Parietal 
Region 
0.00 0.00 0.00 4.1E-05 
Occipital 
Region 
0.00 0.00 0.00 4.9E-05 0.86 
Cerebellum 0.00 0.00 0.00 0.00 0.59 0.70 
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A single factor Analysis of Variance (ANOVA) test was done to test the null hypothesis that 
the means of patients in the HIV stages are equal.  
 
HIV Stages (Baseline) 
 
Anova: Single Factor 
SUMMARY  
Groups Count Sum Average Variance   
Stage 1 28 8502.39 303.6568 44914.42 
  
Stage 2 35 10560.88 301.7394 38542.75 
  
Stage3 27 4624.38 171.2733 11452.64 
  
ANOVA 
 
Source of 
Variation 
SS df MS F P-value F crit 
Between Groups 325977.9 2 162989 5.026758 0.008592 3.101295757 
Within Groups 2820911 87 32424.27 
   
Total 3146889 89 
    
 
Conclusion: the F > F crit, we therefore rejected the null hypothesis. The means of the 
patients in the different HIV stages are not all equal. At least one of the means is different. 
Paired sample T-tests were performed to test each pair of means to determine the source of 
the difference. 
 
Paired sample T tests were used to determine the difference amongst patients in the different 
stages. The p-values in red, in table 4.18 below indicate HIV stages between which there are 
significant differences.   
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Difference between HIV Stages (Baseline) 
 
Stage 2 3 
1 0.97 0.005 
2  0.003 
 
The cerebral perfusion was significantly different between patients in: 
 Stages 1 and 3 
 Stages 2 and 3 
A paired sample T test was done to compare the left and right hemispheres for each patient at 
follow-up.  
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Cerebral Hemispheres: Left versus Right 
(individual patients at Follow-up) 
 
 
Patient Number p Value 
1 0.99 
2 0.99 
3 0.93 
4 0.97 
5 0.94 
6 0.96 
7 0.96 
8 0.99 
 
There were no significant differences between left and right hemispheres for individual 
patients. The cerebral perfusion in all patients was symmetrical. 
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The quantitative data, at follow-up according to dominant cerebral regions is documented 
below. The data is from the last scan done for each patient. 
 
 
Cerebral regions Follow-up Data 
 
 
 
  
Patient 
Number 
Frontal Cingulate 
Central 
Region 
Temporal 
Region 
Parietal 
Region 
Occipital 
Region 
Cerebellum 
1 510.27 487.52 660.03 301.87 166.54 168.76 172.65 
2 754.21 796.30 1079.72 492.73 269.96 286.85 309.73 
3 693.18 645.75 863.60 400.75 235.57 245.67 245.26 
4 452.17 422.23 568.51 288.06 151.85 161.62 164.31 
5 456.50 445.85 610.00 294.26 152.35 160.87 170.49 
6 406.78 399.28 577.30 271.07 136.68 164.82 160.52 
7 535.64 503.91 679.38 325.80 177.22 197.83 196.37 
8 698.01 700.28 909.22 415.51 221.73 228.92 246.81 
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A paired sample T test was done to compare the corresponding regions for all patients at 
baseline and follow-up. The p-values in red below indicate regions for which there are 
significant differences.   
 
 
Cerebral regions at baseline versus follow-up 
 
Cerebral Region p Value 
Frontal 0.004 
Cingulate 0.014 
Central 0.017 
Temporal 0.012 
Parietal 0.005 
Occipital 0.005 
Cerebellum 0.012 
 
 
There were significant improvements noted in each cerebral region. 
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An ANOVA test was done to test the null hypothesis that the means of the dominant cerebral 
regions are equal (at follow-up).  
 
Cerebral Regions at Follow-up 
 
Anova: Single Factor       
SUMMARY  
Groups Count Sum Average Variance 
 
Frontal 8 92 11.5 6 
Cingulate 8 4506.76 563.345 17613.44 
Central 8 4401.12 550.14 21190.38 
Temporal 8 5947.76 743.47 34582.26 
Parietal 8 2790.05 348.7563 6186.028 
Occipital 8 1511.9 188.9875 2271.212 
Cerebellum 8 1615.34 201.9175 2236.869 
ANOVA 
 
Source of Variation SS df MS F P-value F crit 
Between Groups 3383060 7 483294.3 44.45536 1.32E-20 2.178156 
Within Groups 608801.3 56 10871.45 
   
Total 3991862 63 
    
 
Conclusion: the F > F crit, we therefore rejected the null hypothesis. The means of the 
different regions were not all equal. At least one of the means is different. Paired sample T-
tests were performed to test each pair of means to determine individual differences. 
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A paired sample T test was used to determine the difference between individual regions. The 
p-values in red, in the table below indicate regions for which there are significant differences.   
 
Individual regions 
 
 
There were significant differences between most regions. The notable exceptions were 
between: 
 The frontal region and the cingulate 
 The occipital and parietal regions 
 The cerebellum and 
o The parietal region 
o The occipital region 
NB! The regional differences at follow-up are the same as the differences noted at baseline. 
 
  
Region 
Frontal 
Region 
Cingulate Central 
Region 
Temporal 
Region 
Parietal 
Region 
Occipital 
Cingulate 0.85  
 
 
 
 
Central 
Region 
0.04 0.04 
Temporal 
Region 
0.00 0.04 7.4E-05 
Parietal 
Region 
0.00 1.1E-05 0.00 0.00 
Occipital 
Region 
0.00 1.6E05 0.00 0.00 0.59 
Cerebellum 0.00 2.2E-05 0.00 0.00 0.46 0.81 
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A paired sample t-test (2 dependent means) was used to calculate the difference between each 
individual patient at baseline and at last follow-up. The p-values in red, in the table below 
indicate patients for who there are significant differences.   
 
Comparison of Individual patients (all regions)  
Baseline versus Follow-up 
 
Patient Number p Value 
1 0.005 
2 0.003 
3 0.003 
4 0.002 
5 0.005 
6 0.007* 
7 0.001 
8 0.004 
The comparative data indicate significant differences between individual patients at baseline 
and last follow-up. The majority of patients (7) showed significant improvements in their 
cerebral perfusion.   
*NB! The only patient that showed a reduction in cerebral perfusion was 
patient 6.  
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A paired sample T test was used to compare the left cerebral hemisphere for each patient pre 
and post-HAART and the right cerebral hemisphere for each patient pre and post-HAART. 
The p-values in red, in the table below indicate the significant differences.  
 
Pre and Post-HAART data (Hemispheres) 
 
Patient 
Number 
Left Right 
Pre- 
HAART 
Post- 
HAART 
P  
Value 
Pre- 
HAART 
Post- 
HAART 
P  
Value 
1 538.06 1706.08 0.001 539.22 1714.40 0.001 
3 542.75 1315.65 0.001 700.41 1300.49 0.000 
7 455.13 1683.64 0.000 449.36 1646.15 0.000 
8 779.93 1236.27 0.001 786.14 1231.37 0.001 
 
 
All patients showed improved cerebral perfusion for both the left and right hemispheres. 
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A paired sample T test was used to compare the dominant cerebral regions for the patients’ 
pre and post-HAART. The p-values in red, in the table below indicate regions for which there 
are significant differences 
 
Pre and Post-HAART Quantification Data  
(Patients 1; 3; 7 and 8) 
 
 
Patient 
Number 
Frontal Cingulate Central 
Region 
Temporal 
Region 
Parietal 
Region 
Occipital 
Region 
Cerebellum p 
 Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post Pre Post  
1 320.06 510.27 319.88 487.52 414.39 660.03 199.54 301.87 104.96 166.54 112.4 168.76 117.96 172.65 0.002 
3 173.12 693.18 178.39 645.75 243 863.60 113.57 400.75 62.38 235.57 68.24 245.67 65.78 245.26 0.001 
7 264.01 535.64 299.65 503.91 401.05 679.38 168.96 325.80 80.8 177.22 88.84 197.83 97.38 196.37 0.001 
8 221.75 698.01 215.45 700.28 287.09 909.22 132.95 415.51 69.76 221.73 73.09 228.92 77.21 246.81 0.004 
 
All patients had improved overall improved perfusion.  
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A paired sample T test was used to compare the dominant cerebral regions for patient 1. 
Scans 1 and 2 were done pre-HAART. Scan 3 was done post-HAART. The p-values in red, 
in the table below indicate the significant differences between the scans. 
 
Comparison of Patient 1 (all regions)  
Baseline versus Follow-up Scans 
 
Frontal Cingulate 
Central 
Region 
Temporal 
Region 
Parietal 
Region 
Occipital 
Region 
Cerebellum 
P 
Value 
Scan 
1 
Scan 
2 
Scan 
1 
Scan 
2 
Scan 
1 
Scan 
2 
Scan 
1 
Scan 
2 
Scan 
1 
Scan 
2 
Scan 
1 
Scan 
2 
Scan 
1 
Scan 
2 
0.878 
320.06 314.53 319.88 310.88 414.39 409.23 199.54 105.11 104.96 198.92 112.4 111.36 117.96 116.03 
Scan 
1 
Scan 
3 
Scan 
1 
Scan 
3 
Scan 
1 
Scan 
3 
Scan 
1 
Scan 
3 
Scan 
1 
Scan 
3 
Scan 
1 
Scan 
3 
Scan 
1 
Scan 
3 
0.005 
320.06 510.27 319.88 487.52 414.39 660.03 199.54 301.87 104.96 166.54 112.4 168.76 117.96 172.65 
Scan 
2 
Scan 
3 
Scan 
2 
Scan 
3 
Scan 
2 
Scan 
3 
Scan 
2 
Scan 
3 
Scan 
2 
Scan 
3 
Scan 
2 
Scan 
3 
Scan 
2 
Scan 
3 
0.012 
314.53 510.27 310.88 487.52 409.23 660.03 105.11 301.87 198.92 166.54 111.36 168.76 116.03 172.65 
 
Patient 1: 
 No improvement between scans 1 and 2.  
 Improvement between scans 
o 1 and 3 
o 2 and 3 
 
She initiated HAART in the period between scans 2 and 3.  
 
